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ABSTRACT 
Bone tissue is the second most common tissue transplant after blood transfusion 
and as people age, the need for bone transplants is expected to rise even more. 
Despite the great efforts in biomaterial research and development, autologous bone 
remains the benchmark among bone grafts whereas synthetic bone grafts are still 
less-used. Effective and reliable development of synthetic bone grafts require 
efficient cellular assessments in vitro including the evaluation of osteogenic as well as 
vasculogenic potential of the scaffolds. Adult stem cells, including human adipose 
stem cells (hASCs) and human bone marrow stem cells (hBMSCs), provide an 
excellent tool for this as they have been shown to differentiate to bone-forming cells 
and endothelial cells. However, efficient and cost-effective approaches to induce 
osteogenic and endothelial differentiation are still needed. This thesis focuses on the 
study and development of in vitro differentiation strategies for hASCs and hBMSCs 
in 3-dimensional (3D) culture in order to study and verify the feasibility of novel 
bone substitute materials. 
Firstly, two clinically used synthetic bone graft scaffolds, BoneCeramic composed 
of biphasic calcium phosphate and BioRestore composed of bioactive glass (BaG), 
were compared in hASC culture and, the effectiveness of commonly used growth 
factors bone morphogenetic protein (BMP)-2, BMP-7 and vascular endothelial 
growth factor (VEGF) on hASC osteogenesis were compared to OM. As ceramics 
are hard and brittle making them difficult to implant and undesirable to load-bearing 
sites, an elastic β-tricalciumphosphate/poly(L-lactide-co-ε-caprolactone) (β-
TCP/PLCL) composite was developed using supercritical CO2 (scCO2) foaming. 
The capacity of the composites to support hASC osteogenesis and vasculogenesis 
were studied in vitro in hASC culture and in vivo in rabbit femur defect. Finally, 3D 
printed polycaprolactone (PCL)/copper-doped BaG composites were developed 
and their osteogenic and vasculogenic potential was studied in vitro in hBMSC culture 
and in a co-culture of hBMSCs and human umbilical vein endothelial cells 
(HUVECs). 
The two biomaterial scaffolds BoneCeramic and BioRestore demonstrated 
differential effects on hASCs: BoneCeramic induced ALP activity and collagen 
production of hASCs, while BioRestore stimulated hASC proliferation. In 
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comparison to the growth factors, OM was more effective in the osteogenic 
differentiation of hASCs in vitro in BoneCeramic and BioRestore. On the other hand, 
combining the growth factors with OM did not sensitize hASCs to the growth 
factors.  
The β-TCP/PLCL composites supported the viability, proliferation and 
osteogenic differentiation of hASCs reliably in vitro. When studying the osteogenic 
and endothelial differentiation of hASCs in β-TCP/PLCL composites, hASCs 
differentiated towards both lineages when cultured in endothelial medium (EM) 
although the differentiation was left in a premature state. Culture in a cocktail 
medium of OM and EM supported osteogenic but not endothelial differentiation of 
hASCs. The in vivo study confirmed biocompatibility as well as osteoconductivity of 
the composite as no inflammation, fibrous tissue or cyst formation was detected and, 
native bone tissue was able to grow on and in the β-TCP/PLCL composite already 
at 4 weeks.  
In the evaluation of 3D printed PCL/BaG-Cu composites, copper was observed 
to have a dose-dependent cytotoxic effect on hBMSCs in vitro. The PCL/BaG 
composite induced hBMSC osteogenesis while the addition of copper in BaG had 
an inhibiting effect on the osteogenic differentiation of hBMSCs. In co-culture of 
hBMSCs and HUVECs, both PCL/BaG and PCL/BaG-Cu scaffolds supported 
tubule formation, but the added copper did not boost the vasculogenic effect of the 
composite. 
 In conclusion, OM was shown to be a cost-effective osteogenic stimulant in 3D 
culture as compared to exogenously added growth factors. The feasibility of the 
scCO2 foamed β-TCP/PLCL composite as potential a bone graft for clinical use was 
evidenced in vitro and in vivo. The 3D printed PCL/BaG composite showed promise 
in supporting osteogenesis in vitro whereas the addition of copper hindered the 
osteogenic effect of the composite. Both PCL/BaG and PCL/BaG-Cu composites 
supported tubule formation in hBMSC+HUVEC co-culture but the copper did not 
induce the vasculogenic effect of the composite. To conclude, the elastic and 
bioactive synthetic polymer -based composites consisting osteoconductive ceramics 
are highly promising alternatives for synthetic bone grafts when compared to hard 
ceramics. 
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TIIVISTELMÄ 
Luukudos on heti veren jälkeen maailman käytetyin kudossiirre ja väestön 
ikääntyessä luusiirteiden tarpeen odotetaan nousevan nykyisestä. Mittavista 
panostuksista huolimatta biomateriaalikehityksessä ja -tutkimuksessa, potilaiden 
hoidossa synteettisiä luusiirteitä käytetään huomattavasti vähemmän kuin autologisia 
luusiirteitä. Uusien synteettisten luusiirteiden kehityksessä tarvitaan tehokkaita ja 
luotettavia soluviljelymenetelmiä arvioimaan materiaalien kykyä tukea luun ja 
verisuonien muodostumista. Aikuisen kantasolut, kuten rasvakudoksen ja luuytimen 
kantasolut, jotka pystyvät erilaistumaan sekä luusoluiksi, että verisuonten 
endoteelisoluiksi, ovat erinomainen työkalu tähän tarkoitukseen. Toimivia ja 
kustannustehokkaita menetelmiä luu- ja endoteelierilaistukseen täytyy kuitenkin vielä 
kehittää. Tämä väitöskirjassa tutkitaan strategioita aikuisen kantasolujen 
erilaistukseen 3-ulotteisessa ympäristössä, jotta uusien synteettisten luusiirteiden 
soveltuvuutta voidaan arvioida luotettavasti. 
Kahta kliinisessä käytössä olevaa synteettistä luusiirremateriaalia (BoneCeramic 
kalsiumfosfaatti ja BioRestore bioaktiivinen lasi) verrattiin rasvakudoksen 
kantasoluviljelmissä. Samalla tutkittiin yleisesti käytettyjen kasvutekijöiden luun 
morfogeneettisten proteiinien (BMP)-2, BMP-7 ja verisuonen endoteelin 
kasvutekijän (VEGF) tehokkuutta rasvakudoksen kantasolujen luuerilaistuksessa. 
Koska kovien ja hauraiden keraamien istuttaminen siirrekohtaan leikkauksen aikana 
on vaikeaa ja ne sopivat huonosti kuormaakantaviin kohtiin, tutkimuksessa 
kehitettiin elastinen β-trikalsiumfosfaatti/poly(L-laktidi-ko-ε-kaprolaktoni) (β-
TCP/PLCL) komposiitti hyödyntäen ylikriittistä hiilidioksidi prosessointia. Näiden 
komposiittien kykyä tukea luun ja verisuonten muodostumista tutkittiin sekä 
rasvakudoksen kantasoluviljelmissä, että kanin reisiluun puutoksessa. Seuraavaksi 
kehitettiin 3D tulostuksen avulla polykaprolaktoni (PCL)/bioaktiivinen lasi-kupari –
komposiitti, jonka soluyhteensopivuutta sekä kykyä tukea luun ja verisuonten 
muodostumista tutkittiin luuytimen kantasolujen viljelyssä sekä luuytimen 
kantasolujen ja napanuoran endoteelisolujen yhteisviljelyssä. 
BoneCeramic kalsiumfosfaatti ja BioRestore bioaktiivinen lasi vaikuttivat eri 
tavalla rasvakudoksen kantasoluihin: kalsiumfosfaattirakeet lisäsivät 
luuerilaistumista, kun taas bioaktiivinen lasi stimuloi solujen jakautumista. 
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Luuerilaistusliuos oli merkittävästi tehokkaampi luuerilaistaja verrattuna 
kasvutekijöihin rasvakudoksen kantasolujen erilaistuksessa. Rasvakudoksen 
kantasolut eivät herkistyneet kasvutekijöille myöskään silloin, kun kasvutekijät 
yhdistettiin luuerilaistuliuokseen. 
Kehitetyt β-TCP/PLCL komposiitit tukivat rasvakudoksen kantasolujen 
elinkykyä, jakautumista ja luuerilaistumista. Rasvakudoksen kantasolut kykenivät 
erilaistumaan sekä luu- että endoteelisolujen suuntaan komposiiteilla, kun niitä 
viljeltiin endoteelierilaistusliuoksessa, mutta erilaistuminen jäi vaillinaiseksi. Luu- ja 
endoteelierilaistusliuosten sekoituksen näytettiin tukevan solujen luu- mutta ei 
endoteelierilaistumista. Kun komposiitti istutettiin kanin reisiluun puutokseen, 
luukudoksen todettiin kasvavan komposiitin pinnalla ja sen sisällä jo 4 viikkoa 
istutuksen jälkeen. Lisäksi se ei aiheuttanut tulehdusta tai saanut aikaan sidekudoksen 
tai kystien muodostusta. 
Kasvavalla kuparipitoisuudella huomattiin olevan sytotoksinen vaikutus 
luuytimen kantasoluihin, kun soluja viljeltiin PCL/bioaktiivinen lasi-kupari 
komposiiteilla. PCL/bioaktiivinen lasi komposiitti tuki hyvin luuerilaistumista, kun 
taas kuparin lisääminen heikensi komposiitin luun muodostuskykyä. Molemmat 
komposiitit tukivat verisuonirakenteiden muodostumista luuytimen kantasolujen ja 
napanuoran endoteelisolujen yhteisviljelyssä; kuparilla ei huomattu olevan 
merkittävää vaikutusta verisuonittumiseen. 
Yhteenvetona luuerilaistusliuos on tehokkaampi luuerilaistaja 3-ulotteisessa 
ympäristössä kuin yleisesti käytetyt kasvutekijät rasvakudoksen kantasoluille. 
Huokoinen β-TCP/PLCL komposiitti on lupaava synteettinen luusiirre, sillä se on 
kudosyhteensopiva, luunkasvua johtava ja sitä on helppo käyttää ja muokata 
leikkauksen aikana. Lisäksi komposiitti tukee rasvakudoksen kantasolujen 
endoteelierilaistumista, kun niitä viljellään endoteelierilaistusliuoksessa, mutta 
solujen erilaistus ei kehity kypsien endoteelisolujen tasolle 3 viikon erilaistuksen 
aikana. Tulostettu PCL/bioaktiivinen lasi komposiitti tukee luuerilaistumista sekä 
verisuonittumista, mutta kuparin lisääminen komposiittiin heikentää 
luuerilaistumista eikä paranna verisuonittumista. Tämä tutkimus osoittaa, että 
yhdistämällä luunkasvua johtavia keraameja synteettisiin polymeereihin voidaan 
luoda hyvin lupaavia, elastisia synteettisiä luusiirremateriaaleja verrattuna koviin 
keraameihin.  
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1 INTRODUCTION 
Bone tissue engineering (BTE) is a field of science aiming to create constructs that 
mimic natural bone tissue and integrate into the skeletal system without conflict 
allowing and promoting the bone regeneration process. BTE combines biomaterials, 
cells and signaling molecules to produce constructs that restore, maintain or improve 
damaged bone tissue. Hence, BTE is a multidisciplinary area of research combining 
biomaterial engineering, cell biology and medicine. Bone is the second most 
transplanted tissue worldwide and a bone graft or a bone substitute is used in over 4 
million operations annually to treat bone defects (Turnbull et al., 2017). Despite the 
numerous studies presenting potential scaffold materials and applications during the 
last few decades, markedly few of them have advanced in to clinical use (de Misquita 
et al., 2016; Mishra et al., 2016).  
Autologous bone transplants remain the gold standard in orthopedic surgeries as 
they do not cause immune reactions and they have ideal properties to induce bone 
formation in the defect site (Amini et al., 2012). Autograft is usually harvested from 
iliac crest, requiring a secondary surgical site and resulting in notable donor site 
injury, deformity and scarring. However, the amount of autograft bone is limited and 
there are risks related to the harvesting surgery, such as infection and chronic pain 
(Freeman & McNamara, 2017; Mishra et al., 2016; Amini et al., 2012). Therefore, 
autografts are an expensive choice for a bone transplant as well as an unattractive 
choice for the patient. Allografts on the other hand are donor tissues usually received 
from cadavers and they are the second most used bone transplants (Amini et al., 
2012). Allograft bone is abundantly available in different forms yet its use is hindered 
by immune reactions, infections, disease transmission and weakened 
osteoinductivity (Freeman & McNamara, 2017; Amini et al., 2012; Boyce et al., 1999). 
Consequently, there is an apparent and growing need for reliable synthetic bone 
transplants and BTE strategies. 
Among synthetic bone grafts, calcium phosphates (CaPs) and bioactive glasses 
(BaGs) are the most used in treating patients. These ceramic materials can bind to 
bone tissue and even induce bone formation however, they are hard and brittle 
(Turnbull et al., 2017), making them difficult to implant and undesirable for load-
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bearing sites. Synthetic polymers with excellent mechanical properties on the other 
hand do not have biological binding sites for bone tissue. Hence, composites 
combining the characteristics of different material types may be the most promising 
strategy to produce optimal synthetic bone graft materials.  
Adipose and bone marrow stem cells (ASCs and BMSCs) are important tools in 
BTE when studying the interactions between cells and biomaterial scaffolds. As 
these cells can differentiate towards multiple cell lineages, including osteogenic and 
endothelial cell (EC) lineages, in addition to cytocompatibility they allow the 
evaluation of scaffolds’ osteogenic as well as vascular potential in vitro. Efficient and 
reliable osteogenic differentiation is highly relevant to enable the in vitro study of 
engineered bone grafts. Reliable in vitro characterization ensures that promising 
scaffolds proceed to animal studies and on the other hand prevents unnecessary 
animal studies in case of unsuitable scaffolds. Growth factors, such as bone 
morphogenetic protein-2 (BMP-2), are expensive but commonly used to induce 
osteogenic differentiation (Gothard et al., 2014). However, their use in patients has 
resulted in safety concerns (Carragee et al., 2011) and hence safer and more cost-
effective differentiation strategies are needed. 
The formation of vascular network is crucial for the bone regeneration and 
therefore the scaffolds’ ability to support vascularization is important. In fact, the 
lack of vascularization has proved to be a significant challenge in BTE (Rouwkema 
et al., 2008; Rouwkema & Khademhosseini, 2016). The major problem is that 
nutrients and oxygen are able to diffuse at most to only at a maximum of 2 mm 
distance, meaning that cells implanted in larger constructs are left to die after 
implantation (Antonyshyn et al., 2019; Volz et al., 2016). Moreover, angiogenesis of 
vessels growing into the construct in the defect site is too slow to keep the implanted 
cells viable. Therefore, in vitro methods for vascularization are needed in large tissue 
engineered constructs for clinical applications as well as in in vitro models aiming to 
mimic live tissues. In addition, modification of materials by adding vasculogenic 
components, such as copper, is one option to improve vascularization in synthetic 
bone grafts (Wu et al., 2013). 
This thesis aims to study in vitro different cell culture methods and strategies, such 
as medium compositions and supplements, pre-differentiation strategies and co-
culture setups, to achieve more efficient and reliable osteogenic differentiation and 
vascularization in 3-dimensional (3D) culture. Furthermore, the potential of novel 
composites for BTE applications are evaluated in vitro and in vivo. This study provides 
insight on how the osteogenic differentiation and vascularization processes occur 
interlinked with different synthetic bone graft materials.  
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2 LITERATURE REVIEW 
2.1 Bone tissue 
The understanding of the structure and biology of native bone tissue constitute the 
basis for the field of BTE. Bone is a dynamic tissue with various functions, such as 
providing support and protection to our body, enabling moving together with 
muscles, maintaining mineral homeostasis, and homing the biological elements 
needed for hematopoiesis. (Amini et al., 2012). The pattern arrangement of bone 
tissue can be either compact (cortical bone) or trabecular (cancellous bone) with a 
wide range in mechanical strength and modulus. Moreover, the bone matrix is 
composed of an organic and inorganic part. The organic part of bone matrix is 
comprised of cells (osteoblasts, osteocytes, and osteoclasts), collagen (mainly 
collagen type I (COL-1)), proteins (osteocalcin (OCN), osteonectin, osteopontin, 
bone morphogenetic proteins (BMPs), bone sialoprotein II (BSP II)) and 
proteoglycans (Florencio-Silva et al., 2015). The inorganic part on the other hand, 
consist mostly of CaP minerals. The bone matrix has a profound role in regulating 
bone cell activity via adhesion molecules such as integrins (Florencio-Silva et al., 
2015). The combination of flexible collagen fibres reinforced by hydroxyapatite 
crystals makes bone a nanocomposite with good compressive strength and high 
fracture toughness (Amini et al., 2012).  
Osteoblasts are derived from BMSCs. The expression of transcription factors 
runt-related transcription factor-2 (Runx2), distal-less homeobox 5 (Dlx5) and, 
osterix (OSX) is essential for the osteogenic commitment of BMSCs. Mature 
osteoblasts synthesize the bone matrix in two phases: first osteoblasts secrete the 
organic matrix including collagen (mainly type I), osteogenic proteins (such as OCN, 
osteopontin, BSP II and osteonectin) and proteoglycan (Florencio-Silva et al., 2015). 
In the mineralization phase osteoblasts first release matrix vesicles containing 
calcium ions and, these vesicles bind to proteoglycans and other organic matrix 
elements (Florencio-Silva et al., 2015). Osteoblasts also secrete alkaline phosphatase 
(ALP) that keeps degrading phosphate containing compounds leading to the release 
of phosphate ions inside the matrix vesicles, leading to phosphate and calcium ion 
nucleation inside the vesicles forming hydroxyapatite (HA). Finally, the 
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supersaturation of these ions causes the rupture of the vesicles and the HA crystals 
are released into the extracellular matrix (Florencio-Silva et al., 2015). Mature 
osteoblasts can later either undergo apoptosis or, differentiate into osteocytes or, 
bone lining cells.  
Osteocytes are the most abundant cell type (90-95 %) in bone tissue. Osteocytes 
are situated inside the bone matrix and once a mature osteocyte has been closed into 
the bone matrix the expression of typical osteoblast markers is downregulated while 
the expression of osteocyte markers, such as sclerostin, is induced (Florencio-Silva 
et al., 2015). Tunnels named canaliculi, forming the osteocyte lacunocanalicular 
system (Florencio-Silva et al., 2015), connect osteocytes to each other. This system is 
also connected to blood vessels enabling the transport of nutrients and oxygen as 
well as cell signaling molecules (Florencio-Silva et al., 2015). Osteocytes have 
mechanosensitive functions affecting osteoblast-osteocyte bone formation 
(Florencio-Silva et al., 2015). 
Osteoclasts are crucial players in bone remodeling, as they can resorb bone. In 
contrast to osteoblasts, osteoclasts are differentiated from hematopoietic stem cells 
by influence of factors secreted by BMSCs, osteoblasts and osteocytes, such as 
macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear 
factor kappa-B (RANK) ligand (Florencio-Silva et al., 2015). In addition to bone 
resorption, osteoclasts have been shown to have regulatory functions with relation 
to osteoblasts and even hematopoietic stem cells (Florencio-Silva et al., 2015).  
2.1.1 Bone healing 
In contrast to any other tissue, bone has an innate capacity to regenerate and heal 
without the formation of scar tissue. The process of fracture healing can be divided 
in four overlapping phases (Fig. 1). As bone fractures, the trauma initiates 
inflammatory response and hematoma formation in the fracture site. The hematoma 
serves as the initial scaffold for the regeneration process and progenitor and 
inflammatory cells start to migrate into the fracture site where they are activated. The 
progenitor cells start to differentiate towards chondrocytes, which are the main 
players in the formation of cartilaginous soft callus containing mainly collagen and 
proteoglycans. Angiogenesis begins as blood vessels start to grow into the fracture 
site. After the formation of cartilaginous soft callus, the chondrocytes begin to 
undergo apoptosis. Additional progenitor cells are then recruited, and they start to 
differentiate towards osteoblasts. Osteoblast functions lead to the development of 
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hard callus formed of woven bone. Meanwhile the regeneration of vascular network 
continues. At the final stage, the bony callus is reshaped and remodeled by 
osteoclast-osteoblast activity and, eventually resulting in the original bone structure: 
cortical and trabecular arrangement with a marrow cavity. (Amini et al., 2012; Runyan 
& Gabrick, 2017.) 
 
Figure 1.  The different stages of bone healing after trauma. (Amini et al., 2012; Runyan & Gabrick, 
2017.) 
2.2 Vasculogenesis and angiogenesis 
In the development of vascularized BTE constructs, it is also important to appreciate 
the development of vascular networks. Natural vascular networks can form via two 
different processes: vasculogenesis or angiogenesis (Rouwkema & Khademhosseini, 
2016). Vasculogenesis occurs mainly during embryonic development where 
endothelial progenitor cells differentiate to ECs, which proliferate and organize in a 
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previously avascular tissue, forming a vascular network (Rouwkema & 
Khademhosseini, 2016). After extensive trauma, vasculogenesis may also occur in 
adult tissues, when bone marrow endothelial progenitor cells are recruited to the 
defect site where they undergo differentiation. However, most of the vascularization 
and vascular remodeling happen via angiogenesis. In angiogenesis, new vasculature 
forms from the already existing vessels, which is mainly induced by hypoxia in tissues 
(Rouwkema & Khademhosseini, 2016). Hypoxic conditions induce the secretion of 
growth factors and chemokines that stimulate ECs to migrate from the vessel walls 
to form new capillaries (Rouwkema & Khademhosseini, 2016). Under hypoxic 
conditions, a proangiogenic transcription factor hypoxia inducible factor-1 alpha 
(Hif-1α) is activated leading to the activation of numerous proangiogenic genes, such 
as VEGF (Kütscher et al., 2016). Then, when the oxygen level in the tissue rises, the 
migration of ECs ceases (Rouwkema & Khademhosseini, 2016). The development 
of capillaries may continue to arteriogenesis mainly regulated by fluid flow shear 
stress. Arteriogenesis is a maturation phase where the diameter and wall thickness of 
the vessels increase (Rouwkema & Khademhosseini, 2016). 
2.3 Cells and differentiation in bone tissue engineering 
2.3.1 Adult stem cells 
Nowadays, many researchers in varying fields have set their hopes on stem cells to 
provide a treatment or a disease model for their needs. Stem cells are defined as 
undifferentiated cells that have the capacity to both self-renew and differentiate 
towards more specialized cell lineages (Choumerianou et al., 2008). Stem cells may 
be classified according to their origin as embryonic, germinal or, somatic; or 
according to their differentiation potential as totipotent, pluripotent, multipotent or, 
unipotent (Choumerianou et al., 2008). A fertilized egg is totipotent with the capacity 
to differentiate towards all cell types including fetal membranes and placenta. 
Moreover, pluripotent stem cells can be harvested from the inner cell mass of a 
blastocyst with the potential to produce cells from all three germ layers 
(Choumerianou et al., 2008). In addition, pluripotent stem cells can be produced by 
reprogramming somatic cells into a pluripotent state using different methods, also 
known as induced pluripotent stem cells (iPSCs). However, while embryonic stem 
cells and iPSCs have close to an unlimited differentiation potential, their use is 
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restricted by ethical and political, as well as safety and efficacy issues (Lindroos et al., 
2011). Adult stem cells are multipotent stem cells with a limited differentiation 
capacity, and unipotent stem cells are progenitor cells that only differentiate towards 
one cell type (Choumerianou et al., 2008). 
Mesenchymal stem cells 
Adult stem cells are progenitor cells residing in specialized tissues. Mesenchymal 
stem cells (MSCs) are defined as adult stem cells originating from mesenchymal 
tissues, such as adipose tissue, bone marrow, skeletal muscle tissue, synovial 
membranes, dental pulp, cervical tissue, umbilical cord blood, dermal tissue, and lung 
tissue (Mushahary et al., 2018; Ozkul & Galderisi, 2016). As MSCs lack a specific cell 
surface marker, the recognition of MSCs during isolation is challenging and 
inconsistent. In order for more uniform cell characterization, the International 
Society for Cellular Therapy (ISCT) has generated minimal criteria to identify MSCs: 
(1) cells must be plastic-adherent in standard culture conditions; (2) cells must 
express surface markers cluster of differentiation (CD)105, CD73, and CD90, and 
lack the expression of CD45, CD34, CD14 or CD11b, CD79α or CD19, and HLA-
DR and; (3) cells must differentiate into osteoblasts, adipocytes and chondrocytes in 
vitro (Dominici et al., 2006). However, MSCs that meet the above criteria have still 
been shown to represent a heterogeneous cell population with varying phenotype 
and functionality (Mo et al., 2016; Mushahary et al., 2018; Strioga et al., 2012; Tormin 
et al., 2009). Moreover, in some studies a morphologically uniform cell population 
with uniform surface marker expression has been obtained by long culture period 
on plastic for several passages most likely effecting the cell properties (Mo et al., 
2016). 
The differentiation of MSCs is most commonly induced by adding supplements, 
such as growth factors, into the culture medium. In addition, differentiation can be 
induced with mechanical signals like vibration loading (Tirkkonen et al., 2011) and 
stretching (Charoenpanich et al., 2011; Virjula et al., 2017) or, with electrical signals 
(Björninen et al., 2017). Traditionally MSCs have been considered to differentiate 
towards mesenchymal cell lineages, such as adipocytes, osteoblasts and 
chondrocytes. However, MSCs have been shown to differentiate also towards cell 
lines originating from endo- or ectoderm (Mo et al., 2016), such as pancreatic cells 
(Chandra et al., 2009), neuronal cells (Zheng et al., 2017) and, ECs (Miranville et al., 
2004; Planat-Benard et al., 2004). In addition, MSCs originating from different tissues 
have presented varying differentiation potential. For instance, ASCs and BMSCs 
have been demonstrated to differ in differentiation capacity, some studies suggesting 
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that ASCs differentiate more efficiently towards osteogenic lineage in bioactive glass 
(BaG) based scaffolds in contrast to BMSCs (Rath et al., 2016), or that ASCs possess 
better neuronal capacity in comparison to BMSCs (Zheng et al., 2017). However, the 
culture conditions, differentiation protocols and used biomaterials vary greatly 
between studies and these elements effect significantly to the fate of these cells 
(Kyllönen et al., 2013; Strioga et al., 2012). Moreover, Guneta et al. (2016) concluded 
that the microenvironment in vitro also guides the differentiation: when ASCs and 
BMSCs were seeded on adipose tissue (extra cellular matrix (ECM) -coated surface, 
both cell types differentiated towards adipogenic lineage. However, in a 3-
dimensional (3D) environment without biological signals ASCs differentiated 
towards adipogenic lineage and BMSCs towards osteogenic lineage, suggesting that 
the cells display an inherent predisposition towards the lineage defined by their 
native niche (Guneta et al., 2016). In addition, matrix stiffness has been shown to 
affect human adipose stem cells (hASC) and human BMSC (hBMSC) differentiation 
(Wen et al., 2014). 
Because of the variation between MSCs derived from different tissues there has 
been debate about the use of the term MSC. Robey (2017) pointed out that not all 
different MSCs have a common embryonic origin and even though these tissue 
specific progenitor cells have similar cell surface characteristics, they are not 
identical. Therefore, it has been suggested that the terminology concerning these 
cells should be based on the tissue of their origin, such as ASC or BMSC, rather than 
using the term MSC (Robey, 2017). Regardless of the more limited differentiation 
potential of MSCs, they have many desirable characteristics, as there are no ethical 
or political issues related to their isolation and use in contrast to embryonic stem 
cells and they are more stable and safer in contrast to genetically manipulated iPSCs. 
Stem cells from adult tissues include a wide range of progenitor cells with different 
subpopulations expressing varying functionality and phenotype (Mo et al., 2016) 
therefore providing alternatives for many different applications.  
2.3.2 Adipose stem cells 
Adipose tissue is a highly active metabolic and endocrine organ of mesodermal 
origin. Zuk et al. (2001) were the first to report that an MSC population later named 
ASCs can be isolated from the stromal vascular fraction (SVF) based on their ability 
to attach on plastic. SVF is an aqueous fraction derived from adipose tissue by 
enzymatic digestion and it contains various cell types, such as pre-adipocytes, ASCs, 
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ECs and their precursors, macrophages, lymphocytes, smooth muscle cells and 
pericytes (Bora & Majumdar, 2017; Semon et al., 2013; You et al., 2015). SVF has also 
attracted attention in the field of regenerative medicine and the advantage in SVF 
over ASCs lays in the easier acquirement since there is no need for cellular 
separation. In addition, the more heterogeneous cell population of SVF in contrast 
to ASCs may be a reason for the better outcomes in comparative animal studies 
(Bora & Majumdar, 2017; You et al., 2015; Semon et al., 2013). However, the 
heterogeneous cell population is also a limiting factor as SVF contain cell types 
known to cause immune reactions and in contrast to ASCs, is therefore suitable only 
for autologous treatments (Bora & Majumdar, 2017). 
Adipose tissue has become a very popular adult stem cell source for research 
purposes since adipose tissue is an abundant and easily accessible cell source and, 
can be harvested with minimal donor site morbidity (Bajek et al., 2016; Lindroos et 
al., 2011).  Moreover, the yield of ASCs from an adipose tissue sample can be as high 
as 34.4 million cells from 100 ml of lipoaspirate (West et al., 2016) and they are stable 
with minimal chromosomal alterations in in vitro culture (Meza-Zepeda et al., 2008). 
Since clinical treatments usually require a vast number of cells, the high isolation 
yield and stability in in vitro culture make ASCs a promising option also for clinical 
applications (Bajek et al., 2016). 
Adipose stem cell characteristics and culture 
ASCs are characterized after isolation usually according to the aforementioned 
minimal criteria suggested for MSCs by the ISCT (Bourin et al., 2013; Dominici et al., 
2006). Shortly, the cells need to attach on plastic and differentiate towards 
osteogenic, adipogenic and chondrogenic lineages and, the cells need to express a 
specific surface marker profile. The surface marker profile of ASCs differs slightly 
from other MSCs; the differences in the surface marker profiles between ASCs and 
BMSCs, are listed in Table 1. ASCs are positive for markers CD13, CD73, CD90, 
CD105 and lack the expression of CD11b, CD31, CD45 and, CD106 (Bourin et al., 
2013). The expression of CD34 in ASCs varies a lot depending on culture conditions; 
it is expressed usually in low passage ASCs, the expression declining with continued 
cell division (Bourin et al., 2013). Markers CD10, CD36 and CD106 can be used in 
addition to the other markers to better distinguish ASCs from BMSCs, as in contrast 
to BMSCs, CD10 and CD36 are expressed in ASCs whereas CD106 is not (Bourin 
et al., 2013). However, similarly to other characteristics of these cells, also the surface 
marker profile is affected by culture conditions, such as the serum type in the culture 
medium (Patrikoski et al., 2013). 
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Another appealing feature in ASCs is their immunomodulatory and 
immunosuppressing nature. McIntosh and colleagues (2006) demonstrated that 
ASCs have an immunosuppressive profile in vitro, and later ASCs have been shown 
to be immunosuppressive also in vivo (H. Y. Cheng et al., 2014). However, the 
immunogenicity of ASCs may decrease with passaging of the cells (McIntosh et al., 
2006) and with the differentiation of the cells (Niemeyer et al., 2007). Overall, the 
immunosuppressive nature of ASCs makes these cells good candidates for allogenic 
cell transplantation (Niemeyer et al., 2008). Allogenic use of ASCs is also supported 
by the fact that the characteristics, such as proliferation and differentiation capacity, 
of these cells are significantly affected by donor site variability (Cleal et al., 2017) as 
well as donor sex (Aksu et al., 2008), age (Alt et al., 2012; Choudhery et al., 2014) and 
body mass index (Frazier et al., 2013). Therefore, in comparison to autologous 
treatments, it would be more feasible to select a donor cell line with desirable and 
well-characterized qualities for the treatment of numerous patients (Patrikoski et al., 
2019).  
Table 1.  A comparison between ASC and BMSC characteristics (Burrow et al., 2017; 
Vangsness et al., 2015; Bourin et al., 2013). 
    
Adipose stem cells 
(ASCs) 
Bone marrow stem cells 
(BMSCs) 
Isolated from stromal vascular fraction (SVF) bone marrow mononuclear cell fraction 
Positive markers > 70 % CD10, CD13, CD73, CD90, CD105 CD13, CD73, CD90, CD105 
Moderate markers > 30-70 % CD36 CD106 > 2-30 % CD34, CD106 CD10 
Negative markers < 2 % CD11b, CD31, CD45, CD106 CD11b, CD34, CD36, CD45 
Yield  from 1 mL of tissue: 4 737 - 1 550 000 cells 
from 1 mL of tissue: 
30 – 317 400 cells 
Senescence  reached with higher population doublings 
reached with lower population 
doublings 
The culture conditions of ASCs vary between studies, which makes the comparison 
and translation of results challenging. The ASC expansion conditions need to 
support the proliferation but not the differentiation of ASCs whereas; the 
differentiation conditions are designed to induce the desired cell fate effectively.  The 
basic ASC culture medium generally consist of basic medium, such as alpha-modified 
Eagle’s medium (α-MEM) or Dulbecco’s modified Eagle’s medium/Ham’s F12 
(DMEM/F-12) with 10 % of serum (Bajek et al., 2016; Patrikoski et al., 2019). Fetal 
bovine serum (FBS) is widely used in ASC culture however, when the aim is to 
translate the results to the design of cell therapies, it would be more relevant to use 
human serum (HS), xeno-free serum or platelet lysate in the culture of human ASCs 
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(hASCs). In fact, the serum conditions have been shown to affect hASC proliferation 
and differentiation significantly (Kyllönen et al., 2013; Patrikoski et al., 2013), 
indicating the importance of choosing a relevant serum type for the purposes of the 
study. Moreover, when culturing ASCs for cell therapies, all animal-based 
supplements should be replaced with xeno-free substitutes to avoid infections 
(Patrikoski et al., 2019). 
2.3.3 Bone marrow stem cells 
Bone marrow is a soft, semi-solid tissue in the medullary cavities of large bones. 
Friedenstein and colleagues (1968) were the first to report that in addition to 
hematopoietic stem cells, bone marrow also contain a stem cell population able to 
give rise to bone, first referring to these cells as osteogenic progenitor cells. They 
also demonstrated the basis for mesenchymal stem cell isolation procedure 
(Friedenstein et al., 1968). The name MSC came to use only in 1991 when Caplan 
and colleagues (1991) suggested the term based on the differentiation potential of 
these cells towards multiple mesenchymal cell types. 
Bone marrow stem cell characteristics and culture 
BMSCs are isolated from bone marrow mononuclear cell fraction, which is harvested 
in a bone marrow aspiration procedure most commonly from the iliac crest under 
general anesthesia. This is a painful procedure for the patient with the risk of donor 
site morbidity. The amount of harvested aspirate is small and the BMSC yield from 
1 ml of bone barrow is only 30 – 317 400 cells (Vangsness et al., 2015), which is 
significantly lower than that of ASCs. Similarly, to ASCs, also BMSCs are 
characterized after isolation according to the aforementioned criteria set by the ISCT 
(Bourin et al., 2013; Dominici et al., 2006). The slight differences between ASC and 
BMSC surface marker expression profiles are presented in Table 1. BMSCs have 
been shown to be less stable in long time cell culture (Dahl et al., 2008) and reach 
senescence with lower population doubling number than ASCs (Burrow et al., 2017; 
Vidal et al., 2012). Burrow and colleagues (2017) compared patient matched hASCs 
and hBMSCs and demonstrated that although both cell types display deteriorated 
characteristics in extended in vitro culture, hASCs maintain their proliferation and 
differentiation capacity longer in comparison to hBMSCs. Altogether, hASCs seem 
to be a more attractive choice for clinical applications when compared to hBMSCs. 
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However, BMSCs are a highly relevant cell type especially in bone regeneration 
research, as their native niche is in bone. 
Sotiropoulou and colleagues (2006) tested various medium compositions in 
BMSC culture and concluded that αMEM with 10 % FBS, supplemented with 
GlutaMAX and fibroblast growth factor-2 (FGF-2), is the most optimal to maintain 
BMSC proliferation and differentiation capacity during expansion. FGF-2 is used in 
the BMSC culture to induce proliferation and to maintain differentiation capacity 
(Sotiropoulou et al., 2006; Tonti & Mannello, 2008). However, FGF-2 
supplementation has been evidenced to affect differentiation potential of BMSCs, as 
it increases osteogenic and slightly adipogenic differentiation capacity of BMSCs 
(Sotiropoulou et al., 2006). In addition, BMSC characteristics, proliferation and 
differentiation capacity have been shown to be affected by different serum 
conditions (Dahl et al., 2008; Tonti & Mannello, 2008).  
2.3.4 Osteogenic differentiation 
The process of osteogenic differentiation in vitro can be divided into three 
overlapping phases (Fig. 2). Firstly, the osteogenic progenitor cells undergo a 
proliferation phase. Proliferation is highly important since individual cells cannot 
produce bone and osteoblasts that secrete the mineralized ECM need a 3D 
environment (Blair et al., 2017). The cell density needs to be high when cells are 
cultured on plastic in order for the differentiating cells start to form bone in a nodular 
form, creating their own 3D microenvironment (Blair et al., 2017). The expression 
of Runx2 is essential for the osteogenic differentiation to occur, as Runx2-/- mice 
have been shown to totally lack osteoblasts (Komori et al., 1997). During the 
proliferation phase, also the expression of COL-1 and osteopontin are upregulated. 
As cell proliferation declines, cell differentiation proceeds into the matrix maturation 
phase. COL-1 is still produced and secreted into the extracellular space and ALP 
activity is significantly upregulated (Lian & Stein, 1995). OSX expression also follow 
the proliferation phase as it has been shown to act downstream of Runx2 (Almalki 
& Agrawal, 2016). Furthermore, the secretion of OSX is also essential for the 
mineralization as in the absence of OSX, ossification does not occur (Nakashima et 
al., 2002). In addition, for the osteogenic differentiation to proceed, the Runx2 
expression need to go down as the high Runx2 expression has been demonstrated 
to inhibit mineralization, leaving the cells in a premature stage (Komori, 2017). As 
the process proceeds to the mineralization phase, collagenase expression peaks (Lian 
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& Stein, 1995). Collagenase is needed in the remodeling of the forming bone matrix. 
As mineralized matrix starts to accumulate, also several proteins typical to bone, such 
as bone sialoprotein, OCN and osteopontin, can be detected in the ECM (Lian & 
Stein, 1995). The expression of osteopontin is upregulated in proliferation phase, 
and then it declines and again peaks during mineralization (Lian & Stein, 1995). 
OCN, on the other hand, is only expressed by mature osteoblasts (Lian & Stein, 
1995). The expression of homeobox protein DLx5 coincides with the expression of 
OCN and DLx5 has been shown to induce mineralization (Lee et al., 2005). 
 
 
Figure 2.  Graphical description of the osteogenic differentiation phases and the most important 
osteogenic markers expressed during different phases of differentiation. Arrows indicate 
gene expression (up-regulation↑, down-regulation↓). (Almalki & Agrawal, 2016; Blair et al., 
2017; Komori, 2017; Lian & Stein, 1995.) 
Growth factors 
Bone formation in the body is regulated via various osteogenic factors secreted by 
the cells and tissues and many of these factors (such as BMP-2, BMP-7 and VEGF) 
have been used to induce osteogenesis (Gothard et al., 2014). BMPs are a group of 
cytokines in the transforming growth factor-β superfamily (Bessa et al., 2008). BMPs 
form a complex with type I and II serine/threonine kinase receptors and these 
receptors are responsible for phosphorylating receptor-mediated mothers against 
decapentaplegic homolog protein (SMAD)-proteins (Vanhatupa et al., 2015; Y. K. 
Wang et al., 2012). SMAD-proteins on the other hand are transcriptional regulators 
of DNA-binding genes, such as Dlx2 and -5 as well as OSX (Vanhatupa et al., 2015; 
Y. K. Wang et al., 2012). Recombinant human BMP-2 (rhBMP-2) has been used in 
the osteogenic induction in vitro (Vanhatupa et al., 2015; Waselau et al., 2012b), in vivo 
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(Waselau et al., 2012a) and in clinical treatments (Sandor et al., 2014). In addition, the 
effect of BMP-7 on bone formation has been studied in vitro, in vivo and in clinical 
treatments (Haubruck et al., 2018). Haubrauck and colleagues (2018) concluded that 
patients who were treated with rhBMP-2 for tibial nonunion had a significantly 
higher rate of bone healing in comparison to patients treated with rhBMP-7. 
Furthermore, in addition to promoting vascularization, the potential of VEGF to 
induce osteogenesis has been studied in vitro and in vivo (Zhang et al., 2014; Behr et 
al., 2011). Zhang and colleagues demonstrated that localized VEGF and BMP-2 
release induce bone formation via mobilizing and homing of endogenous stem cells 
(Zhang et al., 2014).  
In 2002, the U.S. Food and Drug Administration (FDA) approved two clinical 
products with recombinant BMP-2 and BMP-7 in resorbable collagen scaffolds 
intended for spinal fusion and non-unions in long bones (Bessa et al., 2008). 
However, the large and costly doses of growth factors used in clinical treatments 
have been shown to be related to a wide range of adverse effects (Bodalia et al., 2016; 
Carragee et al., 2011). Even though the industry sponsored clinical trials concerning 
the use of rhBMP-2 reported no adverse events, in 2006 studies started reporting of 
serious complications associated with rhBMP-2 use in different study settings, 
including osteolysis, carcinogenesis, nerve root injury and retrograde ejaculation 
(Carragee et al., 2011). Carragee and colleagues (2011) concluded that the studies 
regarding the safety and efficacy of rhBMP-2 underestimated the adverse effects of 
the product and noticed concerns in conflicts of interest in each of the original 
industry-sponsored publications (Carragee et al., 2011). Nevertheless, rhBPM-2 is 
still considered a suitable and effective bone graft option for adults suffering for 
intance from lumbar pseudarthrosis requiring a revision spinal fusion surgery when 
autologous bone graft is not available (Bodalia et al., 2016; Gothard et al., 2014). 
However, the case of BMP-2 underlines the need for more cost-effective and safer 
osteoinductive approaches. 
Osteogenic medium 
The osteogenic differentiation of both ASCs and BMSCs in vitro is most commonly 
induced using three supplements added into the culture medium: ascorbic 
acid/ascorbic acid-2-phosphate (AA2P), β-glycerophosphate (β-GP) and 
dexamethasone (Dex). The most commonly used composition for osteogenic 
medium (OM) originally developed for BMSC differentiation consist of basal 
medium with 50 μM of AA2P, 100 nM of Dex and 10 mM of β-GP (Coelho & 
Fernandes, 2000). Kyllönen and colleagues, (2013) compared three different OM 
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compositions in hASC differentiation with 10 mM β-GP concentration and varying 
AA2P and Dex concentrations: OM1 as the composition commonly used in BMSC 
differentiation (50 μM AA2P, 100 nM Dex;), OM2 (150 μM AA2P, 10 nM Dex) and 
OM3 (250 μM AA2P, 5 nM Dex). Interestingly, hASCs differentiated more 
effectively towards osteogenic lineage in OM3, which has a higher AA2P and a lower 
Dex concentration when compared to the commonly used OM1 composition 
(Kyllönen et al., 2013). The mode of action of these supplements is well intertwined 
as they induce osteogenesis most effectively when used together. β-GP contributes 
to mineralization through the activity of ALP, as ALP is an enzyme cleaving 
phosphate groups from the added β-GP (Coelho & Fernandes, 2000). Ascorbic acid 
is important for the correct folding of collagens and it also enhances the secretion 
of COL-1 into the ECM, which is highly important for the differentiation to 
proceed.  In turn, Dex is a synthetic glucocorticoid inducing proliferation (Coelho 
& Fernandes, 2000) as well as the transcription of Runx2, which is an essential 
transcription factor in osteogenic differentiation (Langenbach & Handschel, 2013). 
However, even though glucocorticoids have been shown to have an effect on 
transcription factor expression and ALP activity (Blair et al., 2017), bone matrix 
development has been noticed to be more pronounced without glucocorticoids in 
hBMSC culture (Blair et al., 2017; Chang et al., 2006). This may be one reason for 
why the lower Dex concentration resulted in a better osteogenic outcome with 
hASCs in the study of Kyllönen et al. (2013). Furthermore, as Dex induce the 
expression of Runx2 which in fact need to decline for the osteogenic maturation to 
proceed, it is tempting to speculate whether Dex would be beneficial in the beginning 
of the differentiation and its elimination from the OM composition after the 
initiation of the osteogenic differentiation would benefit the in vitro process. 
2.3.5 Identification of osteogenic differentiation 
Reliable verification of osteogenic differentiation is essential in in vitro studies 
concerning BTE. Analysis of ALP activity is one of the most common markers used 
to confirm osteogenic differentiation. Even though, ALP activity up-regulation is 
typical in osteogenic differentiation (Lian & Stein, 1995), ALP activity is not unique 
for osteoblasts as it is also detected in other tissues such as liver and kidney (Whyte, 
2016). Another widely used method to confirm osteogenic differentiation is the 
staining of mineralized matrix with either alizarin S or Von Kossa stain. Staining of 
mineralized matrix is a well-established indicator of osteogenic differentiation 
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however, they are not specific for osteogenic mineralization. Both stains bind to 
calcium minerals but they cannot distinguish between different calcium deposits: in 
addition to mineralization resulting from osteogenic differentiation, calcification of 
cell cultures can be caused by dead cells and, non-apatitic mineralization can be a 
result of the osteogenic supplement β-GP accumulation (Robey, 2017; Langenbach 
& Handschel, 2013; Bonewald et al., 2003). Gene expression analysis of osteogenic 
marker genes is a reliable and widely used method in the verification of 
differentiation as well. Nevertheless, gene expression analysis should be coupled with 
protein level analysis, since the mRNA translation in osteogenic differentiation has 
been shown to be regulated and directly inhibited by microRNAs (Lian et al., 2012). 
Immunocytochemical staining of osteogenic marker proteins is a reliable, qualitative 
method for confirming the osteogenic differentiation, if negative and positive 
controls are used in the process to exclude unspecific staining. Even though the 
detection of early osteogenic markers, such as ALP activity or Runx2 gene 
expression, suggest osteogenesis, the formation of collagenous mineralized matrix 
with the expression of markers only expressed by mature osteoblasts, such as OCN 
or DLx5, are the best indicators of successful osteogenesis. In summary, the 
detection of osteogenic differentiation is the most reliable when various analysis 
methods are used together, and the differentiation is demonstrated on both gene and 
protein level in addition to the formation of mineralized bone matrix. 
2.3.6 Endothelial differentiation 
In vasculogenesis, the differentiation of endothelial progenitor cells into ECs give 
rise to a vascular network. As endothelial progenitor cells differentiate to ECs, they 
start to express endothelial proteins, such as vascular endothelial growth factor 
receptor 2 (VEGFR-2), vascular endothelial cadherin (also known as CD144), von 
Willebrand factor (vWF) and platelet endothelial cell adhesion molecule-1 (PECAM-
1, also known as CD31) (Hristov et al., 2003). vWF is a glycoprotein secreted by ECs 
and megakaryocytes (Sadler 1998). PECAM-1 is highly expressed by ECs in the cell-
cell junctions where it has an important role regulating the EC vascular permeability 
barrier (Lertkiatmongkol et al., 2016). 
The capacity of ASCs to undergo endothelial differentiation was demonstrated 
already in 2004 (Miranville et al., 2004; Planat-Benard et al., 2004) but still the 
endothelial differentiation and development of vasculature are not as well known as 
osteogenic differentiation and there is no established protocol for the differentiation 
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of MSCs into ECs. Both FGF-2 and VEGF are important signaling molecules in 
mature EC survival, proliferation and migration (Cross & Claesson-Welsh, 2001). 
They have also been suggested to be the key signaling molecules in endothelial 
differentiation however; their mode of action is less understood (Marcelo et al., 
2013). Therefore, VEGF (S. Khan et al., 2017; Kukumberg et al., 2017; Zonari et al., 
2012; Colazzo et al., 2010) and FGF-2 (S. Khan et al., 2017; Kukumberg et al., 2017; 
Marino et al., 2012) and their combination have been used in the endothelial 
differentiation of MSCs in vitro. The most used commercial medium in endothelial 
differentiation is Endothelial Growth Medium-2 (EGM-2) from Lonza originally 
meant for the culture of mature ECs (Antonyshyn et al., 2019; Correia et al., 2014), 
which consist growth factors epidermal growth factor (EGF), VEGF and R3 insulin-
like growth factor-1 (R3-IGF-1) as well as hydrocortisone, ascorbic acid and heparin 
with 2 % FBS and antibiotics. In addition to supplements added into the medium, 
also shear stress have been shown to guide BMSCs towards an endothelial lineage 
(M. Cheng et al., 2013; L. Yuan et al., 2013; Dong et al., 2009) however, it has been 
suggested that MSCs need VEGF supplementation in addition to shear stress for 
sufficient endothelial induction (Dan et al., 2015). Furthermore, topographical cues 
combined with VEGF stimulus have been demonstrated to induce endothelial 
differentiation of hBMSCs (Kukumberg et al., 2017).  
Khan and colleagues (2017) studied the effect of VEGF or FGF-2 and their 
combination in the endothelial differentiation of hASCs. They concluded that 
hASCs cultured in medium supplemented with both VEGF and FGF-2 induced the 
differentiation more towards an endothelial type in contrast to hASCs supplemented 
only with VEGF or FGF-2 alone (S. Khan et al., 2017). Moreover, they also reported 
that FGF-2 and VEGF/FGF-2 groups resulted in a more robust differentiation of 
hASCs in comparison to widely used EGM-2 (S. Khan et al., 2017). Interestingly, 
Antonyshyn and colleagues (2019) reported that hASCs do not differentiate into 
mature ECs in the widely used EGM-2 from Lonza. They compared the EGM-2 
differentiated hASCs to ECs derived from umbilical vein, coronary artery and dermal 
microvasculature, and concluded that even though endothelial protein and gene 
marker levels were up-regulated in hASCs, the levels were still significantly lower in 
contrast to the ECs (Antonyshyn et al., 2019). Most of the endothelial differentiation 
studies using human cells are conducted in FBS based media (Antonyshyn et al., 
2019; S. Khan et al., 2017; Kukumberg et al., 2017; Correia et al., 2014). However, 
since proliferation and differentiation of hASCs (Kyllönen et al., 2013; Patrikoski et 
al., 2013) and hBMSCs (Dahl et al., 2008; Tonti & Mannello, 2008) have been shown 
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to be affected by serum conditions, the study of endothelial differentiation of human 
MSCs in HS based media would be important. 
2.3.7 Identification of endothelial differentiation 
Endothelial differentiation is most commonly verified by immunocytochemical 
staining of endothelial marker proteins, such as vWF and PECAM-1, as well as on 
gene expression level of the corresponding endothelial genes. Furthermore, ECs’ 
functionality can be evaluated by a fluorescent-based acetylated low-density 
lipoprotein (AcLDL) uptake assay. (Antonyshyn et al., 2019.) The assay is based on 
ECs’ ability to uptake the fluorescent-labelled AcLDL inside them and these cells 
can be imaged with a fluorescence microscope or quantified with flow cytometry. 
The formation of tubular structures is typical to mature ECs. The formation of 
tubular structures may be seen in immunocytochemical staining of endothelial 
marker proteins but also a sprouting assay can be used, where cells are seeded in a 
basement membrane-like material, such as Matrigel®, where mature ECs start to 
form tubular structures. The evaluation of EC functionality and tubular formation 
ability are highly important in addition to endothelial protein and gene expression 
analyses in order to demonstrate the maturity of the cells reliably. However, it has 
been suggested that the commonly used endothelial markers are not specific enough, 
making the verification of endothelial differentiation challenging (Antonyshyn et al., 
2019).  
2.3.8 Human umbilical vein endothelial cells modelling vasculogenesis 
Human umbilical vein endothelial cells (HUVECs) are commonly used to model 
ECs. In BTE, HUVECs have been used especially in the study and development of 
vascularized constructs. One reason for this is that umbilical veins are easily 
accessible for cell harvesting in contrast to other veins (Cao et al., 2017). Another 
reason for the use of HUVECs as a model EC type in research is that they have been 
shown to express endothelial markers and signaling molecules typical to ECs (Cao et 
al., 2017). Furthermore, HUVECs are able to form vascular structures in vitro both 
alone (Da Pozzo et al., 2012) and in co-culture with MSCs (Correia et al., 2011; 
Tsigkou et al., 2010), as well as in vivo (Pirraco et al., 2014). Moreover, they have been 
demonstrated to be responsive to typical EC stimuli such as shear stress and hypoxia 
(Lewis et al., 2015). This also makes HUVECs a reliable positive control cell type in 
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endothelial differentiation studies. However, there are differences for instance in 
protein expression between ECs isolated from different sites as demonstrated by 
Antonyshyn and colleagues (2019) and this should be taken into account when 
choosing an EC model. 
2.4 Biomaterials in bone tissue engineering 
The requirements for a synthetic bone graft are high, as the ideal scaffold should 
mimic the properties of natural bone tissue.  Firstly, the scaffold needs to be 
biocompatible with non-toxic degradation products and non-inflammatory 
components (Turnbull et al., 2017). In addition, the ideal scaffold is biodegradable 
facilitating the formation of bone ECM as the scaffold degrades and is finally 
replaced by the host tissue (Turnbull et al., 2017). Importantly, the degradation 
process should be controlled as a too fast process can lead to mechanical failure of 
the implant and in contrast, a too slow degradation process may cause an 
inflammatory response towards the implant material (Turnbull et al., 2017). 
Tissue attachment is related to the tissue response caused by the implanted 
material and all materials induce a response in living tissues when implanted into the 
body (Hench, 1991). A toxic material causes the surrounding tissues to die whereas, 
a biologically inactive (nearly inert) material induce the formation of a fibrous capsule 
around itself (Hench, 1991). On the other hand, a biologically active (bioactive) 
material can bond directly with the living tissue (Hench, 1991). Furthermore, bone 
tissue can grow on the surface of an osteoconductive material whereas an 
osteoinductive material induce bone formation even in an ectopic implant site 
(Jones, 2013). Therefore an ideal orthopedic implant should be bioactive, 
osteoconductive and preferably osteoinductive (Turnbull et al., 2017) as well as 
support vascularization (Amini et al., 2012). In fact, Bohner and Miron (2019) 
reviewed the body of literature related to osteoinductive materials and proposed a 
mechanism for materials intrinsic osteoinduction. The authors  suggested that the 
materials intrinsic osteoinductivity is a result of the formation of a biomimetic apatite 
layer on the material surface, optimal scaffold architecture (total porosity, macro- 
and microporosity) to allow blood vessel ingrowth and cell migration and finally, of 
insufficient blood supply to allow a decreased calcium and phosphate ion 
concentration (Bohner & Miron, 2019). However, the specific biological mechanism 
of osteoinduction remains unclear. 
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2.4.1 Scaffold requirements 
The structural demands of a bone substitute include high interconnected porosity 
(porosity for native bone: 60 – 90 %) with the optimal pore size varying between 
150-400 μm to allow cell and tissue ingrowth as well as vascularization (Mathieu et 
al., 2005; Rouwkema et al., 2008; Turnbull et al., 2017).  Furthermore, microporosity 
(pores < 10 μm) of the scaffold induce the surface area for the cells (Turnbull et al., 
2017) and have been shown to improve the osteogenic outcome in vivo (Habibovic 
et al., 2005). Unfortunately, the high porosity is in direct conflict with the mechanical 
stiffness of an implant as the mechanical strength of the material decreases as the 
total porosity rises. Parameters usually used to asses a bone substitute’s mechanical 
integrity include Young’s modulus (also elastic modulus) which describes the 
stiffness of the material. Compressive strength on the other hand is a parameter 
describing the capacity of a material to withstand load that tend to reduce its size. In 
addition, fatigue strength can be used to describe the highest stress a material can 
withstand without breaking. (Turnbull et al., 2017.) For cortical bone the Young’s 
modulus is 7-30 GPa with a compressive strength of 100-230 MPa whereas for the 
porous trabecular bone the Young’s modulus is 0.05-0.5 GPa with a compressive 
strength of 2-12 MPa (Kokubo et al., 2003). The mechanical properties of human 
bone are compared to synthetic bone graft materials in Table 2. 
Table 2.  Mechanical properties of synthetic bone graft materials and human bone. 
Hydroxyapatite (HA); Polycaprolactone (PCL); Polylactide (PLA); Poly(lactide-co-
caprolactone) (PLCL); Bioactive glass (BaG) 
    Compressive strength (MPa) 
Young's 
modulus (GPa) Reference 
Bioglass® 45S5 - 35 (Kokubo et al., 2003) 
Bioglass® 45S6 (porous) 0.3-0.4 - (Chen et al., 2006) 
HA (porous)   6.9-68.9 - (Owen et al., 2018) 
chronOS® (porous β-TCP 
granule) ~5 - 
chronOS product guide (De 
Puy Synthes) 
PCL (porous) 2-3.2 0.052-0.067 (Williams et al., 2005) 
PLA   57.7-70.6 3.4-4.2 (Sarasua et al., 2005) 
PLCL+ 50 wt-% BaG - 0.09 (Tainio et al., 2017) 
Human 
bone 
Trabecular 2-12 0.05-0.5 (Kokubo et al., 2003) Cortical 100-230 7-30 
 
The user-friendliness and easy intra-operative tailoring are yet another significant 
factor in the development of a bone substitute, as the surgeon is the one who 
chooses the implant material and not the patient. From an industrial point of view, 
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large-scale manufacturing with reasonable costs and a long shelf life would also be 
desirable traits for a bone substitute (Amini et al., 2012). As a result of this long list 
of demands, the development of a bone substitute often requires some 
compromising between achieving an optimal cell and tissue response, architecture 
as well as mechanical integrity. 
2.4.2 Calcium phosphates 
Calcium phosphates (CaPs) are a widely used bioactive biomaterial type in BTE 
because they are so like the native bone mineral. CaPs are crystalline, bioactive and 
osteoconductive bioceramics with good corrosion resistance. However, they are 
hard and brittle making them challenging to tailor and undesirable for load-bearing 
sites (Turnbull et al., 2017). CaP ceramics commonly comprise of hydroxyapatite 
(HA) or tricalcium phosphate (TCP) or both known as biphasic CaP (BCP) 
(Campana et al., 2014; Turnbull et al., 2017). Beta-TCP (β-TCP) on the other hand 
has a significantly higher degradation rate in contrast to HA, which is the most stable 
and least soluble of CaPs (Samavedi et al., 2013). Different CaPs have been 
successfully used to treat patients(Prins et al., 2016; Sandor et al., 2014; Mesimäki et 
al., 2009) and there are many CaPs among clinically used bone fillers, such as 
Endobon® HA granules from Zimmer Biomet Dental, chronOS® β-TCP granules 
from De Puy Synthes and, BoneCeramic® HA/β-TCP (60/40%) granules from 
Straumann. 
Osteoinductivity 
Whereas the osteoconductivity of CaPs is clear, there are contradicting results 
concerning the osteoinductive properties of CaPs (Owen et al., 2018). A few in vitro 
studies have demonstrated the induction of osteogenic markers in hASCs cultured 
on β-TCP (Marino et al., 2010) and of hBMSCs cultured on HA (Muller et al., 2008) 
even without the addition of osteogenic supplements. Some studies have also 
demonstrated the osteoinductive properties of CaPs in vivo (Duan et al., 2017; L. 
Wang et al., 2014; Kondo et al., 2006). The osteoinductive properties of CaPs are 
based on the ions released from the material as well as on focal adhesion mediated 
signals arising from protein adsorption and cell attachment (Samavedi et al., 2013; 
Muller et al., 2008) however, the ion dissolution from CaPs is relatively slow when 
compared to that from BaGs. Fig. 3 gives an overview on the different material 
features affecting the biological processes on the surface of CaPs. The 
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osteoinductive capacity of CaPs has been shown to be influenced by the 
macrostructure (dimension, geometry, and porosity), micro- and nanostructure 
(microporosity, grain size, surface topography) as well as by the chemical 
composition of the CaP (Chai et al., 2012). 
 
Figure 3.  CaP characteristics effecting protein adsorption, cell adhesion and differentiation, adapted 
from Samavedi et al. (2013). 
Duan and colleagues (2017) compared the ectopic bone formation capacity of six 
commercial CaPs as well as two TCP granules with either a micron-scale or a 
submicron-scale surface structure in a dog model. The chemical composition of 
CaPs alone did not explain the ectopic bone formation capacity as a silicon-
substituted HA (Si-HA) named Actifuse®, MBCP comprised of BCP and, the self-
manufactured submicron- scale surface structured TCP granules all induced ectopic 
bone formation (Duan et al., 2017). Moreover, the amount of proteins adsorbed onto 
the surface of the materials or, the release of calcium or phosphate ions did not fully 
explain the osteoinductive properties of the CaPs either (Duan et al., 2017). However, 
they showed that the submicron-scale surface structure is more beneficial for 
material-driven bone formation when compared to nanoscale or micron scale 
surface -structures (Duan et al., 2017). Furthermore, later Duan and co-workers 
(2018) studied three chemically identical TCP granules with the same granule size 
but different crystal grain size in a rabbit condyle defect -model. They concluded that 
the submicron structured TCP (crystal grain size 0.77 ± 0.21 μm) induced bone 
formation more and resorbed more when compared to TCP ceramics with larger 
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crystal grains during the 26-week follow-up (Duan et al., 2018). Having the largest 
surface area, the small crystal grain TCP released more calcium ions in comparison 
to TCPs with a larger grain size. Although the fast degradation is beneficial for 
osteogenesis, also a stable surface is important for the basis of bone formation 
(Owen et al., 2018). In contrast to their earlier study conducted in an ectopic site, 
Duan and colleagues (2018) concluded that the induced protein adsorption on the 
surface as well as the higher calcium and phosphate ion release induce the bone 
formation capacity of the TCP granules. The mechanism behind the effect of surface 
structure and topography on osteogenic induction may be the differentiation of cells 
and recruitment of stem cells via mechanotransduction referring to the translation 
of mechanical signals eliciting from the cell-surface interaction, into cellular 
responses (Duan et al., 2017; Gattazzo et al., 2014; Dupont et al., 2011). In addition, 
macrophages and osteoclasts, which derive from the monocyte-macrophage lineage, 
have been shown to be sensitive to surface topography and their activity and 
secretion of cytokines have been evidenced to be beneficial for bone formation on 
CaP surfaces (Duan et al., 2017; Davison et al., 2014; Kondo et al., 2006). 
Effects on angiogenesis 
The degradation of CaPs result in the release of calcium and inorganic phosphate to 
liquid phase (Malhotra & Habobovic, 2016). Although these ions are important for 
osteogenesis and their circulation is crucial for homeostasis (Malhotra & Habobovic, 
2016), their elevated levels have been connected to vascular smooth muscle cell 
apoptosis (Shanahan et al., 2011), EC oxidative stress (DiMarco et al., 2013) and 
apoptosis (DiMarco et al., 2008). CaPs are not inherently angiogenic however different 
modifications have been tested to increase their angiogenic effect, such as addition 
of copper to CaP cement (Zhang et al., 2019) or integration of growth factors to CaP 
scaffolds (Malhotra & Habobovic, 2016). Furthermore, combining CaPs with BaGs, 
which has angiogenic potential, to form ceramic composites is an intriguing 
alternative to produce more optimal bone filler materials to combine the good 
properties of both materials (Karadjian et al., 2019). 
2.4.3 Bioactive glasses 
The whole BaG research field is based on the development of the first BaG, later 
named Bioglass® 45S5, by Hench and colleagues at the beginning of 1970s (Hench, 
2006).  The 45S5 is a degradable BaG composed of 45 wt-% SiO2, 24.5 wt-% Na2O, 
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24.5 wt-% CaO and 6 wt-% P2O5 (Hench, 1991). Bioglass 45S5 binds to bone tissue 
with chemical bonds and induces bone formation away from the implant and in an 
ectopic site making it osteoinductive (Hench, 1991; Jones, 2013). A Finnish-
developed BaG type S53P4 (later named BonAlive®) is highly like the original 45S5, 
only with a slower reactivity. In addition to traditional silicate-based BaGs, such as 
45S5 and S53P4, also phosphate-based BaGs and borate-based BaGs have been 
developed (Jones, 2013). Silicate-based BaGs have a slow resorption rate in the body 
and BaG granules have been shown to preserve in the implant site for years without 
degrading (Lindfors et al., 2010). The partial replacement of silicate with borate in 
S53P4 BaG composition has been proposed as one solution to induce the 
degradation rate of the silicate-based S53P4 BaG (Ojansivu, Mishra et al., 2018). 
Osteoinductive properties 
The mechanism of osteoinduction by BaGs is based on the formation of a 
polycrystalline hydroxyl carbonate apatite bi-layer on the glass surface when 
implanted in living tissues (Hench, 2006). The formed bi-layer induce the adsorption 
of growth factors as well as the attachment and proliferation of osteoblasts (Hench, 
2006). Rath and colleagues (2016) studied the osteogenic differentiation of ASCs and 
BMSCs in 45S5 BaG scaffolds with and without osteogenic supplements in the 
culture medium. Interestingly, they concluded that ASCs seeded in the BaG scaffold 
differentiated towards osteogenic lineage even without the addition of osteogenic 
supplements whereas BMSCs needed the osteogenic supplements in addition to the 
BaG scaffold in order to differentiate (Rath et al., 2016). Furthermore, BaGs have an 
effect also on cells that are not seeded on its surface, as BaGs have been shown to 
induce bone formation via ionic dissolution products. Ojansivu and colleagues 
(2015) studied the effect of four BaG extract media on osteogenic differentiation of 
hASCs. Intriguingly, they concluded that the ionic dissolution products of S53P4 
BaG and of three experimental BaGs alone did not induce osteogenesis of hASCs 
but the addition of osteogenic supplements into the culture medium was needed for 
osteoinduction of hASCs (Ojansivu et al., 2015). However, the BaG extract in OM 
induced hASC osteogenesis significantly more in contrast to OM alone (Ojansivu et 
al., 2015). On the other hand, the ionic dissolution from BaGs induces a rise in pH. 
Monfoulet and colleagues (2014) studied the effect of pH on osteogenic 
differentiation of hBMSCs in vitro and on bone formation in vivo using BCP, coral 
and BaG granules. They showed in vitro that there is a pH range of 7.9–8.27 where 
hBMSC proliferation is not affected, but the osteogenic differentiation of hBMSCs 
is inhibited (Monfoulet et al., 2014). Furthermore, they implanted the cell seeded 
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constructs in mouse subcutis and concluded that bone formation declined 20–30 
fold as pH rose from 7.5 to 7.8 and, bone formation was completely inhibited as pH 
reached 8 (Monfoulet et al., 2014). 
Angiogenic and antibacterial properties 
In addition to osteoinduction, BaGs have been evidenced to have a pro-angiogenic 
effect both in vitro and in vivo (Gorustovich et al., 2010). Bioglass 45S5 induce the 
release of VEGF and FGF-2 in human fibroblasts as well as proliferation and vessel 
sprouting of ECs in vitro (Day, 2005). In addition, S53P4 have been shown to induce 
the release of VEGF in human fibroblasts in vitro (Detsch et al., 2014). During the 
recent years, the addition of angiogenic ions, such as copper, in BaG compositions 
have been studied in order to develop a BaG type to support both osteogenesis as 
well as angiogenesis (Bari et al., 2017; Wu et al., 2013). Wu and colleagues (2013) 
manufactured mesoporous copper doped BaG, which was demonstrated to induce 
the osteogenic differentiation of hBMSCs and the expression of VEGF and hypoxia-
inducible factor (HIF)-1α in hBMSCs. In addition, the S53P4 based borosilicate 
BaGs have also been shown to induce the expression of endothelial genes PECAM-
1 and vWF (Ojansivu et al., 2018). 
On top of everything else, BaGs have presented antibacterial properties in various 
studies (Lindfors et al., 2017; Bari et al., 2017; Wu et al., 2013; Hu et al., 2009). In an 
aqueous environment BaGs undergo surface reactions resulting in ion release, which 
causes a rise in the pH (Hu et al., 2009) as well as induces the osmotic pressure around 
the BaG (Lindfors et al., 2017). Both of these phenomena have been shown to 
contribute to the antibacterial effect of BaGs (Lindfors et al., 2017; Hu et al., 2009). 
Hu and co-workers (2009) evidenced the antibacterial effect of 45S5 in vitro using 
three pathogenic bacteria that could be related to wound healing. Furthermore, 
Romano and colleagues (2014) compared S53P4 in two antibiotic-loaded calcium-
based bone fillers in the treatment of chronic osteomyelitis and concluded that 
S53P4 resulted in an equally good outcome as the antibiotic-loaded bone fillers. In 
fact, a multinational and multicenter study evidenced that S53P4 can be used alone 
without antibiotics in the treatment chronic osteomyelitis (Lindfors et al., 2017). 
Although BaGs are osteoinductive, pro-angiogenic as well as antibacterial, they 
are brittle with low toughness, which make them difficult to tailor and undesirable 
for load-bearing sites (Jones, 2013). As a result, most commercial BaGs are in granule 
or cement form (Jones, 2013). The mechanical properties of 45S5 (Chen et al., 2006) 
are compared to those of other biomaterials and native bone in Table 2. The hard 
and brittle nature of BaGs has limited their clinical use however, due to the superior 
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biological effects of BaGs they are excellent components to be combined for 
instance with synthetic polymers to form composite materials for vascularized bone 
applications.  
2.4.4 Aliphatic polyesters  
Aliphatic polyesters are a biodegradable biomaterial group with highly tailorable 
mechanical and structural characteristics even though they are not bioactive. This 
class include polymers such as polylactide acid (PLA), polyglycolic acid and poly-ε-
caprolactone (PCL). The properties of these polymers can be further modulated by 
blending them or, co-polymerization with other monomers resulting in copolymers, 
such as poly (lactide-co-glycolic acid) or poly (lactide-co-caprolactone) (PLCL) 
(Narayanan et al., 2016). Co-polymerization and blending have been demonstrated 
to affect the polymer properties significantly, such as ionic property, crystallinity, 
solubility, and degradation (Dash & Konkimalla, 2012). Furthermore, PLA, PCL, 
polyglycolic acid and their copolymers are biocompatible and they have been 
demonstrated to support osteogenic differentiation of stem cells in vitro (Z. Wang et 
al., 2016; Campana et al., 2014; Temple et al., 2014; Jeong et al., 2008). 
PLA is a non-toxic, biodegradable, FDA approved material obtained from 
renewable resources with low costs (Gritsch et al., 2019). PLA is processed from 
lactic acid monomers. Lactic acid has a chiral carbon atom and therefore it has two 
stereoisomers: L-lactic acid and D-lactic acid resulting in either poly (L-lactide) or 
poly (D-lactide) or a copolymer of both monomers (Gritsch et al., 2019; Sarasua et 
al., 2005). In addition, PLA can be processed using different techniques, such as 
extrusion, fiber spinning, gas foaming or film casting; allowing the production of 
various structures with varying properties (Gritsch et al., 2019). However, the 
degradation rate of PLA is relatively slow, and the hydrophobic and inert material 
interacts poorly with cells and tissues inducing an inflammatory response when 
implanted into the body (Gritsch et al., 2019).  
PCL is also a biocompatible, biodegradable and FDA approved polymer with 
slow and close to linear hydrolytic degradation profile within a period of 18-24 
months (Teoh et al., 2019). PCL is a highly versatile and tailorable polymer, which is 
why it has been studied and trialed widely both in the field of tissue engineering and 
drug delivery (Dash & Konkimalla, 2012). Moreover, PCL has high mechanical 
strength making it a potential candidate to load-bearing sites as well (Turnbull et al., 
2017).  
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Poly(L-lactide-co-ε-caprolactone (PLCL) is a copolymer of L-lactide and ε-
caprolactone with attractive properties for a BTE implant material: flexible and 
elastic with high tensile strength, controllable degradation rate as well as good 
biocompatibility (Z. Wang et al., 2016; Holmbom et al., 2005). Higher ε-caprolactone 
amount results in a polymer with more flexible and elastic properties (Sartoneva et 
al., 2018; Ahola et al., 2013). However, PLCL is hydrophobic and inert and even 
though it has been used in BTE, it still lacks biological binding sites and therefore 
its interaction with cells or tissues is not optimal in vitro or in vivo (Z. Wang et al., 
2016; Jeong et al., 2008). Therefore, PLCL has been combined with other bioactive 
materials, such as gelatin (Jeong et al., 2008) or silk-fibroin (Z. Wang et al., 2016), to 
improve its interaction with cells and tissues. 
2.4.5 Composites 
Bone is a natural composite with excellent mechanical properties. Individual 
biomaterial types alone have not been able to reproduce the properties of bone tissue 
(Turnbull et al., 2017) and therefore, combining different material types to form a 
synthetic composite may be the best strategy to develop an optimal bone substitute 
material. Aliphatic polyesters and their copolymers provide a versatile basis for a 
bone composite material in terms of mechanical properties and ductility, to be 
further reinforced with bioactive components such as CaPs (Akkouch et al., 2014; 
Haimi et al., 2009), BaGs (Xiao et al., 2017; Haimi et al., 2009) or silk-fibroin (Z. Wang 
et al., 2016). The most used synthetic polymers in composites in BTE are PLA, PCL, 
polyglycolic acid and poly(lactide-co-glycolic acid) (Turnbull et al., 2017). 
Haimi and colleagues (2009) compared hASC attachment, proliferation and early 
osteogenic commitment on PLA/BaG and PLA/β-TCP composites with 10- or 20 
% bioceramic content. Interestingly, the composites did not result in a more robust 
proliferation when compared to plain PLA scaffold (Haimi et al., 2009). Moreover, 
they observed that hASCs proliferated more on PLA/β-TCP composites in contrast 
to PLA/BaG composites although; the PLA/BaG composites induced ALP activity 
of hASCs more when compared to PLA/β-TCP composites (Haimi et al., 2009). 
Akkouch et al. (2014) studied a porous composite consisting COL-1, HA and PLCL 
by culturing and differentiating human dental pulp stem cells on them. The authors 
concluded that ALP activity, osteogenic gene expression and secretion of 
mineralized matrix were notably higher in human dental pulp stem cells cultured on 
the composites in contrast to plain PLCL scaffolds (Akkouch et al., 2014). 
 46 
Montjovent and colleagues (2007) on the other hand fabricated porous PLA/HA 
and PLA/ β-TCP (5 % ceramic content) composites with supercritical CO2 (scCO2) 
foaming and tested their biocompatibility and osteoconductivity in a rat cranial 
defect model. The composites were shown to be biocompatible, but they did not 
result in as good bone formation as the β-TCP scaffold used as a control 
(Montjovent et al., 2007). A reason for this may be the low ceramic content of the 
composites or the insufficient display of the ceramic content on the surface. 
The high ceramic content in composites designed for BTE is desirable although 
it may affect processing. Furthermore, the high ceramic content may also affect the 
creation of a porous structure into a composite material. For instance, with scCO2 
processing, a higher ceramic content has been shown to decrease total porosity and 
increase average pore size of the foamed composite (Mathieu et al., 2006).   
2.5 Bone in vitro models 
In addition to contributing to the development of clinical BTE applications, the 
study of vascularized bone is highly relevant for the development of bone in vitro 
models. The development of relevant 3D in vitro models is important because animal 
models mimic the functions of human body differentially and therefore, fail to 
predict the clinical outcome (Rossi et al., 2018; Salamanna et al., 2016; Pearce et al., 
2007). Functional human cell based in vitro models of bone could decrease the need 
for animal experiments, which would be significant as the in vivo experiments related 
to bone are often painful, time consuming and, expensive. However, the creation of 
a reliable in vitro bone model is challenging, as it requires the formation of mineralized 
bone matrix and inclusion of vascularization and other relevant cell types in the 
specific study, such as osteoclasts and/or immunocytes. 
One highly relevant research area in need of an in vitro bone model is cancer 
(Bersini et al., 2016). Bone tissue is the third most common metastatic site for cancer 
and once bone metastasis has occurred patient survival reduces dramatically 
(Salamanna et al., 2016). As cell-cell and cell-matrix interactions have a key role in 
cancer metastasis, it is not ideal to study bone metastasis in a conventional 2-
dimensional (2D) culture setup (Salamanna et al., 2016). Moreover, as spontaneous 
bone metastases are rare in rodents, cats and dogs in most tumor types (Simmons et 
al., 2015), the need for human cell based vascularized bone in vitro models is evident 
in order to bring further insight to bone metastasis mechanisms. A bone in vitro 
model would also provide an opportunity to study the safety of BTE transplants 
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related to cancer development. In addition to cancer research, bone in vitro model 
has been utilized in the study of Alzheimer disease when studying the role of 
triggering receptor expressed on myeloid cells-2 in bone homeostasis (Rossi et al., 
2018). To create the in vitro bone model, Rossi and colleagues (2018) used hBMSCs 
and differentiated them towards an osteogenic lineage in a perfusion bioreactor on 
porous cross-linked COL-1 scaffolds for 3 weeks. Then, they seeded monocytes into 
the constructs and supplemented the culture system with medium guiding the 
monocytes towards an osteoclast lineage for another 3 weeks (Rossi et al., 2018). The 
created bone model was able to demonstrate the bone matrix deposition and 
remodeling, successfully providing the basis for their study related to bone 
homeostasis (Rossi et al., 2018). 
2.6 Animal models in bone tissue engineering 
The safety and efficacy of a bone substitute or a BTE construct must be evidenced 
in vitro, in vivo and in a clinical trial before it can become a clinically used product or 
a treatment. In vitro models are not able to recreate the complex in vivo environment 
and therefore animal models are needed to test and verify the biocompatibility and 
osteoinductivity of BTE constructs and, to model bone healing of fractures and 
critical defects to study the effect of the used construct (Schindeler et al., 2018; 
Muschler et al., 2010). A major challenge in the in vivo studies related to BTE 
applications, is the lack of standardization related to the used parameters (de 
Misquita et al., 2016). This means that the parameters between studies testing and 
evaluating similar properties vary greatly, which makes translation and interpretation 
of the results challenging. Such parameters include for instance animal species, defect 
site and size, duration of the study as well as time points, chosen surgical techniques 
and instruments, fixation methods, preservation or removal of periosteum or local 
marrow, and the methods used to analyze the results of the study (Gothard et al., 
2014; Muschler et al., 2010). 
There are three different experimental animal models for BTE applications: 
firstly, an ectopic model with a subcutaneous implantation site, which can be used 
to assess the materials intrinsic osteoinductivity in an environment without 
osteogenic resident cells or other osteoinductive factors in proximity (de Misquita et 
al., 2016).  Secondly, an orthotopic model with a calvarial implantation site that 
allows the study of osteoinductivity and bone formation in a non-load bearing site 
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(de Misquita et al., 2016). Finally, an orthotopic model in long bones enabling also 
the study of load bearing of the used implant (de Misquita et al., 2016). 
Small mammals, such as mice and rats, are the most used models in BTE, mostly 
due to their low cost and easy accessibility (Schindeler et al., 2018). Mice and rats are 
useful models in the initial testing of biocompatibility and safety however; when 
aiming at clinical trials larger animals demonstrate a more relevant environment in 
terms of bone structure and load bearing (Muschler et al., 2010). In contrast to 
human, rodents’ skeleton grows and reshapes throughout their lives, as their growth 
plates remain open. In addition, they have a very limited amount of trabecular bone 
and the process of bone remodeling differs significantly (Muschler et al., 2010). 
Rabbits on the other hand, have more trabecular bone when compared to rodents 
and, the bone remodeling process is more like human bone (Muschler et al., 2010). 
However, the bone biology and composition of sheep, dog and pig are highly like 
human bone (Muschler et al., 2010). In addition, larger animals allow the drilling of 
larger defects enabling the evaluation of tissue ingrowth and vascularization, as in 
some cases it is important to exceed the diffusion limit of approximately 200 μm 
(Muschler et al., 2010). The selection of an animal model may be crucial for the 
outcome of the study as noticed by Wang and colleagues (2014). They evaluated the 
osteoinductivity of three CaPs in an ectopic site in rats, rabbits and dogs and 
concluded that ectopic bone formation was detected in dogs, whereas in rabbits and 
rats, only osteoid formation was noted (L. Wang et al., 2014). The authors discussed 
that the differences in osteoinduction between species may be related to differences 
between metabolism, which affects degradation and adsorption kinetics, level of 
growth factors and other secreted factors near the implantation site (L. Wang et al., 
2014). 
2.6.1 Bone formation in vivo 
Different approaches to treat bone defects effectively have been studied in animal 
models. These approaches include the use of a biomaterial scaffold alone, a scaffold 
combined with cells such as ASCs, a scaffold combined with growth factors or, a 
scaffold combined with both cells and growth factors. 
The use of only a biomaterial scaffold is the simplest BTE approach with less 
potential risks. Furthermore, a biomaterial-based application is subjected to a lower 
level of regulation during commercialization when compared to approaches using 
cells or growth factors. However, for a biomaterial to be effective alone it needs to 
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be osteoconductive or osteoinductive. As demonstrated in a number of in vivo 
studies, CaPs and BaGs alone (Duan et al., 2018; Duan et al., 2017; L. Wang et al., 
2014; H. Yuan et al., 2010) or, combined with synthetic or natural polymers in a 
composite (Fennema et al., 2018; Pihlman et al., 2018; Xiao et al., 2017) have the 
ability to induce bone formation even without the addition of cells or inductive 
factors. 
Yuan and colleagues (2010) compared β-TCP to autologous bone transplant and 
to rhBMP-2 delivered in a collagen sponge (Infuse® Bone Graft, Medtronic) in a 
critical sized bilateral iliac wing defect in sheep. The authors concluded that the β-
TCP resulted in a more pronounced bone formation when compared to Infuse® and 
in an equal level of bone formation as the autologous bone transplant (H. Yuan et 
al., 2010). Furthermore, the use of cells in an aggregated form in contrast to 
individual cells has been shown to result in increased cell viability, anti-inflammatory 
effect as well as tissue formation (Gionet-Gonzales & Leach, 2018). Fennema and 
colleagues (2018) on the other hand compared the osteogenic potential of aggregated 
hASCs, hBMSCs and SVF cells with and without rhBMP-2 delivered with CaP 
microparticles and enveloped in a plateletrich plasma hydrogel in an ectopic site in 
immunodeficient mice. The authors concluded that hBMSCs combined with CaP 
microparticles and enveloped in a plateletrich plasma induced bone formation and 
showed a higher bone maturity when compared to hASCs, SVF cells or rhBMP-2 
(Fennema et al., 2018). Moreover, rhBMP-2 induced ectopic bone formation more 
in contrast to hASCs (Fennema et al., 2018).  
2.7 Clinical landscape in bone engineering 
Majority of tissue engineering and biomaterial research justify the importance of their 
research with the clinical need of novel treatments, materials or strategies. Although 
numerous strategies and materials have been studied during the last few decades in 
the field of BTE, only a fraction of these have been translated into clinical use (de 
Misquita et al., 2016; Mishra et al., 2016). Tissue engineering combines a scaffold, 
cells and bioactive molecules (such as growth factors) however, in 2016 Mishra and 
colleagues reported that there were no clinical BTE applications consisting all three 
elements. There are most likely different reasons behind this lack of translation of 
conducted preclinical research, which we may speculate. Firstly, novel inventions 
may require patenting, which needs to be well timed, prior to publishing the research 
behind the invention. Moreover, patenting is expensive, and the inventors rarely 
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have the expertise to follow-through the patenting process whereas they may have 
more interest to publish their results quickly. Furthermore, the pathway of a BTE 
application from bench to clinic is strongly regulated. In fact, it has been proposed 
that the unawareness of the regulatory requirements as well as the high cost of the 
whole translation process of new BTE products is a major reason for the difference 
between the amount and investment for preclinical research and clinical BTE 
applications (Mishra et al., 2016).  
The pathway of clinical translation for a BTE application is described in Fig. 4. A 
BTE application may be cell-based, biomaterial-based, growth factor based or, be a 
combination of two or three of these. After demonstrating its effectiveness and 
safety in preclinical studies (in vitro and in vivo), depending on the regulative 
authorities the effectiveness and safety may need to be evidenced in clinical trials.  If 
the clinical trials are successful, the product may be approved for market. Depending 
on the product and the requirements of the regulative authorities, the manufacturer 
may also need to conduct post-approval studies to further demonstrate the long-
term safety and behavior of the application. (Mishra et al., 2016.) 
 
Figure 4.  The clinical translation pathway for BTE applications. A BTE application may comprise of 
all three tissue engineering components (cells, material, growth factors), or of two of them 
or of only one of them. After successful preclinical studies, the next step is clinical trials 
before a product may receive marketing approval. Thereafter, post-approval studies may 
be required to show the long-term effects and behavior of the product. (Mishra et al., 
2016.) 
2.7.1 Regulation related to commercialization of medical devices 
The safety and efficacy of a bone substitute need to be demonstrated on different 
levels before it can be approved for clinical use. The European Medical Agency 
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(EMA) classifies a bone substitute material as a medical device. Medical devices as 
products are regulated on national level, such as by VALVIRA in Finland, and the 
EMA is involved in the assessment of medical devices under European Union (EU) 
legislation. The regulation of medical devices confirms that only safe and functional 
devices are on the market. Stem cell -based products are classified as advanced 
therapeutic medicinal products (ATMP) and their translation is notably more 
regulated as compared to medical devices (Ho-Shui-Ling et al., 2018). 
In order to introduce a new product into the market the manufacturer needs to 
provide a Declaration of Conformity and place a CE (Conformité Européenne) mark 
onto the product to indicate the conformity. CE marking is a certification mark that 
indicates the accordance with safety, health and environmental product standards 
that are required of products sold in the European Economic Area (EEA). 
Furthermore, for the product the CE marking enables freedom of movement, as no 
additional authoritative approval is required from the CE marked products within 
Europe. In order to receive a CE mark, medical devices must undergo a conformity 
assessment to show that they fulfil the legal requirements, verify their safety and, to 
show that they perform as intended.  At the same time, the ISO 13485 –standard 
(International Organization for Standardization, 2016) defines the requirements for 
a quality management system for the different stages of medical device’s life cycle, 
such as design, development, production, storage and distribution, installation and 
maintenance. For instance, European Union (EU) -directive for medical devices 
(Medical Devices Directive – 93/42/EEC) refers to the ISO 13485 -standard as a 
part of their approval process. 
To select the correct compliance route for a specific medical device, the device 
needs to be classified according to the classification provided by the European 
Commission. The conformity assessment is carried out in a graduated level of 
control, by categorizing the devices based on their inherent risk level (class I, class 
IIa, class IIb and class III) as described in the guidelines related to the application of 
the council directive 93/42/EEC on medical devices (European Commission, 2015). 
This means that a more rigorous assessment is applied to devices with a higher risk 
level. For instance, wound dressings that serve as mechanical barriers are classified 
as class I devices. In turn, an osteoconductive bone substitute material without any 
biological or animal-based additives is classified as a class III device, as it is implanted 
surgically, it remains long term (> 30 days) in the body and it absorbs fully or mainly 
in the body (European Commission, 2015). Moreover, a class III bone substitute 
material that has shown potential in preclinical studies needs to evidence its safety 
and functionality in a clinical trial to receive a CE mark, as stated in the regulation 
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(EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on 
medical devices. 
On the other hand, when aiming to the United States (U.S.) market, medical 
devices need to abide by the regulation set by the FDA. According to the 
classification of FDA, a bone filler without any biological or animal-based additives 
may be classified as a class II device (U.S. Food and Drug Administration, 2018a). 
Class II medical devices require a Premarket Notification 510(k), which “must 
demonstrate that the device is substantially equivalent to one legally in commercial 
distribution in the United States: (1) before May 28, 1976; or (2) to a device that has 
been determined by FDA to be substantially equivalent” (U.S. Food and Drug 
Administration, 2018b). Approximately only 10-15 % of class II medical devices are 
required a clinical trial. 
Altogether, the translation of new BTE applications is highly regulated on 
different levels. This means that the whole translation process takes a long time and 
therefore it must be well planned and organized. Furthermore, the relevant 
developmental steps need to be conducted according to relevant standards, such as 
the ISO 13485 –standard for medical devices, for the acquired results to be 
acceptable by the regulative authorities. 
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3 AIMS OF THE STUDY 
The aim of this study was to assess the suitability of synthetic bone grafts for BTE. 
Furthermore, to combine the clinically used bioactive ceramics to synthetic polymers 
and assess the potential of novel composites in BTE in vitro and in vivo. In addition, 
the study aimed to develop effective differentiation strategies for osteogenesis and 
vasculogenesis in vitro. The specific aims of the studies I-IV are listed below: 
 
I The aim was to compare the effect of two commercially available 
clinical bone substitutes BioRestore and BoneCeramic in hASC 
culture in vitro. In addition, to achieve osteogenic differentiation 
efficiently in the biomaterial scaffold commonly used growth factors 
BMP-2, BMP-7 and VEGF are compared. 
II  The hard and brittle ceramic phase is combined to an elastic polymer 
to create an easier-to-use composite scaffold. The osteogenic and 
vasculogenic potential of a novel β-TCP/PLCL composite are 
evaluated in hASC culture in vitro. Furthermore, to analyze different 
differentiation strategies and medium compositions to achieve both 
osteogenic and endothelial differentiation of hASCs in the same 
composite. 
III The study aim was to further develop the structure and composition 
of the β-TCP/PLCL composite and characterize its properties. In 
addition, to analyze the cytocompatibility and osteogenic capacity of 
the composite in hASC culture in vitro. Finally, to evaluate the 
biocompatibility and osteoconductivity of the composite in vivo by 
implanting them in a rabbit femur defect. 
IV The aim was to use 3D printing to create PCL/BaG and PCL/BaG-
Cu composites for vascularized BTE and analyze their properties 
and bioactivity. In addition, to evaluate the effect of the composites 
on proliferation, osteogenesis and vasculogenesis in hBMSC culture 
and in a co-culture of hBMSCs and HUVECs in vitro. 
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4 MATERIALS AND METHODS 
4.1 Biomaterial scaffolds used in the study 
4.1.1 Commercial scaffolds 
In study I, two commercial biomaterials, Straumann® BoneCeramic granules 
(Straumann AG, Basel, Switzerland) and Inion BioRestoreTM BaG scaffolds (Inion 
Oy, Tampere, Finland), were compared. The granular BoneCeramic is a BCP with 
60 % HA (100 % crystalline) and 40 % β-TCP. The composition of BioRestore BaG 
scaffold is described in Table 3. The porous BioRestore scaffolds were manufactured 
as described in the original publication. Details of biomaterial characteristics are 
listed in Table 4. Prior to cell seeding, the granules and scaffolds were incubated in 
corresponding medium for 48 h. 
4.1.2  ScCO2 foaming of β-TCP/PLCL composites 
The β-TCP/PLCL composites with 40 wt-% ceramic content in study II and with 
50 wt-% ceramic content used in study III, were manufactured by using scCO2 as 
described in patent by Paakinaho and Kellomäki (2019) and in original publications. 
Briefly, the composite material was processed by melt-mixing PLCL (70L/30CL; 
Purasorb PLC7015, Corbion Purac Biomaterials, Gorinchem, the Netherlands) with 
50 wt-% β-TCP (Plasma Biotal Ltd., Buxton, UK). Then, the composite was foamed 
with scCO2, by using a Supercritical Carbon Dioxide Reactor System (SFE250, 
Waters Ltd., MA, USA).  
Composite characteristics are presented in Table 4. In study III, a dynamic 
compression treatment was conducted for the composites in an aqueous 
environment at 37°C for minimum of 20 cycles with a compression level of at least 
50 % prior to in vitro and in vivo studies. For the in vitro studies in studies II and III, 
the composites were incubated in basic medium (BM; Table 5) for 24 h before 
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seeding the cells. For the in vivo study in study III, the composites were pre-
compressed in blood collected from the bony defect site. 
4.1.3 3D printing of Cu2+ doped BaG/PCL composites 
The Cu2+ doped BaG/PCL composites in study IV were 3D printed by direct ink 
writing as described in the original publication. The 2 BaG compositions used in the 
composites are described in Table 3. In brief, the BaG batches were melted in a Pt 
crucible at 1360 °C for 3 h, cast, annealed, crushed, and remelted to ensure their 
homogeneity. The annealed glass block was crushed and gradually fractionated and 
the finest powder fraction (Ø ≤ 45 μm) was further grinded to obtain the finest 
particles for ink formulation. To obtain a viscous solution, PCL was dissolved in 
acetone, which was used as a carrier for BaG particles in ink formulation. The BaG 
particles were dispersed into the viscose PCL solution homogeneously with a 
planetary centrifugal mixer (ARE-250, Thinky Corporation). The compositional 
ratios (wt-%) between PCL and BaG or BaG-Cu were 4:1, 2:1, or 1:1. Scaffold 
fabrication via direct ink writing was conducted using an adapted Korean Institute 
for Machinery and Materials (KIMM) Bioplotter. The ink was loaded into a fluid 
dispensing system (Optimum by Nordson EFD) and a stainless steel precision tip 
(25GA, Nordson EFD) was used as the dispensing nozzle. The scaffolds were 
printed layer-by-layer by extruding the ink into a cold ethanol bath. Then, the 
scaffolds were soaked in absolute ethanol for 24 h and the ethanol was changed every 
8 h. Finally, the scaffolds were left to dry prior to further characterizations. For 
sterilization before cell culture experiments, the scaffolds were incubated 2 x 10 min 
in 70 % ethanol and then left to dry for 2 h. The scaffolds were incubated for 48 h 
in BM (Table 5) prior to cell seeding. 
Table 3.  Composition of BaGs in studies I and IV. 
 wt-% 
 Na2O K2O MgO CaO P2O5 B2O3 SiO2 TiO2 CuO 
BioRestore 11.1-12  15-17.1  2.8-3.3  12.7- 15.2  2.7-3.8  1-1.4 48.5-52  0- 0.6   - 
S53P4 23   -   - 20 4   - 53   -   - 
S53P4-Cu 23   -   - 19 4   - 53   - 1 
 
 56 
Table 4.  Biomaterials used in studies I-IV. 
Biomaterials in 
studies I-IV Sterilization Composition 
Dimensions/ 
sample size 
Porosity, pore 
size 
Straumann® 
BoneCeramic 
granules 
I sterile package 
60 % HA and 40 % 
β-TCP 
0.25 g of 0.5-1.0 mm 
sized granules 
90 % 
100-500 μm 
Inion BioRestoreTM 
BaG scaffold I 
70 % 
ethanol BaG 
square 
7x7x3 mm 70 % 
40 wt-% β-TCP in 
PLCL  II γ-irradiation 
40 wt-% β-TCP in 
PLCL Ø=10mm, h=3mm 
67 % 
340 ± 130 μm 
50 wt-% β-TCP in 
PLCL  III γ-irradiation 
50 wt-% β-TCP in 
PLCL 
in vitro: 
Ø=8mm, h=3mm 
in vivo: 
Ø=3.2mm, h=10mm 
Ø=4mm, h=10mm 
65-67 % 
380 ± 130 μm 
PCL/ BaG(S53P4)-
Cu composites IV 
70 % 
ethanol 
PCL/BaG or 
PCL/BaG-Cu in 
ratios 1:1, 2:1 or 4:1 
square 
10x10x1-4 mm 60 % 
4.1.4 Scaffold characterization 
The morphology and surface topography of the Straumann® BoneCeramic granules 
and Inion BioRestoreTM bioactive glass scaffolds in study I and, the scCO2 processed 
β-TCP/PLCL composites in study III, were imaged by using a scanning electron 
microscopy (SEM; Philips XL-30; Philips, Eindhoven, The Netherlands) as 
described in the original publications. In addition, even though not included in the 
original publication of study II, the scCO2 processed β-TCP/PLCL composites used 
in study II were also imaged using SEM (Jeol JSM T-100, Freising 
Germany). 
The scCO2 processed β-TCP/PLCL composites (studies II and III) and the 
PCL/BaG scaffolds (study IV) were imaged by using an Xradia MicroXCT-400 x-
ray imaging system (Carl Zeiss X-ray Microscopy Inc., Pleasanton, USA) as described 
in the original publications. 
In study IV, the PCL/BaG-Cu scaffolds were evaluated by using a LEICA 
M205A optical microscope. The bioactivity of the PCL/BaG-Cu composites in 
study IV was analyzed for 30 days in SBF and the formation of CaP precipitates was 
confirmed with a SEM-EDXA (EDXA, LEO Gemini 1530 with a Thermo Scientific 
UltraDry Silicon Drift Detector, X-ray detector by Thermo Scientific). 
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4.1.5 Mechanical testing of scaffolds 
In study III, the mechanical testing of scCO2 processed β-TCP/PLCL composites 
was conducted for both intact and pre-compressed scaffolds (Ø = 8 mm, h = 3.5 ± 
0.6 mm) as dry at RT and in an aqueous solution at 37 °C with Instron Electropuls 
E1000 (High Wycombe, UK) as described in the original publication. The elastic 
modulus was calculated based on the linear section of the stress-strain curve, 
between 0 and 20 % strain. 
The compressive response of the BaG-Cu/PCL scaffolds in study IV was 
analyzed with a Shimadzu EZ-L Universal Mechanical Tester as described in the 
original publication. The compressive modulus was determined based on the stress 
versus engineering strain curves. 
4.1.6 Hydrolytic degradation of composites in vitro and in vivo 
In study III, the hydrolytic degradation of the porous β-TCP/PLCL composites was 
studied in vitro and in vivo at 4-, 12- and, 24-week time points as described in the 
original publication. The in vitro study was conducted at 37 °C in SBF and the in vivo 
study as intramuscular implantation in rabbit supraspinatus muscle. As a reference, 
a porous PLCL (70/30) polymer scaffold was used. The number average molecular 
weight (Mn), weight-average molecular weight (Mw) and polydispersity of the scaffold 
samples were calculated against polystyrene standards at RT.  
4.1.7 Ion release from PCL/BaG-Cu composites 
The ion release profile of PCL/BaG and PCL/BaG-Cu composites in study IV was 
determined in SBF at 37 °C as described in the original publication. The samples 
were incubated in SBF for 30 days and analyzed at 6 h, 24 h, 3 d, 7 d, 14 d, 22 d and 
30 d. The Ca, P, Si and Cu ion concentrations in samples were determined with an 
inductively coupled plasma optical emission spectrometer (ICP-OES) (Optima 5300 
DV, Perkin Elmer, Shelton, CT). 
The Cu2+ release was also analyzed from the culture medium during the 14-day 
hBMSC culture as described in the original publication. The Cu2+ concentration in 
medium was analyzed by utilizing the ICP-OES analysis and the aforementioned 
protocol. 
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4.2 Cell isolation, characterization and culture 
4.2.1 Human adipose stem cells 
hASCs were used in studies I, II and III and the cells were isolated from adipose 
tissue samples received from surgeries at the Department of Plastic Surgery, 
Tampere University Hospital with the patients’ consent. The hASCs used in studies 
were obtained from (I) 11 donors (mean age 50 ± 14 years), (II) six donors (mean 
age 44 ± 14 years) and, (III) three donors (mean age 40 ± 11 years). The studies were 
carried out under authorization of the Ethics Committee of the Pirkanmaa Hospital 
District, Tampere (R15161). Isolation of hASCs was conducted using a mechanical 
and enzymatic protocol as described in the original publications. Isolated hASCs 
were expanded in BM (composition described in Table 5). The hASC culture 
experiments were conducted at passages 2 to 5 in studies I-III. 
4.2.2 Human bone marrow stem cells 
The hBMSCs used in study IV were extracted from a bone marrow aspirate obtained 
from a surgical procedure at the Department of Orthopedics and traumatology, 
Tampere University Hospital with the patient’s consent. The donor was an 80-year-
old female. The study was carried out in agreement with the Ethics Committee of 
the Pirkanmaa Hospital District, Tampere (R15174). The hBMSCs were isolated 
using centrifugation through a Ficoll gradient as described in the original publication. 
Isolated hBMSCs were expanded in BM (composition described in Table 5) and the 
experiments were conducted at passage 3. 
4.2.3 Human umbilical vein endothelial cells 
HUVECs used in study IV were isolated from an umbilical cord received from a 
planned Cesarean section at the Department of Obstetrics and Gynecology, 
Tampere University Hospital with the patient’s consent. The study was conducted 
under authorization of the Ethics Committee of the Pirkanmaa Hospital District, 
Tampere (R13019). The HUVEC extraction procedure is described in the original 
publication. The isolated HUVECs were cultured in EGM-2 (Lonza; composition 
presented in Table 5) and the experiments were conducted at passage 3. 
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Table 5.  Different media compositions used in studies I-IV. Basal medium (BM), osteogenic 
medium (OM), endothelial medium (EM), endothelial growth factor (EGF). 
Medium Composition 
BM
 
BM for hASCs in 
study I 
DMEM-F12 with 5-10 % (v/v) FBS, 1 % (v/v) antibiotics and 1 % (v/v) L-alanyl-L-
glutamine 
BM for hASCs in 
study II and III 
DMEM-F12 with 5-10 % (v/v) HS, 1 % (v/v) antibiotics and 1 % (v/v) L-alanyl-L-
glutamine 
BM for hBMSCs 
in study IV MEM Alpha Medium with 5 % HS and 1 % antibiotics with 5 ng/mL of human FGF-2  
OM
 OM for hASCs 
BM with 250 μM ascorbic acid 2-phosphate (AA2P), 10 mM β-glycerophosphate (β-
GP and 5 nM dexamethasone (Dex) 
OM for hBMSCs BM with 200 μM ascorbic acid 2-phosphate (AA2P), 10 mM β-glycerophosphate (β-GP) and 5 nM dexamethasone (Dex) 
EM
 EGM-2 
Endothelial basal medium (EBM)-2 supplemented with GA-1000, EGF, VEGF, FGF-
2, R3-IGF-1, heparin, hydrocortisone, ascorbic acid and 2 % (v/v) FBS 
EM EBM-2 supplemented with GA-1000, EGF, VEGF, FGF-2, R
3-IGF-1, and 2 % (v/v) 
HS  
4.2.4 Cell characterization  
To verify the mesenchymal origin of hASCs (studies I-III) and of hBMSCs (study 
IV) and to characterize the isolated HUVECs, the surface marker expression of the 
cells was determined by a fluorescent-activated cell sorter (FACSAria; BD 
Biosciences, Erembodegem, Belgium) at passage 1-3 as described in the original 
publications.  
The surface marker expression of hASCs and hBMSCs are presented in Table 6. 
Their surface marker profile verified the mesenchymal origin of the isolated cells 
(Bourin et al., 2013; Dominici et al., 2006). The HUVECs were positive for markers 
CD31 (99.5 %), CD73 (99.9 %), CD105 (99.9 %), CD146 (99.9%), whereas the 
expression of CD90 (5.7 %) and VEGFR2 (3.8 %) was low. Furthermore, the 
expression of CD34 (42.9 %), CD36 (12.2 %), CD144 (12.9 %), CD202B (35.6 %) 
and VEGFR3 (27.8 %) was moderate in the isolated HUVECs. 
4.3 Optimization of endothelial medium for hASCs 
In study II, 2 medium compositions were compared in order to optimize EM for 
hASC differentiation. hASCs were cultured in BM, EGM-2 (Lonza) or in a HS-based 
version of EGM-2 (EM; described in Table 5). The comparison was repeated with 3 
hASC lineages at passage 2. The optimization is described in the original publication. 
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Based on the results of the comparison described in more detail in the original 
publication, EM was selected for the 3D experiments in study II. 
Table 6.  Surface marker expression of hASCs and hBMSCs cultured in HS or FBS used in 
studies I-IV. Results are expressed as mean ± SD. 
Surface markers 
Study I   Study II Study IV  Study III     
hASCs (FBS) hASCs (HS) hASCs (HS) hBMSCs (HS) 
CD14 Serum lipopolysaccharide binding protein 0.96 ± 0.63 0.6 ± 0.6 1.5 ± 0.6 0.4 
CD19 B lymphocyte-lineage differentiation antigen 0.7 ± 0.4 0.4 ± 0.2 1.1 ± 0.2 1 
CD34 Sialomucin-like adhesion molecule 19.8 ± 21.1 34.8 ± 32.2 15.2 ± 11.1 0.1 
CD45 Leukocyte common antigen 1.4 ± 0.4 1.6 ± 0.3 1.4 ± 0.5 1.8 
CD73 Ecto-50-nucleotidase 96.5 ± 3.4 98.2 ± 1.3 97.8 ± 0.7 99.8 
CD90 Thy-1 (T-cell surface glycoprotein) 99.6 ± 0.2 99.8 ± 0.1 99.5 ± 0.1 85.1 
CD105 SH-2 endoglin 87.1 ± 21.7 98.3 ± 1.2 98.8 ± 0.5 99.8 
HLA-DR Major histocompatibility class II antigens 0.8 ± 0.5 0.6 ± 0.1 1.2 ± 0.7 97.2 
4.4 Cell culture in different scaffolds 
In study I, the hASCs were seeded at a density of 9.7 x 104 cells per BoneCeramic 
granule sample or BioRestore scaffold, in a 50 μl medium drop. The cells were left 
to attach for 3 h before adding 1 mL of corresponding medium. In the first part of 
study I, rhBMP-2 (Genscript, Pisataway, NJ, USA), rhBMP-7 (Sigma-Aldrich), and 
VEGF (rhVEGF165; R&D Systems) were added to BM and compared with OM. 
In the second part of study I, the growth factors were added to OM. The 
concentrations of rhBMP-2, rhBPM-7 and VEGF were respectively 50 ng/mL, 100 
ng/mL and, 20ng/mL. 
In study II, the differentiation of hASCs in β-TCP/PLCL composites was studied 
in 2 parts. Firstly, hASCs were cultured in 2 experimental groups: OM and EM while 
BM served as a control. Before seeding the cells into the scaffolds, hASCs were 
cultured for 5 days in BM, EM or OM in polystyrene. In Part I of the study, 120 000 
hASCs (510 cells/ mm3) were seeded at day 0 per scaffold in 50 μL of medium. Cells 
were allowed to attach for 3 h prior to adding 1 mL of corresponding medium. 
Secondly, the differentiation of hASCs in the composites was studied in 2 additional 
experimental groups: OM-cocktail and EM-cocktail. In OM-cocktail group, hASCs 
were cultured for 5 days in OM before seeding 60 000 cells into the scaffolds at day 
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0. Then, hASCs seeded constructs were supplemented with OM for 7 days. At day 
7, another 60 000 cells were seeded into the scaffolds. The hASCs seeded at day 7 
were cultured for 5 days in EM before cell seeding in scaffolds. After the day 7 cell 
seeding, the cell seeded constructs were supplemented with a cocktail medium of 
OM and EM (1:1) for the rest of the experiment. In EM-cocktail group, hASCs were 
cultured for 5 days in EM before cell seeding 60 000 cells into the scaffolds at day 0. 
Thereafter, hASCs seeded in scaffolds were supplemented with EM for 7 days. At 
day 7, another 60 000 cells were seeded into the scaffolds. The hASCs seeded at day 
7 were cultured for 5 days in OM prior to cell seeding at day 7. After the day 7 cell 
seeding, the cell seeded constructs were supplemented with a cocktail medium of 
OM and EM (1:1) for the rest of the experiment. In Part II of the study (OM-cocktail 
and EM-cocktail), 60 000 hASCs (255 cells/mm3) were seeded per scaffold in a 50 
μL volume of medium at day 0 and day 7. Cells were allowed to attach for 3 h prior 
to adding 1 mL of corresponding medium.  
In study III, the hASCs were seeded in β-TCP/PLCL composites at a density of 
510 cells/ mm3 in 50 μL of medium. Cells were allowed to attach for 2-3 h before 
adding 500 μL of BM or OM per well. In alizarin red staining, a 2D control was used: 
500 cells were seeded in 1 ml of BM or OM in a 24-well plate (Nunc, Roskilde, 
Denmark). 
In the first part of study IV, the PCL/BaG and PCL/BaG-Cu scaffolds’ ability 
to support hBMSC viability, proliferation and early osteogenic differentiation were 
assessed. 50 000 hBMSCs were seeded in a 50 μL volume of OM per scaffold. Cells 
were allowed to attach for 3 h prior to adding 2 mL of OM per well. Secondly, the 
ability of PCL, PCL/BaG (4:1) and PCL/BaG-Cu (4:1) to support vascularization 
was evaluated in co-culture of hBMSCs and HUVECs. Due to the detected 
inhibitory effect of high copper content caused by PCL/BaG-Cu (2:1) and (1:1), they 
were excluded from the co-culture experiments. The printed scaffolds (10x10x1mm) 
were cut in quarters and 20 000 hBMSCs were seeded per scaffold quarter. hBMSCs 
were cultured for 6 d in OM. Thereafter, 20 000 HUVECs were seeded into the 
scaffolds and the medium was changed to EGM-2 (Lonza, Basel, Switzerland) for 
the rest of the experiment.  
4.5 Cell viability and proliferation 
Cell viability was evaluated qualitatively in studies I, III and IV by staining the cells 
with fluorescent live/dead-staining probes (Molecular Probes/ Invitrogen, Eugene, 
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OR, USA) as described in the original publications. Representative images of living 
cells (green fluorescence) and dead cells (red fluorescence) were acquired with an 
Olympus IX51 phase contrast microscope with fluorescence optics and Olympus 
DP30BW camera (Olympus, Tokyo, Japan). 
In study IV, hBMSC viability was also quantitatively assessed by using a lactate 
dehydrogenase (LDH) activity assay (Abcam, Cambridge, UK) as described in the 
original publication. Absorbance was determined at 450 nm with a microplate reader 
(Victor 1420 Multilabel Counter; Wallac; Turku, Finland). 
Proliferation was analyzed quantitatively in studies I-IV at different time points 
by determining the total amount of DNA by CyQUANT Cell Proliferation Assay 
Kit (Molecular Probes, Eugene, OR, USA; Invitrogen) as described in the original 
publications. Fluorescence in samples was measured at 480/520 nm with a 
microplate reader (Victor 1420 Multilabel Counter). 
4.6 Analysis of osteogenic and endothelial differentiation in vitro 
Osteogenic differentiation of hASCs and hBMSCs was analyzed using various 
osteogenic markers and methods in studies I-IV as presented in Table 7. Endothelial 
differentiation of hASCs in study III and, vascularization in co-culture of hBMSCs 
and HUVECs in study IV were analyzed with different techniques as presented in 
Table 8. 
ALP activity in samples was determined in studies I-IV at various time points as 
described in the original publications. The ALP activity was determined from the 
same cell lysates as total DNA content. Absorbance was measured at 405 nm (Victor 
1420 Multilabel Counter). Absorbance values were normalized to cell amount in 
study IV. 
Soluble total collagen in samples was quantified in studies I and III by using Sircol 
Soluble Collagen Assay (Biocolor, Carrickfergus, United Kingdom) as described in 
the original publication. Absorbance in samples was measured from two parallel 100 
μl samples in a 96-well plate (Nunc) using a microplate reader (Victor 1420 Multilabel 
Counter) at 540 nm. 
Alizarin red staining after 14 and 21 days in studies II and III was used to assess 
the formation of mineralized matrix in samples as described in the original 
publications. Stained scaffolds were photographed, then the stain was extracted, and 
the intensity of the dye was determined by measuring absorbance at 540 nm (Victor 
1420 Multilabel Counter). 
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Endothelial (PECAM-1, vWF and CD144) and osteogenic marker proteins 
(COL-1 and OCN) were detected with immunocytochemistry using an indirect 
staining method in studies II-IV as described in the original publications. The used 
primary and secondary antibodies as well as their dilutions are presented in the 
original publications. The stained samples were imaged using an Olympus IX51 
phase contrast microscope with fluorescence optics and Olympus DP30BW camera 
(Olympus, Tokyo, Japan). Images were edited and constructed by using Adobe 
Photoshop. In the 2D medium optimization experiments in study III, the samples 
were imaged with fluorescence optics using a digital inverted microscope (AMG 
EVOS). 
Quantitative real-time reverse transcription polymerase chain reaction (qRT-
PCR) analysis was used to evaluate the relative expression of osteogenic and 
endothelial genes in studies II-IV as described in the original publications. The 
primer sequences and accession numbers for RPLP0 (human acidic ribosomal 
phosphoprotein large P0) and osteogenic genes ALP, COL-1, Runx2a, OSX, DLx5 
are presented in the original publications. For analysis of endothelial gene vWF a 
commercial primer assay was used. The reactions were carried out with ABIPRISM® 
7300 Sequence Detection System. qRT-PCR data was normalized to the expression 
of RPLP0. The results were processed by using AbiPrism 7300 Sequence Detection 
System -software (Applied Biosystems). 
Table 7.  Markers, methods and time points used to analyze the osteogenic differentiation of 
hASCs (I-III) and hBMSCs (IV). 
Study Marker for osteogenic differentiation Detection technique Time points 
I ALP activity ALP activity assay 7 d, 14 d Soluble total collagen amount Sircol soluble collagen assay 7 d, 14 d 
II 
ALP activity ALP activity assay 14 d, 21 d 
Mineralized matrix formation Alizarin red staining 14 d, 21 d 
Gene expression of ALP, COL-1, 
Runx2a, OSX and DLx5 qRT-PCR 14 d, 21 d 
III 
ALP activity ALP activity assay 7 d, 14 d, 21 d 
Soluble total collagen amount Sircol soluble collagen assay 7 d, 14 d, 21 d 
Mineralized matrix formation Alizarin red staining 14 d, 21 d 
Protein expression of COL-1 and 
osteocalcin 
Immunocytochemical staining 
and fluorescence microscopy 
7 d, 14 d, 21 
d 
Gene expression of Runx2a, OSX and 
DLx5 qRT-PCR 14 d, 21 d 
IV 
ALP activity ALP activity assay 7 d, 14 d 
Gene expression of Runx2a, osteocalcin 
and DLx5 qRT-PCR 11d, 20 d 
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Table 8.  Markers, methods and time points used to analyze endothelial differentiation and 
vascularization in studies III and IV. 
Study Marker for endothelial differentiation Detection technique Time points 
III 
Vessel formation in Matrigel Sprouting assay 20 d 
Protein expression of PECAM-1, vWF 
and CD144 
Immunocytochemical staining 
and fluorescence microscopy 14 d, 21 d 
Gene expression of PECAM-1 and vWF qRT-PCR 14 d, 21 d 
IV 
Protein expression of PECAM-1 and 
vWF 
Immunocytochemical staining 
and fluorescence microscopy 13 d, 20 d 
Gene expression of PECAM-1 and vWF qRT-PCR 6 d, 11d, 20 d 
4.7 Analysis of bone formation in vivo 
The animal study in study III was conducted in accordance with The Animal 
Experiment Board in Finland (ESAVI/5398/04.10.07/2014). In the in vivo 
experiment, 20 female New Zealand white rabbits were used and handling of rabbits 
as well as the surgeries are described in detail in the original publication.  Briefly, a 
3.2 mm diameter and 10 mm deep hole was drilled above the lateral collateral 
ligament of the right femoral condyle. The β-TCP/PLCL composite scaffolds (3.2 x 
10 mm) were pre-compressed in blood collected from the drilling hole and placed 
into the defect. For the analysis hydrolytic degradation in vivo, a skin incision was 
made midline over the spine between the scapulae and two β-TCP/PLCL 
composites (4 x 10 mm) were implanted into the right supraspinatus muscle and two 
PLCL scaffolds (4 x 10 mm) into the left supraspinatus muscle. The rabbits were 
randomly divided in groups and euthanized 4-, 12- and, 24 weeks after the procedure. 
Micro-CT analysis (MicroXCT-400, Zeiss) was performed on all the harvested 
femoral condyles before histological preparation as described in study II. Thereafter, 
histological preparation was carried out and the sectioned samples were histologically 
stained (Masson-Goldner’s Trichrome (MGT) staining). The intramuscular implants 
were collected for the hydrolytic degradation analysis. 
4.8 Statistical testing 
In study I, the statistical testing was conducted with SPSS version 19 (IBM, Armonk, 
NY, USA). Depending on the comparison, a one-way analysis of variance (ANOVA) 
with a Tukey post hoc test or, a Student’s t-test for independent samples were used. 
The statistical testing is described in more detail in the original publication. Statistical 
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analyses in studies II-IV were conducted with SPSS version 22 or 23 (IBM, Armonk, 
NY, USA) using non-parametric tests due to low sample size and non-linearly 
distributed data. In studies II and III, a Mann-Whitney U-test with Bonferroni 
correction were used as described in the original publications. In study IV, a Kruskal-
Wallis test with Mann-Whitney U post hoc test and Bonferroni correction were used 
as described in the original publication. The results were considered significant when 
p < 0.05. 
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5 RESULTS 
5.1 Scaffold characterization 
5.1.1 Scaffold architecture and surface topography 
All scaffolds used in studies I-IV were imaged using SEM and a summary panel of 
the results is presented in Fig. 5. When comparing the SEM images of the scaffolds, 
they exhibit distinctly different surface architecture for the seeded cells. 
In study I, both BoneCeramic granules and BioRestore scaffold were shown to 
have a high porosity. Furthermore, BioRestore exhibited a larger surface area, as it 
is composed of small sized fibers. BoneCeramic on the other hand demonstrated 
more surface roughness when compared to BioRestore.  
 
Figure 5.  Representative SEM images of the different biomaterials used in the study. Scale bars 500 
μm. 
In study II, scCO2 processed PLCL composites with 40 wt-% β-TCP were used. The 
micro-CT analysis gave a scaffold porosity of 67 % with an average pore size of 340 
± 130 μm. In study III, in addition to the scaffold architecture the SEM images 
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exhibited the effect of the used pre-compression treatment on the scCO2 processed 
β-TCP/PLCL (50 wt-% ceramic content) composites as presented in the original 
publication. The used β-TCP granules had a larger particle size as compared to 
composites in study II. Prior to the pre-compression treatment β-TCP was mainly 
visible on the cutting surface on the composite whereas a PLCL film mostly covered 
the β-TCP granules elsewhere. After the pre-compression the PLCL surface 
ruptured and the β-TCP granules protruded on display. Moreover, the pre-
compression treatment tore additional holes into the polymer surfaces. According 
to the micro-CT analysis scaffold porosity was 65-67 % with an average pore size of 
380 ± 130 μm and, the micro-CT imaging confirmed the effect of the pre-
compression treatment. The structure of the composite in study III is notably 
different as compared to the composite used in study II (Fig. 5). 
In study IV, the SEM imaging showed that the surface roughness of the PCL-
based composites increased as the BaG-Cu content in the composites elevated as 
shown in the original publication. All the scaffolds in study IV had a total porosity 
of 60 % according to the micro-CT analysis. 
5.1.2 Mechanical properties of the scaffolds 
In study III, the compressive stress at 20- and 50 % strain as well as the modulus 
were determined. The compression treatment and the physiological temperature of 
37 °C had a significant effect on the mechanical properties of the scCO2 processed 
PLCL with 50 wt-% β-TCP composite as shown in the original publication. As dry, 
the pre-compression decreased the modulus significantly when compared to an 
intact composite however, the difference was diminished after 1h at 37 °C in aqueous 
solution. Furthermore, the same phenomenon was observed in the analysis of 
compressive stress at 20- and 50 % strain. In addition, the warming and wetting of 
the intact composite decreased the modulus significantly when compared to dry 
intact composite. The modulus and strength increased between 1h and 7 d when 
analyzed at 37 °C in an aqueous environment.  
In study IV, the printed PCL/BaG-Cu composites (4:1, 2:1 and 1:1) 
demonstrated reinforced mechanical properties as compared to PCL scaffold. The 
compressive Young’s modulus for PCL scaffold was 5.9 MPa. Among the 
PCL/BaG-Cu composites with compositional ratios 4:1, 2:1 and 1:1; PCL/BaG-Cu 
(2:1) demonstrated the highest E value (12.5 MPa) whereas PCL/BaG-Cu (1:1) had 
the lowest E value (7.19 MPa). 
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5.1.3 Hydrolytic degradation of β-TCP/PLCL composites 
In study III, the Mn and Mw change during the 24-week follow-up showed that the 
in vitro degradation is a lot like the degradation in vivo for both β-TCP/PLCL (50 wt-
%) composites and PLCL polymer scaffolds. The molecular weight of the scaffolds 
decreased significantly already during the first 4 weeks. The polymer scaffold had a 
higher initial Mn and Mw in comparison to the composite, but the difference was 
evened out during the degradation already in 4 weeks. After the 4-week time point, 
no clear differences between the degradation of the two scaffold types or between 
the in vitro or in vivo environments were observed. The residual L-lactide monomer 
content after processing for the PLCL scaffold was 0.09 wt-% and for the β-
TCP/PLCL composite 0.06 wt-%. 
5.1.4 Bioactivity and ion dissolution profile of PCL/BaG-Cu composites 
In study IV, notable CaP precipitation on the strut surfaces was only observed after 
7 d of immersion. After 30 days, a clear CaP layer had formed on the surfaces of 
PCL/BaG-Cu (2:1) and PCL/BaG-Cu (1:1) composites while only small aggregates 
of CaP were observed on PCL/BaG-Cu (4:1). The CaP precipitates had a 
characteristic cauliflower-like morphology with a Ca/P ratio of 1.56, which is close 
to that of natural bone mineral (1.67).  
When considering Si release, a burst release was observed within 3 days of 
immersion with all composites, which is most likely associated to the initial 
dissolution of BaG-Cu particles exposed on the surface of the composites. After 3 
days, the BaG-Cu dissolution slowed down. With PCL/BaG-Cu (4:1), a low level of 
Si was detected most likely due to the low BaG-Cu content. With PCL/BaG-Cu 
(2:1), a continuous Si release at a close to constant level was observed for the rest of 
the immersion. Whereas with PCL/BaG-Cu (1:1), after 7 d of immersion the 
released Si reached a saturation level at ~ 60 mg/L in SBF. The release trend of Cu 
was similar to that of Si. A higher Cu2+ concentration in SBF was measured with 
PCL/BaG-Cu (1:1) as compared to the other composites. The ion concentration 
profiles of Ca and P in SBF were reflected on the CaP precipitation on the surfaces 
of the composites. With PCL/BaG-Cu (2:1) and PCL/BaG-Cu (1:1) the P ion 
concentration decreased immediately during the first few days of immersion most 
likely due to formation of a CaP layer. In contrast, the P concentration remained 
high with PCL/BaG-Cu (4:1) composite during the first two weeks. This was in line 
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with the fact that CaP precipitation was observed only after 14 days of immersion 
with PCL/BaG-Cu (4:1). 
The Cu2+ concentration was also analyzed from culture medium during the in vitro 
experiment. At 0 d, the scaffolds had been pre-incubated for 48h in BM and the 
Cu2+ concentration in PCL/BaG-Cu composites in compositional ratios (4:1), (2:1) 
and (1:1) were 35 μM, 70 μM and 117 μΜ, respectively. hBMSC amount was low in 
PCL/BaG-Cu (4:1) at day 7 but as the Cu2+ concentration decreased to 20 μM as a 
result of medium changes and dissolution slowdown, hBMSC proliferation was 
enhanced. Most likely due to high Cu2+ concentrations, hBMSC proliferation was 
inhibited in PCL/BaG-Cu (2:1) and PCL/BaG-Cu (1:1) composites during the 14-
day experiment. 
5.2 Cell viability and proliferation 
In study I, hASCs seeded on both BioRestore and BoneCeramic materials were 
viable and proliferated well for the whole 2-week culture period as demonstrated by 
live/dead staining in the original publication and proliferation assay (Fig. 6). 
BioRestore supported hASC proliferation better as compared to BoneCeramic, as 
cell number was significantly higher in BioRestore than in BoneCeramic in BM and 
OM at day 14. Furthermore, hASCs proliferated significantly more in OM in contrast 
to BM in both BioRestore and BoneCeramic. Concerning the growth factors, BMP-
2 and VEGF in BM resulted in similar proliferation levels as BM in both BioRestore 
and BoneCeramic. In turn, BMP-7 resulted in a lower cell number as compared to 
BM in BioRestore. In contrast, in BoneCeramic BMP-7 did not inhibit proliferation. 
Overall, OM demonstrated superior potential to induce proliferation and osteogenic 
differentiation of hASCs when compared to the tested growth factors. The viability 
and cell number with OM + growth factors were comparable to those with plain 
OM, although slightly higher than with BM + growth factors. In BioRestore the 
slight hindering effect of BMP-7 on proliferation was observed even when combined 
with OM.  
In study II, EM induced hASC proliferation significantly less than OM at both 
time points (Fig. 7B). In addition, cell number in EM group was at the same level as 
that in BM group. The effect of OM on hASC proliferation was evident, as hASCs 
proliferated significantly more in OM when compared to BM and EM at 14- and 21 
days (Fig. 7B). Concerning the effect of the cocktail medium, both OM-cocktail and 
EM-cocktail groups resulted in significantly higher cell numbers than BM. 
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Figure 6.  Proliferation of hASCs in study I at 3-, 7-, and 14-day time points on BioRestore and 
BoneCeramic. hASCs are cultured in BM, OM or BM + growth factors. Results are 
expressed as mean + SD (n = 6; *p < 0.05 between the indicated groups; #p < 0.05 when 
compared to other groups within that time point). 
 
Figure 7.  Proliferation of hASCs in scCO2 -foamed β-TCP/PLCL composites in study A) III (50 wt-% 
β-TCP in PLCL) at 7-, 14- and 21-day time points and, B) II (40 wt-% β-TCP in PLCL) at 
14- and 21-day time points. Results are expressed as mean ± SD (n = 9; *p < 0.001, **p < 
0.05). 
According to live/dead staining in study III, hASC viability on β-TCP/PLCL 
composites was good in both BM and OM and, OM seemed to support hASC 
proliferation better in contrast to BM. In concordance with live/dead staining, the 
cell amount was significantly higher in OM in contrast to BM at all time points (Fig. 
7A). 
In study IV, hBMSC viability was good in all scaffolds at 14-day time point, as 
the number of dead cells was low (Fig. 8A). When compared to the plain PCL 
scaffold, the elevating BaG content in composites seemed to induce hBMSC 
proliferation. According to live/dead staining, the higher copper content had an 
inhibitory effect on hBMSC amount on scaffolds (Fig. 8A). Overall, the LDH 
activity was at a relatively low and constant level with all the scaffolds during the first 
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9 days, indicating low cytotoxicity of the studied scaffolds as shown in the original 
publication. In contrast to live/dead staining results, the Cu2+ released from 
PCL/BaG-Cu (2:1) and PCL/BaG-Cu (1:1) composites did not induce elevated 
LDH levels in the culture medium. The addition of BaG in PCL had an increasing 
effect on hBMSC proliferation with all BaG contents at both time points (Fig. 8B). 
Regarding the role of Cu2+ in the composites, also the cell amount results supported 
the inhibitory effect of rising Cu2+ concentration. The amount of hBMSCs in 
PCL/BaG-Cu (4:1) was low at day 7 however, the cell amount elevated to a similar 
level as that in PCL/BaG (4:1) at 14 days.  
 
Figure 8.  Viability and proliferation of hBMSCs in study IV in PCL, PCL/BaG and PCL/BaG-Cu 
composites cultured in OM. A) Live/dead staining at 14 d (live cells stained green and 
dead cells stained red). Scale bars 500 μm. B) Total DNA amount in samples at 7- and 14 
days expressed as mean ± SD (n = 4). 
This is most likely connected to the initial burst release of Cu2+ as demonstrated in 
Cu2+ concentration analysis from the culture medium. When the Cu2+ concentration 
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decreased to 20 μΜ, the cells retained their proliferative capacity. The Cu2+ 
concentration remained at a high level during the 14 days with PCL/BaG-Cu (2:1) 
and (1:1) composites indicating a clear inhibitory effect of higher Cu2+ concentration 
on hBMSC proliferation. 
5.3 Osteogenic differentiation 
5.3.1 Alkaline phosphatase activity 
In study I, both BioRestore and BoneCeramic in BM supported ALP activity in 
hASCs. However, with BoneCeramic, the effect of OM was more significant and 
consistent when compared to BM or growth factors, as OM + BoneCeramic 
combination induced significantly higher ALP activity when compared to all other 
groups (Fig. 9). Concerning ALP activity of hASCs in BioRestore, OM induced ALP 
activity significantly more than BMP-2 or BMP-7, but not when compared to BM.  
 
Figure 9.  ALP activity of hASCs in study I at 3-, 7-, and 14-day time points on BioRestore or 
BoneCeramic. hASCs are cultured in BM, OM or BM + growth factors. Results are 
expressed as mean + SD (n = 6; *p < 0.05 between the indicated groups; #p < 0.05 when 
compared to other groups within that time point). 
In turn, BMP-2 and VEGF resulted in a comparable level of ALP activity as BM 
with both BoneCeramic and BioRestore. In addition, BMP-7 induced a clearly lower 
level of ALP activity in comparison to BM in BioRestore.The effects of growth 
factors on ALP activity were mostly similar in both BoneCeramic and BioRestore. 
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However, in BoneCeramic the negative effect of BMP-7 on ALP activity was 
significant. On the other hand, VEGF induced ALP activity significantly more than 
BMP-7, but not more than BM. Interestingly, adding growth factors in OM did not 
result in enhanced ALP activity in comparison to plain OM as shown in the original 
publication. However, the negative effect of BMP-7 on ALP activity was diminished 
when combined with OM. 
In study II, ALP activity analysis demonstrated significant induction in EM group 
when compared to BM or OM at 14- and 21 days. At 21-day time point, ALP activity 
in OM was significantly higher when compared to BM. Furthermore, ALP activity 
was significantly enhanced in EM-cocktail in contrast to BM at both time points. 
In study III, ALP activity was significantly higher in OM than in BM after 7 and 
14 days in culture. In addition, ALP activity in both BM and OM elevated 
significantly from 7 days to 14 days whereas the rise from 14 days to 21 days in BM 
or OM was modest. ALP activity was donor-dependent and especially hASCs from 
one donor gave higher ALP activity results than the other donor cells. 
In study IV, ALP activity increased in all scaffold types from 7 d to 14 d. In turn, 
ALP activity decreased with rising BaG and BaG-Cu content. Surprisingly, the plain 
PCL induced ALP activity more than in any of the composites. In turn, PCL/BaG-
Cu (4:1) gave a higher ALP activity result than PCL/BaG (4:1). 
5.3.2 Total soluble collagen quantification 
In study I, BoneCeramic induced collagen production of hASCs significantly more 
when compared to BioRestore (Fig. 10). Furthermore, collagen production of 
hASCs in BoneCeramic in BM or BM combined with growth factors was 
significantly higher than in BioRestore at 7 and 14 days (Fig. 10). Moreover, OM 
elevated collagen production in both biomaterials at 14 d, with the highest collagen 
level in BoneCeramic combined with OM. Equally low collagen production was 
induced by all growth factors and BM in hASCs cultured in BioRestore. In contrast, 
in BoneCeramic at 7 days BMP-2 induced significantly higher collagen amount when 
compared to BM and OM. Also, VEGF induced significantly higher collagen 
amount in comparison to BMP-7 but not higher than BM. In turn, combining 
growth factors with OM did not increase total collagen production as compared to 
OM alone as shown in the original publication. 
In study III, the total collagen production did not notably differ between BM and 
OM groups after 7-, 14-, or 21 days in culture as presented in the original publication. 
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Total collagen amount elevated slightly in both BM and OM from 7 to 14 days 
whereas, the soluble collagen amount declined from 14 d to 21 d. 
 
Figure 10.  Soluble collagen amount in study I at 7- and 14-day time points on BioRestore or 
BoneCeramic. hASCs are cultured BM, OM or BM + growth factors. Results are 
expressed as mean + SD (n = 6; *p < 0.05 between the indicated groups; #p < 0.05 when 
compared to other groups within that time point). 
5.3.3 Production of mineralized matrix 
In study II, hASCs were able to produce mineralized matrix on the β-TCP/PLCL 
composite surface in all groups already at 14 d (Fig. 11). As observed at both 14 d 
and 21 d, larger strongly stained areas of mineralized matrix were present in OM in 
contrast to BM or EM. In addition, OM-cocktail and EM-cocktail induced 
mineralized matrix formation more when compared to BM (Fig. 11). Quantitative 
results demonstrated that mineralization was the strongest in OM whereas EM 
induced the lowest mineralization at both time points as shown in the original 
publication. However, there were no significant differences between the groups in 
mineral amount. Furthermore, no significant increase in the calcium mineral amount 
from 14 d to 21 d was observed in any of the groups. 
In study III, hASCs produced a dense mineralized matrix on the β-TCP/PLCL 
composite surface in both BM and OM already at 14 days (Fig. 12A). Furthermore, 
hASCs produced a notably thicker mineralized matrix on the scaffold when 
compared to hASCs cultured on cell culture plastic (2D) at 21 d. As the staining of 
mineralized matrix was quantified, there was no difference between BM and OM at 
14 d whereas, after 21 days of culture the mineral amount in OM was significantly 
higher when compared to that in BM (Fig. 12B). 
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When comparing the effect of the 50 wt-% β-TCP/PLCL (study III) composite 
to that of the 40 wt-% β-TCP/PLCL (study II) composite on mineralization by 
hASCs, the composite with 50 wt-% ceramic content seems to induce more 
mineralization in both BM and OM conditions. 
 
Figure 11.  Representative images of mineralized matrix staining of hASC seeded β-TCP/PLCL 
composites with 40 wt-% mineral content in study II after 14- and 21 days in experimental 
groups (scaffold Ø = 10 mm). Stained blank scaffold without seeded cells presented on 
the right lower corner. 
 
Figure 12.  Staining of mineralized matrix in study III in hASC seeded β-TCP/PLCL composites with 
50 wt-% mineral content. A) Representative images of Ca-mineral stained cell-scaffold 
constructs after 14- and 21 days and, of hASC cultures on cell culture plastic (2D) after 21 
days. Stained blank scaffold without seeded cells is presented on the left of 21 d OM 
scaffold (scaffold Ø = 8 mm; well Ø = 1.55 cm). B) Quantitative Ca-mineral amount after 
14- and 21 days expressed as mean ± SD. Statistical significance indicated as p* < 0.05 (n 
= 9). 
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5.3.4 Immunocytochemical staining of osteogenic markers 
In study II, COL-1 staining was carried out at 7 d, 14 d, and 21 d. When considering 
the COL-1 expression in BM, the induction was modest at all time points (Fig. 13A). 
However, the COL-1 staining in OM revealed the development of a collagenous 
matrix during the 3-week experiment: at 7 d cells were producing COL-1 
intracellularly; at 14 d the cells were still producing COL-1 intracellularly but they 
were also secreting COL-1 into the extracellular space; and finally, at 21 d the 
intracellular production had ceased and a dense extracellular COL-1 matrix can be 
seen in the representative image (Fig. 13A). In addition to COL-1, ASCs expressed 
OCN in both BM and OM conditions at both time points however; the intensity of 
the staining was stronger in OM at both time points (Fig. 13B). 
 
Figure 13.  Immunocytochemical staining of osteogenic marker proteins in hASC seeded in β-
TCP/PLCL composites in study II. A) COL-1 at 7-, 14 and, 21 days and; B) OCN at 21 d 
time point. COL-1 and OCN are stained green and nuclei are stained blue. Scale bar 100 
μm. 
5.3.5 Osteogenic gene expression 
In study II, similar to ALP enzymatic activity results the gene expression of ALP 
was significantly elevated in EM when compared to BM at 14 d and at 21 d. 
Moreover, the ALP expression in EM-cocktail group was significantly higher than 
that in BM at 14 d. However, the effect of OM was seen in Runx2a gene expression, 
which was significantly induced in OM when compared to BM and EM, and in both 
cocktail groups relative to BM. On the other hand, COL-1 expression did not differ 
significantly between experimental groups. In turn, the expression of OSX was 
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higher in EM relative to BM and OM at day 14. However, the cocktail groups did 
not have a notable effect on OSX expression when compared to BM. Then again, 
DLx5 expression was elevated in OM when compared to BM and EM at day 14 and, 
the expression was also elevated in both cocktail groups when compared to BM at 
day 21. qRT-PCR analysis of genes OSX and DLx5 were repeated with only 2 donor 
lines and due to small sample size statistical testing was not carried out. 
In study III, the relative expression of osteogenic genes ALP, Runx2a, OSX and 
DLx5 did not differ significantly between BM and OM at any of the time points (Fig 
15A-D). However, the expression of Runx2a and OSX were elevated in OM when 
compared to BM at all time points. 
In study IV in hBMSC culture, the gene expression of Runx2a was higher in PCL 
and PCL/BaG-Cu (4:1) in contrast to PCL/BaG (4:1) at days 11 and 20 (Fig. 16A). 
Then again, in hBMSC+HUVEC co-culture PCL/BaG (4:1) promoted Runx2a 
expression more at both time points when compared to PCL and PCL/BaG-Cu (4:1) 
scaffolds. The copper containing composite seemed to decrease the expression of 
OCN (Fig. 16B) and DLx5 (Fig. 16C) while, the PCL/BaG (4:1) scaffold induced 
the expression of those at both time points and both culture setups. Overall, the 
expression of osteogenic genes was higher in hBMSC culture than in the co-culture 
setup. 
 
Figure 14.  Relative osteogenic gene expression of A) ALP, B) Runx2a, C) OSX and, D) DLx5 in 
hASCs in study III at 7-, 14- and 21-day time points. Results are expressed as mean ± 
SD. 
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Figure 15.  Relative gene expression of osteogenic marker genes A) Runx2a, B) OCN and, C) DLx5 
in hBMSC and hBMSC+HUVEC culture setups at 13 d and 20 d time points in study IV. 
Results are expressed relative to hBMSCs cultured for 6 days on PCL scaffold (n = 3, 
mean + SD). 
5.4 Endothelial differentiation of hASCs in β-TCP/PLCL 
composites 
 
In study II, endothelial induction in hASCs in β-TCP/PLCL composites was 
achieved when cultured in EM for 3 weeks. The expression of endothelial proteins 
CD31, CD144, and vWF were detected in EM-cultured cells at 14 and 21 days (Fig. 
16A, B). However, the cells expressing the vascular markers were not organized as 
no tubular formation was observed. While according to the immunocytochemical 
staining the expression of CD31 and vWF was clear in EM, in EM-cocktail the 
expression of those went down from day 14 to 21. Furthermore, endothelial proteins 
CD31, CD144 or vWF were not expressed in BM, OM, or OM-cocktail groups 
during the 3-week experiment, as shown in the original publication. 
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The gene expression of vWF varied between donors but the trend between them was 
similar: the expression of vWF was elevated in EM and EM-cocktail as compared to 
the other groups at 14 and 21-day time points (Fig. 16C). Like immunocytochemical 
staining, vWF gene expression in EM-cocktail decreased from 14 to 21 days. 
 
Figure 16.  Endothelial differentiation of hASCs in β-TCP/PLCL composites in study III. Protein 
expression of A) CD31 and, B) vWF in BM, EM and EM-cocktail groups at 14 d and 21 d 
time-points. C) Relative vWF gene expression in experimental groups at 14 d and 21 d 
time points. Results are expressed as mean ± SD (n = 6). 
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5.5 Vascularization in PCL/BaG-Cu composites 
In study IV in hBMSC culture, CD31 protein was expressed in PCL/BaG (4:1) and 
PCL/BaG-Cu (4:1) composites, whereas cells cultured in PCL did not induce CD31 
expression, as demonstrated in the original publication. Furthermore, the CD31 
expression in hBMSCs in both PCL/BaG (4:1) and PCL/BaG-Cu (4:1) composites 
seemed more pronounced at 13 d than at 20 d. In contrast to immunocytochemical 
staining, the qRT-PCR of PECAM demonstrated higher expression in PCL than in 
the composites at all time points (Fig. 17A). In turn, vWF was not notably expressed 
at protein level in any of the scaffolds in hBMSC culture during the experiment. 
Moreover, qRT-PCR demonstrated low vWF expression in all scaffolds in hBMSC 
culture (Fig. 17B).  
 In immunocytochemical staining of hBMSC+HUVEC co-cultures, CD31 was 
expressed in all scaffold types at 13- and 20-day time points (Fig. 18). Moreover, 
visible tubule formation was observed in all scaffold types. In PCL scaffold, the 
tubular structures were thick but relatively sparse, while the BaG-containing scaffold 
induced the formation of a denser network of thinner tubes. In turn, the BaG-Cu 
containing composite induced tubule formation to a lesser extent when compared 
to the BaG-containing composite (Fig. 18). Considering the staining of vWF, tubular 
formation was seen in PCL and the BaG containing composite already at 13 d and, 
the amount of the formed tubes increased from 13 d to 20 d especially with the BaG 
containing composite. The BaG-Cu containing composite did not induce vWF 
protein expression in the co-culture setup. In turn, the gene expression of PECAM 
was highly upregulated in the co-culture when compared with the hBMSC culture in 
all scaffolds, however no clear differences were observed between the scaffolds in 
either culture setup (Fig. 17A). Still, in the co-culture setup, the PECAM gene 
expression elevated from 11d to 20 d in all scaffolds. The relative vWF gene 
expression followed a highly similar pattern as PECAM; the expression level was 
higher in the co-culture and differences between the scaffolds were minimal (Fig. 
17B). In addition, the vWF gene expression increased from 11 to 20 days in the co-
culture setup. Furthermore, the vWF expression level was slightly elevated in BaG-
Cu containing composite when compared to PCL and BaG containing composite. 
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Figure 17.  Gene expression results of endothelial marker genes A) PECAM and, B) vWF in hBMSC 
and hBMSC+HUVEC culture setups at 6 d, 13 d and 20 d time points in study IV. Results 
are expressed relative to hBMSCs cultured for 6 days on PCL scaffold (mean + SD, n = 3). 
 
Figure 18.  Expression of endothelial proteins CD31 and vWF in study IV in PCL, PCL/BaG (4:1) and 
PCL/ BaG-cu (4:1) scaffolds at 13- and 20-day time points. Scale bar 500μm. 
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5.6 The effect of β-TCP/PLCL composites on bone formation in 
vivo 
The ability of the PLCL with 50 wt-% β-TCP on bone formation in rabbit distal 
femur defect was evaluated in study III with histological MGT staining and micro-
CT imaging 4-, 12- and 24 weeks after implantation. At 4 weeks, the MGT staining 
revealed that bone was able to grow on the surface of the composite and, bone 
formation was also detected inside the composite. Furthermore, the bone growth on 
the surface and inside the composite increased with time as seen at 12- and 24 weeks. 
Importantly, the MGT staining demonstrated that no induction of inflammation, 
formation of fibrous tissue or cysts during the 24 weeks were detected. The micro-
CT imaging confirmed the MGT staining results. Furthermore, especially the 
representative micro-CT images reveal how the composite degraded during the 24-
week experiment in rabbit femur. 
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6 DISCUSSION 
6.1 Scaffold architecture and properties affect cell and tissue 
response in BTE 
The current study includes the evaluation of two commercially available 
BoneCeramic materials that have shown potential in bone regeneration in vivo and in 
patients: BioRestore BaG scaffold (Lappalainen, Karhula et al., 2016a; Clozza et al., 
2014; Clozza et al., 2012) and BoneCeramic BCP granules (Beger et al., 2018; 
Lappalainen et al., 2016a; Schmitt et al., 2013). In addition, the effect of PLCL and 
PCL based composites consisting either β-TCP, BaG or BaG-Cu on osteogenic 
differentiation and bone formation were evaluated. A summary of the effects of the 
scaffolds used in this study on bone formation in vitro are presented in Fig. 19. 
Furthermore, the biomaterials are all manufactured via different methods resulting 
in different scaffold architectures and surface topographies. As CaPs and BaGs are 
the most relevant bioactive components in bone substitutes, this study provides an 
opportunity to evaluate the characteristics, feasibility and performance of plain 
bioceramics and composites consisting them in BTE. 
A major difference between BoneCeramic granules and BioRestore scaffold used 
in study I was their ability to enhance hASC proliferation, as BioRestore induced 
hASC proliferation significantly more than BoneCeramic. This phenomenon is most 
likely related to the difference in 3D architecture of the scaffolds as the fibre-formed 
BioRestore provides a larger surface area for the seeded cells in contrast to the 
BoneCeramic granules. Secondly, BoneCeramic enhanced collagen production in 
hASCs significantly more when compared to BioRestore in BM, and the effect was 
even more notable in OM. A previous study compared β-TCP to autologous bone 
graft and commercial Infuse® Bone Graft (rhBMP-2 delivered in a collagen sponge) 
in a critical sized bone defect in sheep, concluding that β-TCP resulted in an equal 
bone formation as autograft and to superior bone formation when compared to 
Infuse® (H. Yuan et al., 2010). Furthermore, as Duan and colleagues (2017; 2018) 
reported that in CaPs the grain size and micropore size at the submicron scale are 
connected to an induced bone formation in vivo, the rougher micron-scale surface of 
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BoneCeramic to BioRestore may also have benefitted the better performance of 
BoneCeramic. 
A similar positive effect to BoneCeramic is seen with another CaP in studies II 
and III with β -TCP/PLCL composites. In study III the composite contained 50 wt-
% and in study II 40 wt-% of β -TCP in PLCL. In addition, the composites in study 
III were pre-compressed resulting in increased β -TCP display on the composite 
surface as compared to an intact composite. When comparing the representative 
alizarin red staining images in studies II and III, the effect of β -TCP is evident. The 
composite’s higher ceramic content and display of β -TCP in study III resulted in 
the formation of an intensely stained and continuous mineralized matrix on the 
composite surface even in BM. Whereas in study II, only separate areas of well-
stained mineralized matrix were observed on the composite surfaces even in the best 
performing group OM. Also, like BoneCeramic in study I, the β -TCP/PLCL 
composites in study III induced the secretion of soluble collagen well and, the 
immunocytochemical staining further demonstrated the formation of a continuous 
COL-1 matrix on the surface of the scaffolds especially in OM. The formation of a 
collagenous matrix, consisting mostly of type I collagen, is strongly related to the 
early phase of bone formation. In fact, dense collagenous matrix itself has been 
shown to induce osteogenic differentiation of MSCs in vitro (Buxton et al., 2008). The 
more rapid and robust collagen production may be an advantage in more rapid and 
effective bone formation, as the formation of the organic matrix including collagen 
needs to occur prior to the mineralization phase (Florencio-Silva et al., 2015). 
BioRestore and BoneCeramic scaffolds have later been compared also in a rabbit 
cranial defect model either alone (Lappalainen, Karhula et al., 2016b) or combined 
with ASCs (Lappalainen et al., 2016a). Both studies by Lappalainen and colleagues 
concluded that the BoneCeramic granules resulted in more pronounced bone 
formation as compared to BioRestore during the 6-week follow-ups (Lappalainen et 
al., 2016a; Lappalainen et al., 2016b). In contrast to study I where BioRestore induced 
hASC proliferation, in study IV hBMSC proliferation in PCL/BaG composites was 
reduced with higher BaG content during the first week but the difference was evened 
out after that, which is most likely a result of the initial burst release of BaG ions. A 
reason for this is most likely the different composition of the BaGs. The 
composition of BioRestore is more similar to an experimental BaG 1-06 than S53P4 
used in study IV, and 1-06 has been shown to be less reactive as compared to S53P4 
in hASC culture (Ojansivu, Hyväri et al., 2018). Furthermore, ALP activity was 
elevated with the decreasing BaG content in the PCL-based composites. Similarly, 
Haimi and colleagues (2009) compared PLA/β-TCP and PLA/BaG composites in 
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hASC culture and concluded that the PLA/β-TCP composite induced hASC 
proliferation and ALP activity more as compared to the PLA/BaG composite. One 
reason for the weaker performance of BaG and BaG consisting composites may be 
the pH rise caused by BaGs as Monfoulet and colleagues (2014) demonstrated when 
comparing the osteogenic capacity of BaG to BCP based on pH values both in vitro 
and in vivo. 
 
Figure 19.  Summary of the effect of the used CaPs and BaGs on bone formation in vitro. CaPs 
(BoneCeramic and β-TCP in PLCL) demonstrated better osteogenic potential as 
compared to BaGs. In PCL/S53P4 and PCL/S53P4-Cu scaffolds lower BaG and Cu 
content resulted in a better osteogenic outcome. High Cu-content had a cytotoxic effect. 
(+++ high expression/secretion; ++ moderate expression/secretion; + low 
expression/secretion)  
When considering the ability to support vascularization, hASCs were able to express 
endothelial markers when cultured in β-TCP/PLCL composite in study II. 
Nevertheless, the study setup failed to induce the formation of tubular structures, 
but this may also be the result of the limited endothelial potential of EM as well as 
hASCs as discussed later. However, the β-TCP/PLCL composites have previously 
been shown to support vascularization in a rabbit cranial defect (Pihlman et al., 2018). 
The osteogenic potential of CaPs has in fact been linked to ECs and vascularization 
as osteogenic differentiation of MSCs first occurs near capillaries and the internal 
ceramic surfaces of porous CaPs (Tang et al., 2018). Furthermore, it has been 
proposed that pericytes associated to capillaries undergo osteogenic differentiation 
near CaPs (Tang et al., 2018). In study IV, both PCL/BaG and PCL/BaG-Cu 
composites supported the formation of tubular structures in hBMSC+HUVEC co-
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culture in EGM-2. BaGs have been demonstrated to have a vasculogenic effect in 
vitro and in vivo (Gorustovich et al., 2010). Furthermore, in study IV the use of a 
commonly used, mature EC type as a tool in the evaluation of the scaffolds’ vascular 
potential was a more reliable strategy as compared to study II, where only hASCs 
were used as a cell source. HUVECs are known to form tubular structures when 
cultured in EGM-2, which is developed specifically for EC culture while the 
endothelial differentiation capacity of hASCs has been under debate (Antonyshyn et 
al., 2019). 
6.2 The relevance of mechanical properties of BTE scaffolds 
and the significance of the polymer phase in composite 
strength 
Many times, the development of novel bone substitutes aims to create materials that 
would mimic the mechanical properties of bone so well that the defect site could 
bear load or that the treated defect site would not require additional metallic fixation. 
Even though this would be ideal, the requirements for a scaffold material are so 
manifold that the development of a bone substitute material may need 
compromising between achieving a good cell and tissue response, user-friendliness 
and ideal mechanical properties (Turnbull et al., 2017). 
The developed β-TCP/PLCL composite in study III was created to serve as a 
synthetic scaffold for the regeneration of native bone similarly, as the formed callus 
serves as a natural scaffold for the bone regeneration process during bone healing. 
Therefore, the modulus of the composite (as dry 9.0 MPa or 1.2 MPa after pre-
compression) is closer to the modulus of cartilage (2.4-10 MPa) (Beck et al., 2016) 
than to modulus of trabecular bone (10.75-13.66 GPa) (Peters et al., 2018). Among 
clinical products, the closest comparable composite bone void filler to the β-
TCP/PLCL composite is chronOSTM Strip (DePuy Synthes), also manufactured 
from PLCL and β-TCP granules. The compressive strength of the β-TCP/PLCL 
composite analyzed dry at room temperature was 1.1 MPa at 20 % strain and 3 MPa 
at 50 % strain. To compare, the compression strength of trabecular bone has been 
reported to vary from 2 to 12 MPa (Kokubo et al., 2003). To our knowledge the 
mechanical properties of chronOSTM Strip composite has not been reported 
however; the compressive strength of the chronOS® β-TCP granules is of the same 
order as the strength of the β-TCP/PLCL composite (5 MPa; product manual of 
chronOS®). Moreover, aliphatic polyester based composites consisting β-TCP have 
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demonstrated compression strengths of 5.4 MPa (Shikinami et al., 2006) and 3.5 MPa 
(Mathieu et al., 2006), which are also highly similar to that of the developed β-
TCP/PLCL composite.  
In contrast to hard and brittle ceramic bone substitutes, the elasticity of the 
composite allows the dense and tight fitting of the material into a defect. This can 
be considered a significant advantage firstly for the operating surgeon, as the 
composite material is easier to implant and mold even by cutting intraoperatively, 
when compared to most clinically available bone substitute materials as concluded 
by Pihlman and colleagues (2018). Secondly, in contrast to many clinically used hard 
ceramic granules that can be poured or placed into a defect site, the elastic composite 
material can be tightly pushed and fitted into the defect, which ensures that the 
composite remains immobile in its place. This is highly important, as a common 
complication in bone fracture healing is a non-union of the bone defect, which the 
FDA defines as the incomplete healing of a fracture within 9 months after injury 
(Panteli et al., 2015). A major factor contributing to the development of a non-union 
is insufficient stabilization as the bone regeneration process is disturbed if the defect 
site is not mechanically stabile (Panteli et al., 2015). 
When considering the mechanical properties of synthetic polymer-based 
composites, these results suggest that the mechanical properties of the polymer 
phase are more significant than those of the incorporated ceramic phase. In study 
III, the modulus and compression strength of the 50 wt-% β -TCP in PLCL were 
analyzed both dry at RT and in physiological environment (aqueous solution at 37 
°C). The compression treatment lowered the modulus and strength significantly at 
20- and 50 % strain, when the samples were tested dry at RT. Intriguingly, the 
difference was diminished in the physiological environment. The glass transition 
temperature of PLCL is between 21 °C and 22 °C (Ahola et al., 2013) which is why 
at 37 °C the polymer chains are mobile making the composite elastic whereas the β-
TCP particles do not reinforce the composite matrix. Even though CaPs have been 
reported to be able to form weak chemical bonding to PLA, at least in a BCP-PLA 
composite this kind of bonding has been shown to be negligible (Bleach et al., 2002). 
When incubated at 37 °C there was a rise from 1h at 37 °C to 7 d at 37 °C in modulus 
and strength, demonstrating that the β-TCP/PLCL composites started to recover 
after the initial decrease in mechanical properties. This increase in modulus may be 
caused by the reorganization of the polymer chains in aqueous environment at 37 
°C, such as crystallization or aging of the material, allowing the polymer chains to 
organize into energetically more stable conformations (Pan et al., 2007; Zong et al., 
1999). Contradictory to our results, van der Pol and colleagues (2010) suggested that 
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increasing the β-TCP content over 5 wt-% in a scCO2 processed composite would 
make the PLLA-based (intrinsic viscosity of raw material 1.6 dL/g) composite more 
brittle and make it lose its ability to recover after deformation. In addition, Mathieu 
and colleagues (2005; 2006) reported that higher than 5 wt-% HA content in PLLA 
(intrinsic viscosity of raw material 1.6 dL/g) made the composite fragile. In the β-
TCL/PLCL composite, the addition of the elastic caprolactone in lactide polymer 
backbone makes the polymer phase more elastic and therefore the higher filler 
content does not cause the same problems as with the PLLA based composites. 
However, the effect of rising filler content on mechanical properties of polymer-
based composite is seen in study IV with PCL/BaG-Cu composites. The addition 
of BaG-Cu enhances the compressive modulus of the PCL-based composites up to 
approximately 30 % filler content. Nevertheless, as the filler content rises to 
approximately 50 %, the modulus decreases notably. One reason for the negative 
effect of rising filler content in polymer-based composites is the agglomeration of 
filler particles and void formation in the composite matrix as the particles are not 
chemically bonded to the polymer matrix and are able to move (Bleach et al., 2002). 
Overall, it seems that to improve the mechanical properties of synthetic polymer-
based composites, the development needs to focus on tuning the polymer 
composition and chemistry rather than trying to improve the mechanical properties 
by increasing the ceramic content. 
Polymer degradation kinetics may be affected by different parameters, such as 
processing method, so that the molecular degradation profile in vitro may model the 
degradation in vivo relatively well (Weir et al., 2004) or they may differ considerably 
(Koepp et al., 2004). In study II, the hydrolytic degradation of β-TCP/PLCL 
composites was shown to be highly similar both in vitro and in vivo. This finding 
enables the study and observation of the degradation process as well as the following 
structural changes of the composite in in vitro in the future. The differences between 
the degradation rates of PLCL and the composite during the first 4 weeks are related 
to the β-TCP filler, which slows down the hydrolytic degradation of the polymer by 
neutralizing acidic degradation products of the lactide-based polymer phase 
(Niemelä, 2005). Previously, non-foamed scaffolds of PLCL and β-TCP/PLCL 
composite, with different initial molecular weight but with similar residual monomer 
content, were studied in vitro (Ahola et al., 2013). To compare, the molecular weight 
of the non-foamed scaffolds was at an equal level after 12 weeks incubation at 37 °C 
as with the foamed scaffolds (Ahola et al., 2013). 
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6.3 OM induction is more effective than exogenously added 
BMP-2, BMP-7 or, VEGF in the osteogenic differentiation of 
hASCs 
In BTE, the osteoinductive effect of BMPs has been widely trusted (Lappalainen et 
al., 2016a; Sandor et al., 2014; Sandor et al., 2013; Mesimäki et al., 2009) however, the 
safety and effectiveness of them has been challenged (Young & Mirarchi, 2015; P. 
Zuk et al., 2011; Carragee et al., 2011; Garrison et al., 2007). Therefore, in study I, OM 
was studied as a cost-effective alternative to growth factors to induce the osteogenic 
differentiation of hASCs. The used OM supplemented with AA2P, β-GP and Dex 
has previously been optimized for hASC differentiation (Kyllönen et al., 2013). 
Study I was the first report to show the advantage of OM over exogenously added 
BMP-2, BMP-7 or VEGF in the osteogenic differentiation of hASCs in 3D culture. 
The addition of BMP-2 or VEGF in BM did not induce the osteogenic 
differentiation of hASC more than BM alone with either BoneCeramic or 
BioRestore scaffolds. Furthermore, BMP-7 significantly reduced hASC proliferation 
and ALP activity with both scaffolds. To study the effects of these growth factors 
further, they were also combined to OM. Intriguingly, the combination of BMP-2, 
BMP-7 or VEGF with OM did not boost the osteogenic effect of OM, indicating 
that plain OM is enough for the osteogenic differentiation of hASCs in vitro. When 
considering the negative effect of BMP-7 on hASC osteoinduction, its combination 
with OM diminished the inhibitory effect.  
In contrast to the results in study I, exogenously added BMP-2 (Song et al., 2011; 
Knippenberg et al., 2006) (Knippenberg et al., 2006; Song et al., 2011), BMP-7 (Al-
Salleeh et al., 2008) and VEGF (Behr et al., 2011) have been proposed to induce the 
osteogenic differentiation of hASCs. In turn, it has been suggested that growth 
factors separately are not as effective as a combination of them. For instance, the 
use of BMP-2, FGF-2 and VEGF synergistically and sequentially was shown to 
induce osteogenesis of rat osteoblasts significantly more than using the growth 
factors separately (P. Li et al., 2014). 
Among the studied growth factors, BMP- 2 is the most widely studied in the 
differentiation ASCs (Vanhatupa et al., 2015; Mehrkens et al., 2012; Waselau et al., 
2012b; P. Zuk et al., 2011; Song et al., 2011; Knippenberg et al., 2006). Some studies 
have proposed concentrations between 50-100 ng/mL to be osteoinductive with 
ASCs (Song et al., 2011; Knippenberg et al., 2006) and, others have reported that 
ASCs are not responsive to BMP-2 concentrations between 10-100 ng/mL 
(Mehrkens et al., 2012; Waselau et al., 2012b; P. Zuk et al., 2011). In turn, a short and 
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low concentration treatment (15 min; 10 ng/mL) with BMP-2 has been shown to 
induce osteogenic differentiation of ASCs (Knippenberg et al., 2006). Vanhatupa and 
colleagues (2015) studied the effects of BMP-2 in hASCs and discovered that BMP-
2 enhance both osteogenic and adipogenic differentiation of hASCs in a donor-
dependent way. The donor variation may be one reason for the contradicting results 
between different studies. The authors also demonstrated that hASCs were more 
sensitive to BMP-2 when cultured in HS-based medium in contrast to FBS-based 
medium (Vanhatupa et al., 2015). Study I was conducted in FBS-based medium, 
which may have contributed to the ineffectiveness of the growth factors. Moreover, 
the conformation of BMP-2 was shown to affect its functionality, as hASCs were 
more responsive to mammalian-produced rhBMP-2 than to that produced in E. coli 
(Vanhatupa et al., 2015). In study I, the rhBMP-2 was produced in E. coli, which also 
partly explain the lack of its effect on hASCs. In addition, other factors may explain 
the different outcomes between studies, such as animal-derived ASCs (Knippenberg 
et al., 2006), differences between 3D (Waselau et al., 2012b) and 2D culture, cell 
densities as well as medium compositions. Evidently, the BMP-2 related cell signaling 
is a complex interaction of various factors and all the reciprocal actions are not yet 
known. 
Similar to study I, BMP-7 has been shown to have a negative effect on osteogenic 
differentiation of rat BMSCs (Wongwitwichot & Kaewsrichan, 2017). Another study 
observed a negative effect of BMP-7 on osteogenic differentiation of human 
periodontal ligament stem cells however, they also noticed an inductive effect of 
BMP-7 on the osteogenic differentiation hMSCs (Ern et al., 2017). On the other 
hand, BMP-7 has been observed to induce signaling routes related to tenogenesis 
more than those related to osteogenesis or chondrogenesis in the culture of primary 
human tenocyte-like cells (Klatte-Schulz et al., 2016). Overall, the cell signaling events 
related to BMP-7 use still require more elucidation although it appears that BMP-7 
is not an optimal candidate for osteogenic differentiation. 
6.4 scCO2 processed β-TCP/PLCL composite is cytocompatible 
and osteogenic in vitro and biocompatible and 
osteoconductive in vivo 
Synthetic polymer-based composites filled with CaPs have shown promise in BTE 
and among biomaterials composites may be the most promising strategy for a 
synthetic bone graft with most optimal properties (de Misquita et al., 2016). ScCO2 
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foaming is an excellent processing method for polymer-based tissue engineering 
scaffolds. The method only uses CO2 and is therefore non-toxic, cost effective, and 
requires low critical parameters (TC 304 K, PC 7.5 MPa) allowing the addition of 
biomolecules, such as growth factors, into the material during processing (Duarte et 
al., 2013). 
Previously, Mathieu and colleagues (2006) concluded that in scCO2 processing a 
higher ceramic content reduce porosity and increase average pore size of the 
composite (Mathieu et al., 2006). Furthermore, the authors also suggested that 5 wt-
% β-TCP content is an upper limit to achieve an interconnected and homogenous 
pore structure (Mathieu et al., 2006). Contradictory to this report, study III presents 
a composite with 50 wt-% β-TCP content with high porosity (65-67 %) and average 
pore size of 380 μm processed by using scCO2. Previously, PLA/β-TCP composites 
with 10 % ceramic content and 74 % porosity (Mathieu et al., 2006) and, 
PCL/fibroin/hydroxyapatite (70/20/10 %) composites with average porosity of 
69.7 % (Diaz-Gomez et al., 2017) have been manufactured with scCO2 foaming. 
Study II also reports a solution to uncover the ceramic granules covered by a polymer 
surface – a problem related to scCO2 processing of polymer-ceramic composites. 
The reported pre-compression treatment resulted in the tearing of the polymer 
surface, enabling the display of the β-TCP granules. This is highly important in the 
early interaction of cells and tissues with the composite, as PLCL is not bioactive 
and lacks biological binding sites (Jeong et al., 2008; Z. Wang et al., 2016) while β-
TCP is bioactive and osteoconductive (Barrere et al., 2006; Chatterjea et al., 2013). In 
addition, the additional holes in the PLCL pore surfaces, which gave rise during the 
pre-compression, enhanced interconnectivity and micro-porosity of the composites. 
Study III demonstrated the cytocompatibility of the novel composite in vitro.  
ALP activity was induced in BM and OM, although the level of ALP activity was 
significantly enhanced in OM when compared to BM during the first 2 weeks. Both 
ALP activity and ALP gene expression were highest at 14 days, which is logical as 
high ALP expression occurs in matrix maturation phase of the osteogenic 
differentiation (Lian et al., 2012). The total soluble collagen amount was comparable 
in both BM and OM but unexpectedly the soluble collagen amount decreased from 
14 to 21 days. This may be caused by the mineralization of collagen fibrils that are 
the basic building blocks on bone ECM (Nair et al., 2013) as the mineralization may 
hinder the solubility of collagen. Alizarin red staining confirmed the high level of 
mineralization of hASC culture in the scaffolds in both BM and OM and, as the 
immunocytochemical staining demonstrated the formation of COL-1 matrix in the 
composites as well, we may conclude that hASCs were able to develop a mineralized 
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collagen matrix typical to bone when cultured in the β-TCP/PLCL composites. The 
expression of late osteogenic marker protein OCN and also of osteogenic genes was 
in agreement with literature related bone formation as ALP and Runx2a expression 
peaks occurred at the early phase of differentiation while OSX expression peaked 
later (Lian et al., 2012). In studies II and III, the presence of OM enhanced the 
osteogenic effect of the composite material. In study II, the gene expression of 
Runx2a was significantly higher in OM and OM-cocktail groups compared to BM 
and EM. The trend in ALP and Runx2a gene expression as well as in quantified 
mineralization results in BM and OM were very similar in both studies II and III. 
Although, there were more significant differences in study II between BM and OM 
conditions than in study III, and a reason may be the higher β-TCP content of the 
composite in study III as well as enhanced display of the ceramic granules as a result 
of the pre-compression treatment. In study III, the comparison of mineralization in 
the composite and on cell culture plastic (2D) in BM further underlines the 
composite’s inherent osteogenic potential in vitro. Also, in study II, concurrent 
enhancement of ALP activity and ALP gene expression with mineral formation was 
detected in EM, also indicating the composite’s inherent osteogenic potential. 
Previously, a nanocomposite of poly-(lactic-co-glycolicacid) with 40 wt-% of 
amorphous calcium was shown to support the co-culture and further differentiation 
of hASC derived endothelial and osteogenic cells (Gao et al., 2014). Furthermore, a 
composite consisting of 60 % β-TCP in PLLA has been shown to perform similarly 
to plain β-TCP in osteogenesis in vivo (Aunoble et al., 2006). 
The osteoconductivity of the β-TCP/PLCL composites was demonstrated in 
study III in a rabbit femur defect model. Previously, PLA implants (Pihlajamäki et 
al., 2006) have induced an inflammatory reaction caused by acidic degradation 
products, leading to the formation of fibrous tissue surrounding the implant. In 
contrast, the β-TCP/PLCL composite was shown to be biocompatible as no fibrous 
tissue formation, cysts or inflammation were observed during the 24-week follow-
up. Furthermore, the composite was demonstrated to be osteoconductive as based 
on the representative MGT staining and micro-CT images, bone tissue grew on the 
composite surface and was able to penetrate the porous composite already 4 weeks 
after implantation. In a previous study, a PLA/β-TCP (95/5 wt-%) composite 
foamed by using scCO2 caused the formation of a clear fibrous layer between the 
composite and mineralized tissue after 8- and 16 weeks in sheep femur defects (van 
der Pol et al., 2010). Similarly to the results in study III, Pihlman and colleagues (2018) 
implanted the same porous β-TCP/PLCL composites in a rabbit calvarial defect, 
demonstrating the osteoconductivity and ingrowth of both bone and vascular tissue. 
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The authors also reported that the β-TCP/PLCL composite provided structural 
support in the defect site by blocking the bulging soft tissues around the defect 
(Pihlman et al., 2018).  
6.5 hASC endothelial differentiation potential may be limited 
Tissue engineered synthetic bone grafts are still limitedly used in the clinic while 
autologous and allogeneic bone grafts remain the gold standard in treating large bone 
defects. One reason for the weak success of BTE grafts is that the implanted cells 
die without proper vasculature to transport them oxygen and nutrients (Pirosa et al., 
2018; Rouwkema et al., 2008). As hASCs have been shown to have the potential to 
differentiate towards both osteogenic and endothelial lineages, the hypothesis was 
that hASCs could provide a single cell source for engineering vascularized bone 
grafts. 
In study II, hASCs demonstrated to have ability to differentiate towards an 
endothelial phenotype in 2D culture conditions when cultured in a modified version 
of EGM-2 based on HS instead of FBS and excluding hydrocortisone and ascorbic 
acid from the supplements. hASCs formed tubular structures in EM more 
extensively when compared to EGM-2 however, the vessel network was not as 
organized as that formed by HUVECs. Previously, endothelially differentiated ASCs 
have been shown to remain less matured in contrast to mature ECs (Antonyshyn et 
al., 2019; Volz et al., 2016). Furthermore, Antonyshyn and colleagues (2019) reported 
that even though differentiated hASCs express the commonly used endothelial 
markers and even demonstrate EC functionality in an AcLDL uptake assay, their 
expression levels remain in a significantly lower level when compared to those of 
mature ECs. The authors proposed that the endothelial differentiation potential of 
hASCs is limited however, they used EGM-2 in the differentiation of hASCs 
(Antonyshyn et al., 2019) even though FGF-2 and a combination of VEGF/FGF-2 
have been shown to be more effective in the endothelial induction of hASCs (S. 
Khan et al., 2017). In turn, DNA methylation reduction was shown to increase 
endothelial marker expression, suggesting that ASC endothelial potential is 
epigenetically restricted (Culmes et al., 2013). Furthermore, Cheng and colleagues 
converted hASCs into functional endothelial-like cells via lentiviral transduction (F. 
Cheng et al., 2018). Nevertheless, epigenetic modification and viral transduction are 
not safe enough methods to be used in clinical treatments. It is also debatable 
whether the implanted cells used for treating patients would need to be mature, as it 
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has been suggested that undifferentiated MSCs have a higher angiogenic capacity 
than endothelially differentiated MSCs (Guo et al., 2016). Furthermore, the 
endothelial potential of ASCs has been under debate and different studies have 
suggested that the endothelial potential of hASCs is related to a hASC subpopulation 
such as CD34+/CD31- hASCs (Miranville et al., 2004), SSEA-4+ hASCs (Mihaila et 
al., 2013) or CD45-/CD31- hASCs (Antonyshyn et al., 2019). In addition, as human 
SVF consist approximately 20 % of ECs (Kanthilal & Darling, 2014), it has been 
speculated whether the endothelial capacity of hASCs gives rise from the 
proliferation of this EC population or from differentiation. Ell and colleagues (2017) 
cultured hASCs from 18 different donors in a co-culture, seeding the hASCs on top 
of endothelial progenitor cells. The authors demonstrated that the intrinsic 
endothelial potential of hASCs could be evoked merely by culturing hASCs in 
contact with ECs (Ell et al., 2017). Furthermore, they observed notable donor 
variation in hASC endothelial potential and discussed that diseases and conditions, 
such as diabetes type 2, metabolic syndrome and obesity, may have a fundamental 
impact on hASCs. Also, alarmingly maternal obesity has been shown to result in 
epigenetic modifications in adipose tissue gene expression of the offspring (Ell et al., 
2017; Attig et al., 2013). Low-level inflammation, which is related to insulin resistance 
as well as metabolic syndrome, leads to adipose tissue fibrosis and hindered 
neoangiogenesis eventually causing hypoxia (Ell et al., 2017; T. Khan et al., 2009). 
Pro-longed inflammation may lead to epigenetic changes in the adipose tissue and 
cause the harvested cells to behave differentially even in non-hypoxic conditions (Ell 
et al., 2017; Stenvinkel et al., 2007). 
When cultured in the β-TCP/PLCL composites in EM in study II, hASCs were 
able to differentiate towards an EC phenotype, as the cells expressed endothelial 
proteins CD31 and vWF and, the relative expression of vWF was enhanced. 
However, as tubular formation was not observed, the differentiation remained in a 
pre-mature state. The expression of CD31 and vWF was clear in EM at 14 and 21 d 
whereas in EM-cocktail their expression went down from 14 to 21 d. Similarly, the 
gene expression of vWF in EM-cocktail declined from 14 to 21 d. A reason for this 
may be the OM components including β-GP added after 7 days of culture. ALP 
cleaves inorganic phosphate from β-GP and high inorganic phosphate levels have 
been shown to impair angiogenesis, EC migration, tube formation, and EC survival 
(Di Marco et al., 2013; Di Marco et al., 2008). Therefore, β-GP may have limited or 
even inhibited the endothelial differentiation of hASCs. Then again, endothelial 
differentiation of hASCs has been shown to occur in semi-solid or gel-like materials 
such as fibrin (Correia et al., 2014; Hutton et al., 2013) or Matrigel (Planat-Benard et 
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al., 2004). Considering the endothelial differentiation of hASCs, seeding them in 
fibrin into the β-TCP/PLCL composites may have resulted in a better endothelial 
outcome. Based on the results of study II and IV and the debate related to hASC 
endothelial capacity, a mature EC type, such as HUVECs, would be a more attractive 
choice for the evaluation of angiogenic potential of novel biomaterial scaffolds. 
6.5.1 hASCs alone are not a promising cell-source for the engineering of 
vascularized bone 
In study II the aim was to induce both endothelial and osteogenic differentiation of 
hASCs in the same culture in β-TCP/PLCL composites. hASCs have the potential 
to differentiate towards both lineages however, an efficient and controllable method 
to induce hASC differentiation towards both lineages have not been reported. 
Differentiation of hASCs towards both osteogenic and endothelial lineages was 
achieved in EM in β-TCP/PLCL composites. Endothelial marker proteins CD31, 
CD144 and, vWF and relative vWF gene expression as well as ALP activity and 
relative ALP and OSX gene expressions were elevated in EM. However, when 
considering the endothelial differentiation, tubular formation was not observed. In 
addition, hASCs produced mineralized matrix in EM although, to a lesser extent than 
in other groups. In contrast to study II, previously osteogenic supplements were 
needed for osteogenic differentiation of hASCs following the endothelial induction 
(Correia et al., 2014). Furthermore, Gardin and colleagues (2012) required osteogenic 
supplements in addition to endothelial supplements for hASC osteogenic induction 
even though they used a HA scaffold. The osteogenic induction in EM is most likely 
a result of β-TCP/PLCL composite as it was shown to induce osteogenic 
differentiation of hASCs even in BM in both studies II and III. Overall, the 
differentiation pathways were still in a premature state after 3-week culture in EM. 
As mechanical stimulation enhance both osteogenic (Virjula et al., 2017; Tirkkonen 
et al., 2011) as well as endothelial differentiation (Colazzo et al., 2014) of hASCs, a 
mechanical stimulus may have benefitted the in vitro setup in study II. 
The induction of both osteogenic and endothelial differentiation paths in the 
same cell culture in vitro has been shown to be challenging also by other authors 
(Correia et al., 2014; Hutton et al., 2013). In fact, it has been proposed that osteogenic 
and endothelial differentiation pathways may be mutually inhibitory (Correia et al., 
2011; Hutton et al., 2013). One reason may be the negative effect of inorganic 
phosphate related to osteogenic supplements on ECs (Di Marco et al., 2013; Di 
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Marco et al., 2008). In study II, the cocktail medium of EM and OM supported the 
osteogenic differentiation, but not the endothelial differentiation of hASCs. In 
contrast, Gardin and colleagues (2012) reported that a medium consisting osteogenic 
supplements (β-GP, DEX and ascorbic acid) as well as FGF-2 and endothelial cell 
growth factor induced the expression of both osteogenic and endothelial genes in 
hASCs cultured in a HA scaffold. When comparing the simultaneous differentiation 
of hASCs towards both osteogenic and endothelial lineages in cocktail groups similar 
to study II the best strategy was to start with osteogenic differentiation of hASCs for 
3 weeks followed by addition of undifferentiated hASCs and a 2-week culture in 
EGM-2 (Correia et al., 2014). In contrast, Hutton and colleagues (2013) cultured 
hASCs in fibrin gel and concluded that the best strategy for achieving both 
osteogenic and endothelial pathways in the same culture is to induce first a strong 
endothelial population and then continue with the osteogenic differentiation.  
As the inorganic phosphate causes problems in the endothelial differentiation of 
hASCs, it may be more feasible to first produce a well-established tubular network 
and then add the osteogenic precursors and continue with osteogenic differentiation. 
In addition, as the endothelial differentiation capacity of hASCs has been questioned, 
it may be more beneficial to choose another cell source to provide ECs for a 
vascularized bone model. Altogether, the results between studies concerning the 
simultaneous osteogenic and endothelial differentiation of hASCs differ greatly, 
underlining the complexity of the study area. The parameters of the studies, such as 
medium composition, scaffold type, culture period, used analysis methods, vary 
greatly, which makes it challenging to reach conclusions.  
6.6 Incorporation of copper in PCL/BaG composite does not 
provide benefit for vascularized bone engineering 
The dissolution of Si, Ca, P and Na induce both intra- and extracellular responses in 
cells at the BaG interface contributing to both osteogenesis and angiogenesis. In 
study IV, the incorporation of Cu into S53P4 was designed to release the Cu2+ locally 
to even more enhance vascularization. However, the specific mechanisms of Cu2+ 
affecting hBMSCs and HUVECs were observed to be complex.  
In line with previous studies, the ionic dissolution products from S53P4 did not 
strongly affect the proliferation of hBMSCs (Qazi et al., 2017; Weng et al., 2017). 
However, the Cu2+ released from the PCL/BaG composites had a dose-dependent 
inhibitory effect on hBMSC proliferation. The cytotoxic effect of Cu2+ in vitro is 
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mainly based on the generation of reactive oxygen species. Weng and colleagues 
(2017) reported a dose- and exposure duration dependent cytotoxicity of Cu2+ 
released from Cu-BaG nanofibers using different cell types, including HUVECs, 
ASCs and BMSCs. Furthermore, a high Cu2+ concentration produced by 
mesoporous BaG-Cu microparticles incorporated in nanocellulose hydrogel was 
shown to be cytotoxic for 3T3 fibroblasts (X. Wang et al., 2016). In turn, Wu and 
colleagues (2013) compared mesoporous BaG-Cu scaffolds and their extracts with 
varying amounts of Cu2+ and, demonstrated that a high Cu2+ concentration 
significantly decreased proliferation of hBMSCs. In study IV, the highest Cu2+ 
concentration in the culture medium varied from 50 μM (PCL/BaG-Cu 4:1) to 140 
μM (PCL/BaG-Cu 1:1). In study IV, hBMSCs were able to maintain their 
proliferative capacity when the Cu2+ concentration was lower than 20 μΜ. 
Furthermore, study IV was conducted in a static model with fixed medium change 
intervals resulting in accumulation of Cu2+ between the medium changes. 
Altogether, these Cu2+ concentrations are still clearly lower than the 157 μM level, 
which Wu and colleagues (2013) proposed to be inhibitory for hBMSC proliferation. 
In turn, another study reported that a 50 μM Cu2+ concentration reduces hBMSC 
proliferation while increasing their osteogenic and adipogenic differentiation 
potential (Rodriguez et al., 2002). Importantly, when considering the osteogenic 
differentiation process, the proliferation phase is followed by matrix maturation and 
mineralization phases during which the high proliferation has already ceased (Lian 
& Stein, 1995). 
Even though the PCL/BaG and PCL/BaG-Cu scaffolds supported ALP activity 
in hBMSCs, the rising BaG and BaG-Cu content had a lowering effect on ALP 
activity. The study of Wu and colleagues (2013) demonstrated that rising Cu2+ 
concentration had a slight increasing effect on ALP activity in hBMSCs, but the 
difference was not significant. Similarly, Rath and colleagues (2014) detected no 
significant effect by Cu2+ concentration on ALP activity in hBMSCs cultured in the 
Cu-doped 45S5 BaG scaffolds. In fact, it may be sufficient to have a distinct 
induction of ALP activity, rather than trying to achieve a high ALP activity level, as 
the function of ALP in osteogenic differentiation is to ensure the presence of Pi and 
decrease pyrophosphate concentration to allow mineralization (Ojansivu et al., 2015). 
The osteogenic differentiation of hBMSCs was also evaluated based on 
osteogenic gene expression in both hBMSC culture and hBMSC+HUVEC co-
culture setups using PCL, PCL/BaG 4:1 and PCL/BaG-Cu 4:1 scaffolds.  
Intriguingly, the copper containing composite enhanced the expression of early 
osteogenic marker gene Runx2a evidently more when compared to PCL/BaG 
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composite in hBMSC culture. The expression is Runx2 is required for the osteogenic 
differentiation to occur. Nevertheless, for the differentiation to proceed to 
maturation the high Runx2 expression needs to decrease, because the high Runx2 
expression inhibits osteogenic maturation maintaining the cells in a premature stage 
(Komori, 2017). For this reason, the late and high expression of Runx2a at 20-day 
time point together with the low expression of late osteogenic marker genes OCN 
and DLx5 in PCL/BaG-Cu 4:1 scaffold suggests that osteogenesis is in a stagnant 
state. PCL/BaG 4:1 induced the gene expression of OCN and DLx5 more when 
compared to PCL/BaG-Cu 4:1 at both time points, pointing out the negative effect 
of Cu2+ on hBMSC osteogenesis. Similarly, a previous study concluded that copper 
supplementation decreased the expression of ALP activity, expression of osteogenic 
genes and formation of bone nodules in rat BMSCs in vitro (S. Li et al., 2014). In an 
animal model the authors also demonstrated that Cu2+ ions induce vascularization 
while inhibiting collagen type I formation and accumulation in vivo (S. Li et al., 2014). 
The hBMSC+HUVEC co-cultures were supplemented with EGM-2 after the 
HUVECs were seeded at day 6, explaining the lower osteogenic gene expression 
levels when compared to hBMSC culture setup.  
Both PCL/BaG 4:1 and PCL/BaG-Cu 4:1 scaffolds enhanced the expression of 
endothelial proteins vWF and CD31 and, induced the formation of tubular network 
more in both hBMSC and hBMSC+HUVEC culture setups when compared to plain 
PCL scaffold. Previously, 45S5 BaG was demonstrated to support the tubular 
formation in fibroblast and EC cultures (Gorustovich et al., 2010) and, the 
dissolution products of S53P4 have been shown to enhance VEGF secretion of 
human fibroblasts (Detsch et al., 2014). Proteins CD31 and vWF were more strongly 
expressed in the co-culture setup than in hBMSC culture. In agreement with this, the 
Cu-doped 45S5 scaffolds have been shown to enhance the VEGF secretion and 
tubular formation in a co-culture of hBMSCs with human dermal microvascular ECs 
(Rath et al., 2014). In addition, the authors observed that copper alone did not 
enhance the VEGF secretion in ECs but the presence of hBMSCs was also required 
(Rath et al., 2014) suggesting that BaG has a paracrine effect on hBMSCs such as to 
secrete factors that influence the ECs. Predictably, the endothelial gene expression 
of PECAM and vWF were elevated in co-culture setup when compared to hBMSC 
culture with all scaffold types (PCL, PCL/BaG 4:1 and PCL/BaG-Cu 4:1). Because 
several previous reports have proposed that copper ions induce vascularization (X. 
Wang et al., 2016; Rath et al., 2014; Wu et al., 2013), it was surprising to detect so little 
difference between PCL/BaG 4:1 and PCL/BaG-Cu 4:1 scaffolds. Only the vWF 
gene expression in the co-culture was slightly elevated in the Cu-containing scaffold 
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when compared to PCL/BaG 4:1. The conflicting conclusions between studies may 
result from different scaffold design including BaG composition, used cell type or 
medium composition. For instance, Detsch and colleagues (2014) demonstrated that 
that BaG granule size had a significant effect on VEGF release in fibroblasts: granule 
sizes of 0.5-0.8 mm and 1.0-2.0 mm induced VEGF secretion while granule sizes of 
2.0–3.15 mm inhibited it. Altogether, PCL/BaG-Cu 4:1 scaffold supported 
vasculogenesis and tubular formation in the co-culture setup but the angiogenic 
effect of Cu2+ was not significant as compared to PCL/BaG composite. The 
angiogenic effect of S53P4 itself may be enough and the addition of copper does not 
significantly boost this effect. 
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7 CONCLUSIONS 
In this thesis, the effect of different synthetic bone graft materials on bone formation 
in vitro and in vivo were evaluated. Ceramic components commonly used as bone 
grafts were firstly studied in vitro and then successfully integrated in PLCL- and PCL-
based composites. The study focused on analyzing how osteogenesis and 
vasculogenesis occur with the biomaterial scaffolds in vitro and in vivo. The main 
conclusions of the four studies included in this thesis are described below: 
I Both biomaterials BioRestore and BoneCeramic support the viability and 
proliferation of hASCs in vitro. However, the materials affect hASCs differentially: 
BioRestore promotes hASC proliferation while BoneCeramic enhances the 
osteogenic differentiation. Furthermore, osteogenic medium enhances hASC 
osteogenesis in 3D culture significantly more as compared to the traditionally used 
growth factors BMP-2, BMP-7 and VEGF. By contrast, growth factors combined 
with either biomaterial do not stimulate proliferation or osteogenic differentiation as 
compared to basal medium. Furthermore, BMP-7 consistently inhibits proliferation 
and osteogenic differentiation of hASCs in 3D culture. In turn, the addition of 
growth factors in OM does not significantly benefit the hASC osteoinduction. The 
most robust osteogenic outcome with hASCs is achieved with BoneCeramic 
combined with OM. 
II The elastic scCO2-processed β-TCP/PLCL composite supports both 
osteogenic and endothelial differentiation of hASCs in vitro when cultured in 
endothelial medium. As no tubular formation was observed, the combination of 
endothelial medium and the composite cannot induce mature endothelial 
differentiation during the 3-week protocol. Cocktail medium of osteogenic medium 
and endothelial medium (1:1) supports osteogenic but not endothelial differentiation 
of hASCs.  
III A highly porous, biodegradable, elastic and easy-to-handle β-TCP/PLCL 
composite was developed to serve as a synthetic bone graft. The study is the first to 
report a scCO2 processed composite with a high ceramic content (50 wt-%) and high 
 101 
porosity (65-67 %) for bone tissue engineering.  To increase the bioactivity of the 
composite, the otherwise polymer embedded β-TCP particles can be uncovered by 
a dynamic compression treatment. The β-TCP/PLCL composite is cytocompatible 
and supports hASC proliferation and osteogenic differentiation in vitro. Furthermore, 
the composite is biocompatible and osteoconductive in vivo as demonstrated in a 
rabbit femur defect. 
IV The incorporation of BaG-Cu to PCL enhances the mechanical properties 
of the printed scaffolds as compared to PCL scaffold. The composites provide 
sustained release of biologically relevant inorganic ions and, a bioactive CaP 
precipitate layer forms on the surface of the PCL/BaG-Cu composites in SBF in 
vitro. However, copper released from PCL/BaG-Cu composites has a dose-
dependent inhibitory effect on hBMSC proliferation. PCL/BaG composite supports 
hBMSC osteoinduction while the incorporation of copper diminishes the osteogenic 
effect. Both PCL/BaG and PCL/BaG-Cu composites support the formation of 
tubular structures in hBMSC+HUVEC co-culture showing that the added copper 
does not enhance the vasculogenic potential of the composite. 
These findings demonstrate that by adding β-TCP or BaG in an inert synthetic 
polymer phase, bioactive composites can be created with scCO2 foaming and 3D 
printing. Especially the developed osteoconductive β-TCP/PLCL composite is a 
promising synthetic bone graft for clinical use. Both hASCs and hBMSCs serve 
reliably as tools in the in vitro study of synthetic bone graft materials. Furthermore, 
these cells are differentiated cost-effectively and efficiently to bone-forming cells 
with OM in vitro.  However, considering the evaluation of vasculogenic effect of the 
materials, HUVECs provide a more consistent cell type for in vitro studies.  
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Abstract
Human adipose stem cells (hASCs) have been recently used 
to treat bone defects in clinical practice. Yet there is a need 
for more optimal scaffolds and cost-effective approaches 
to induce osteogenic differentiation of hASCs. Therefore, 
?????????????????????????????????? ??????????????????????
(BMP-2 and BMP-7), vascular endothelial growth factor 
(VEGF), and osteogenic medium (OM) for the osteo-
induction of hASCs in 3D culture. In addition, growth 
factors were tested in combination with OM. Commercially 
available bioactive glass scaffolds (BioRestore) and 
biphasic calcium phosphate granules (BoneCeramic) 
were evaluated as prospective carriers for hASCs. Both 
biomaterials supported hASC-viability, but BioRestore 
resulted in higher cell number than BoneCeramic, whereas 
BoneCeramic supported more significant collagen 
???????????? ??? ????????????????????????????? ????????????
with plain OM, promoting higher alkaline phosphatase 
activity and collagen production than growth factors. In fact, 
treatment with BMP-2 or VEGF did not increase osteogenic 
differentiation or cell number significantly more than 
maintenance medium with either biomaterial. Moreover, 
BMP-7 treatment consistently inhibited proliferation and 
osteogenic differentiation of hASCs. Interestingly, there 
???????????????????????????????????????????????????????
????????? ?????? ??????????????? ??????????????????????
???????????????? ???????? ????????????? ?????? ?????????????
more than growth factors in 3D culture.
Keywords: Adipose stem cells; mesenchymal stem cells; 
bone tissue engineering; bioactive glass; biphasic calcium 
phosphate; growth factors; osteogenic differentiation; in 
vitro culture; 3D scaffolds.
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?????????????????? ?????
Introduction
Tissue engineered bone has emerged as a potential 
alternative to meet the increasing need for bone 
replacements in clinical medicine and to overcome the 
limitations of autologous grafts as well as the risks related 
??????????????????????????????????????????????????????????
regeneration via autologous stem cell transplantation 
is a promising approach to treat large bone defects. 
For example, patient’s own multipotent mesenchymal 
stem cells (MSCs) can be isolated from adipose tissue, 
expanded ex vivo, and transplanted to the defect site 
using biomaterial scaffold as a carrier (Mesimaki et al., 
2009; Thesleff et al., 2011). Among adult stem cells, 
human adipose stem cells (hASCs) are readily available 
multipotent cells having the potential to differentiate 
into lineages of mesenchymal tissues, including bone, 
cartilage, fat, tendon, muscle, and marrow stroma (Zuk 
et al., 2001; Zuk et al., 2002; Park et al., 2010; Choi et 
al., 2012). The osteogenic capacity of ASCs has been 
demonstrated in both in vitro  (Zuk et al., 2002; De 
Girolamo et al., 2007) and in vivo studies (Cowan et al., 
2004; Hicok et al., 2004; Hattori et al., 2006; Di Bella et 
al., 2008; Behr et al., 2011). In addition, our group has 
reported several clinical cases, where autologous hASCs 
combined with biomaterials have been used to repair 
cranio-maxillofacial defects (Mesimaki et al., 2009; 
Thesleff et al., 2011).
 In order to enhance the bone formation capacity, 
a number of inducing factors have been tested in 
combination with biomaterials and cells. Based on the 
fact that bone formation is modulated by a number of 
osteogenic factors released from the bone and surrounding 
tissues during the repair process, recombinant bone 
morphogenetic protein (BMP)-2 and BMP-7 have been 
utilised in clinical applications in order to stimulate bone 
healing (Samartzis et al., 2005; Garrison et al., 2007; 
Clokie and Sandor, 2008). Similar to BMPs, vascular 
endothelial growth factor A (VEGF-A) has been used to 
promote angiogenesis and osteogenesis of MSCs in vitro 
(Behr et al., 2011; D’Alimonte et al., 2011) and in vivo 
(Roldan et al., 2010; Behr et al., 2011). However, critical 
views on the use of BMPs have been emerging lately due 
to their short half-lives, expensiveness and ineffectiveness 
(Garrison et al., 2007; Garrison et al., 2010; Zuk et al., 
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2011). The clinical use of growth factors has been hindered 
??????????????????????????????????????????????????????????
in humans. Large doses of exogenous growth factors may 
cause unexpected physiological effects ranging from 
bone resorption (Giannoudis et al., 2007) to heterotopic 
???????????? ????????? ??????????? ????????????? et al., 
2008). Hence, alternative methods for effective osteo-
induction of MSCs are under investigation (Kim et al., 
2003; Kim et al., 2005; McCullen et al., 2010; Tirkkonen 
et al., 2011).
 For example, osteogenic medium (OM) supplemented 
with L-ascorbic acid 2-phosphate (AsA2-P), dexamethasone 
??????????????????????????????????????????????????????
used for the osteogenic differentiation of MSCs in vitro 
(Zuk et al., 2001; Ogawa et al., 2004; Giusta et al., 
2010; Rada et al., 2011). The in vivo studies have also 
shown the advantage of OM-induction in ASC-based 
????????????????????????????????????????????????????? ???
detected with the OM-induced ASCs compared to the 
non-induced ASCs (Dudas et al., 2006; Yoon et al., 2007; 
Di Bella et al., 2008; Schubert et al., 2011). However, 
the osteo-induction efficiency of OM has not been 
systematically compared to BMP-2, BMP-7 and VEGF 
with hASCs in vivo or in vitro. Although in vivo studies 
are required in the future to demonstrate the utility of OM 
?????????????????????????????????????????in vitro data is of 
fundamental importance before it is reasonable to initiate 
in vivo studies.
 In addition to effective osteo-induction, suitable 
biomaterial carriers for supporting the hASC proliferation 
and differentiation are required for successful bone 
regeneration. Bioactive glass and biphasic calcium 
phosphate, both biomaterials currently used in cranio-
maxillofacial (Peltola et al., 2006; Peltola et al., 2008; 
Frenken et al., 2010; Clozza et al., 2012b) and orthopaedic 
surgery (Lindfors et al., 2010; Garrido et al., 2011), were 
compared as prospective carriers for hASCs in the current 
study. Synthetic bioceramics are among the most promising 
biomaterials for the use of bone tissue engineering largely 
due to their capacity to form bone-like apatite layers 
??? ????????????? ?????????????? ??????? ?? ???????????????
facilitates their strong bonding to bone (Hench, 1998; 
Kokubo et al., 2003). Furthermore, bioactive glass and 
calcium phosphate biomaterials are capable of promoting 
bone formation through the dissolution of Ca and P ions 
(Xynos et al., 2000; E et al., 2010). Essential characteristics 
for silicate bioactive glasses include high Na2O and CaO 
content, high CaO/P2O5 ratio, and SiO2 content less than 
60 mol%. Biphasic calcium phosphates, in turn, consist of 
varying ratios of hydroxyapatite (HA) and beta-tricalcium 
??????????????????? ?????????????????????????????????
??????????????????????????????? ? ???? ?????????????????
widely used as it offers controlled degradation and optimal 
osseous substitution (Frenken et al., 2010; Ghanaati et al., 
2012).
 While searching for an optimal approach to treat 
patients with adipose stem cells, the aim of the present 
????????????????????????????????????????????????????
VEGF and OM for the osteogenic differentiation of hASCs 
in clinically relevant 3D environment. In addition, BMP-2, 
BMP-7 and VEGF were tested in combination with OM.
Materials and Methods
Biomaterial characterisation and preparation
Two commercially available biomaterials, Straumann® 
BoneCeramic granules (Straumann AG, Basel, Switzerland) 
and Inion BioRestoreTM (Inion Oy, Tampere, Finland) 
bioactive glass scaffolds were compared as 3D carriers 
for hASCs in this study. The morphology and surface 
topography of both materials was examined using scanning 
electron microscopy (SEM; Philips XL-30; Philips, 
Eindhoven, The Netherlands). The biomaterial samples 
were air-dried and sputter coated with gold prior to analysis 
with SEM.
 The fully synthetic, granular form Straumann® 
BoneCeramic composed of biphasic calcium phosphate 
with 60 % hydroxyapatite (HA; 100 % crystalline) and 
???????????????????????????? ???????????? ????? ??? ?????
study. BoneCeramic has a porosity of 90 %, and a granule 
size between 0.5 and 1.0 mm with interconnected pores of 
100-500 μm in diameter. For cell culturing, 0.25 g aliquots 
of sterile BoneCeramic granules were transferred onto 24-
well plates (Nunc, Roskilde, Denmark) using an analytical 
balance that was placed inside a laminar hood. The granules 
were incubated in 1 mL of corresponding medium (Table 
1) for 48 h prior to cell seeding.
Table 1. The compositions of different media used in the study.
 Medium Supplements
 Maintenance medium (MM) DMEM/F-12, 10 % FBS, 1 % L-glutamine, 1 % antibiotics
Osteogenic medium 
(OM)
??????????????????????????????????????????????????????????? ????????????????????
(Sigma-Aldrich, MO, USA) in MM
Pa
rt
 I MM + BMP-2 50 ng/mL bone morphogenetic protein-2 (Genscript, NJ, USA) in MM
MM + BMP-7 100 ng/mL bone morphogenetic protein-7 (Sigma-Aldrich) in MM
MM + VEGF 20 ng/mL vascular endothelial growth factor (R&D Systems Inc, MN, USA) in MM
Pa
rt
 II
OM + BMP-2 50 ng/mL BMP-2 (Genscript, NJ, USA) in OM
OM + BMP-7 100 ng/mL BMP-7 (Sigma-Aldrich) in OM
OM + VEGF 20 ng/mL VEGF (R&D Systems Inc, MN, USA) in OM
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 The Inion BioRestoreTM bioactive glass scaffolds used 
in this study had a nominal composition of 11.1-12.0 wt% 
Na2O, 15.0-17.1 wt% K2O, 2.8-3.3 wt% MgO, 12.7-
15.2 wt% CaO, 2.7-3.8 wt% P2O5, 1.0-1.4 wt% B2O3, 0.0-
0.6 wt% TiO2 and 48.5-52 wt% SiO2. The porous bioactive ???????????????? ???? ????????????????? ??????????????????
previously (Moimas et al.?????????????????????????????????
?????????????????????????????? ????????? ?????????????
???????????????????????????????????????????????????????
conditions to obtain desired structural and mechanical 
properties. Scaffolds with porosity of 70 % and dimensions 
of 7 x 7 x 3 mm were used in this study.
 Before cell seeding, the bioactive glass scaffolds were 
sterilised with 70 % ethanol followed by several steps 
of washing with Dulbecco’s phosphate-buffered saline 
(DPBS; Lonza Biowhittaker; Verviers, Belgium), and 
incubated in 1 mL of corresponding medium (Table 1) for 
48 h.
Cell isolation, characterisation and culture
Adipose tissue samples were acquired from surgical 
procedures in the Department of Plastic Surgery, Tampere 
University Hospital with the patients’ written consent. 
The study was conducted in accordance with the Ethics 
Committee of the Pirkanmaa Hospital District, Tampere, 
Finland (R03058). The adipose tissue samples were 
obtained from 11 donors (mean age 50 ± 14 years).
 The adipose tissue was manually chopped into small 
fragments and digested with collagenase type I (1.5 mg/
mL; Invitrogen/Life Technologies, Carlsbad, CA, USA) 
in a water bath at 37 °C for 60 min, and the hASCs 
were isolated by centrifugation. Following isolation, the 
hASCs were expanded in T75 cm2? ???????????? ??????
(Nunc) in maintenance medium (MM) consisting of 
??????????????????????????????????? ?????????????????
F-12 (DMEM/F-12 1:1) (Invitrogen, Paisley, UK), 
10 % foetal bovine serum (PAA Laboratories, Pasching, 
Austria), 1 % antibiotics (100 U/mL penicillin; 100 U/mL 
streptomycin; Lonza Biowhittaker, Basel, Switzerland) 
and 1 % L-glutamine (GlutaMAX I; Invitrogen). After 
expansion hASCs were cryo-preserved in gas phase 
nitrogen in freezing solution consisting of 10 % dimethyl 
sulphoxide (Hybri-Max; Sigma-Aldrich, St. Louis, MO, 
USA) in foetal bovine serum (PAA Laboratories, Pasching, 
Austria).
 After primary cell culture (at passage 1-2) the hASCs 
?????????????????????????????????????????????????? ???????
(FACSAria; BD Biosciences, Erembodegem, Belgium). 
Monoclonal antibodies against CD14-PE, CD19-PE, 
CD49d-PE, CD73-PE, CD90-APC, CD106-PE, (BD 
Biosciences); CD45-FITC (Miltenyi Biotech, Bergisch 
Gladbach, Germany); CD34-APC, HLA-ABC-PE, HLA-
DR-PE (Immunotools, Friesoythe, Germany); and CD105-
PE (R&D Systems, Minneapolis, MN, USA) were used. 
The analysis was performed on 10,000 cells per sample 
and unstained cell samples were used to compensate for 
??????????????????????????????????????
 The hASCs needed for the study were thawed and 
expanded in maintenance medium in T75 cm2 polystyrene 
?????????????? ????????????????????????? ????????????????
BoneCeramic granules at a density of 9.7 x 104 cells per 
well, and similarly to the BioRestore scaffolds at a density 
of 9.7 x 104 cells per scaffold, using a small volume (50 μL) 
of MM. The cells were let to attach at +37 °C for 3 h 
before adding 1 mL of corresponding medium (Table 1). 
Fresh medium was changed 3 times per week. During each 
medium change the growth factors were freshly added to 
the medium from frozen aliquots avoiding multiple freeze-
thaw cycles in order to keep the growth factors active. The 
experiments were repeated 3-6 times using one donor cell 
line per each repeat.
? ??????? ?????????????????????????????????????????? ???
2 (rhBMP-2; Genscript, Pisataway, NJ, USA), BMP-7 
(rhBMP-7; Sigma-Aldrich), and VEGF-A (rhVEGF165; 
R&D Systems) were added to MM and compared with 
osteogenic medium (OM). In the second part of the 
study, the growth factors were combined with OM. The 
compositions of the different media used in the study are 
described in Table 1. The concentrations of BMP-2 (Barr 
et al., 2010), BMP-7 (Shen et al., 2010) and VEGF (Behr 
et al., 2011) used in this study were based on literature.
Cell viability
Cell attachment and viability were evaluated qualitatively 
using Live/dead-staining probes (Molecular Probes/
Invitrogen, Eugene, OR, USA) at day 3, 7 and 14. The 
hASCs were incubated for 45 min at room temperature 
with a mixture of 0.5 μM calcein acetoxymethyl ester 
(Molecular Probes) and 0.25 μM ethidium homodimer-1 
(Molecular Probes). Images of the viable cells (green 
fluorescence) and dead cells (red fluorescence) were 
obtained using an Olympus IX51 phase contrast microscope 
??????????????????????????????????????????????????
(Olympus, Tokyo, Japan).
Cell number
The cell number of the samples was studied at 3-, 7- and 
14-day time points by determining the amount of total DNA 
by CyQUANT Cell Proliferation Assay Kit (CyQUANT; 
Molecular Probes) according to the manufacturer’s 
?????????? ??????? ???????????????? ??????????? ????
bound to cellular nucleic acids.
 The cells were washed with DPBS and lysed with 
500 μL of 0.1 % Triton-X 100 buffer (Sigma-Aldrich). 
The Triton cell lysates were frozen and stored at -70 °C 
until analysis. After thawing three parallel 20 μL samples 
of each cell lysate were pipetted on a 96-well plate (Nunc) 
and mixed with 180 μL of working solution containing 
CyQUANT GR dye. Fluorescence was measured at 
480/520 nm with a microplate reader (Victor 1420 
Multilabel Counter; Wallac, Turku, Finland).
Alkaline phosphatase activity
Alkaline phosphatase (ALP) activity was analysed at 3-, 
7- and 14-day time points. ALP cleaves phosphate groups 
from p-nitrophenol phosphates at pH 10.4 liberating 
yellow-coloured p-nitrophenol and phosphate. The rate 
of p-nitrophenol formation is proportional to the catalytic 
concentration of ALP in the sample. The ALP activity was 
determined from the same Triton-X 100 cell lysates as the 
cell number.
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 Three parallel 20 μL samples were pipetted on a 
MicroAmpTM Optical 96-well plate (Applied Biosystems, 
CA, USA). The reaction was started by pipetting 90 μL 
of working solution per well, containing 50 % of alkaline 
buffer solution (2-amino-2-methyl propanol; 1.5 M; 
pH 10.3; Sigma-Aldrich) and 50 % of stock substrate 
solution (p-nitrophenol phosphate; Sigma-Aldrich) and 
incubated for 15 min at 37 °C. The reaction was stopped 
by adding 50 μL of NaOH (1 M, Sigma-Aldrich) and the 
colour intensity was determined with a microplate reader 
(Victor 1420) at 405 nm.
Collagen assay
The amount of collagen was determined at 7- and 14-day 
time points by Sircol Soluble Collagen Assay (Biocolor, 
Carrickfergus, Northern Ireland). The basis of the assay 
was binding of Sirius red dye to [Gly-X-Y] peptide 
sequence of mammalian collagen types I-V. Production of 
collagenous matrix was measured, as it was not possible 
to analyse mineralisation due to the calcium containing 
3D-scaffolds.
 For the measurement, acid-soluble collagen was 
extracted from the cultures by 0.5 M acetic acid (Merck, 
Darmstadt, Germany) containing 0.1 mg/mL pepsin 
(Sigma-Aldrich) for 2 h at 4 °C. The collagen content was 
determined from 100 μL samples, with 1 mL of Sircol Dye 
reagent (Sirius Red in picric acid; Biocolor) added to each 
aliquot and incubated with gentle shaking for 30 min. The 
samples were centrifuged at 12,000 rpm for 10 min, and the 
collagen-dye pellet was washed once to remove unbound 
dye with 750 μL of ice-cold Acid-Salt Wash Reagent 
(acetic acid, sodium chloride and surfactants; Biocolor). 
After centrifugation, the supernatant was discarded and 
the collagen-bound dye was released by adding 250 μL 
of Alkali Reagent (0.5 M sodium hydroxide; Biocolor). 
The dye intensity was measured from two parallel 100 μL 
samples on a 96-well plate (Nunc) with a microplate reader 
(Victor 1420) at 540 nm.
Statistical analysis
Statistical analyses were performed with SPSS version 19 
(IBM, Armonk, NY, USA). Data were reported as mean and 
standard deviation (SD). The effects of different culture 
conditions on cell number, ALP activity, and collagen 
content were compared using a one-way analysis of 
variance (ANOVA) with Tukey post hoc test. The results 
????????????????????????????????p < 0.05. The effect of 
culture duration was analysed using a Student’s t-test for 
independent samples for collagen content (day 7 versus 
day 14), and one-way ANOVA for cell number and ALP 
activity for comparing 3-, 7- and 14-day time points. In 
????????????????? ????????????????????????????????????????
control medium and compared with OM, the experiments 
for cell number and ALP activity were repeated using 6 
donor lines (n = 6), and the analysis of collagen content 
was repeated with 3 donor lines (n = 3). In the second part, 
where growth factors were tested in combination with OM, 
all experiments were repeated using 3 donor lines (n = 3).
Results
Scanning electron microscopy
The scanning electron microscopy (SEM) images (Fig. 
1) illustrated the macro structure (Fig. 1a,b) and surface 
roughness (Fig. 1e,f) of the biomaterials. Based on the 
SEM images a larger surface area may be expected for 
??????????????????????????????????????????????????????????
left side). Regarding surface topography, BoneCeramic 
exhibited more surface roughness than BioRestore (Fig. 
??????? ???????????? ?????????????????????????????????????
of both biomaterials. More detailed information on material 
characteristics of BioRestore scaffold has been provided 
previously (Haimi et al., 2009a).
Flow cytometric surface marker expression analysis
???? ???? ??????????? ????????? ??????? ??? ?????????????
that the hASCs used in this study expressed the surface 
markers CD73, CD90, CD105, and lacked the expression 
of the CD14, CD19, HLA-DR, the haematopoietic marker 
CD45, and the vascular cell adhesion molecule CD106. 
The expression of CD34, CD49d and HLA-ABC, was 
?????????? ???????????????????? ????????????????????????
the mesenchymal origin of the cells in agreement with 
literature (Dominici et al., 2006; McIntosh et al., 2006; 
Lindroos et al., 2010).
Table 2. Surface marker expression of undifferentiated hASCs at passage 1-2. The results are 
displayed as mean percentage of the surface marker expression (n = 11).
Antigen Surface protein Mean SD Expression
CD14 serum lipopolysaccharide binding protein 1.8 1.1 negative
CD19 B lymphocyte-lineage differentiation antigen 0.8 0.7 negative
CD34 sialomucin-like adhesion molecule 17.4 8.3 moderate
CD45 leukocyte common antigen 1.4 1.1 negative
CD49d integrin a2, VLA-4 41.7 20.0 moderate
CD73 ecto-50-nucleotidase 90.4 9.4 positive
CD90 Thy-1 (T cell surface glycoprotein) 99.3 0.6 positive
CD105 SH-2, endoglin 95.7 4.4 positive
CD106 VCAM-1 (vascular cell adhesion molecule) 1.1 1.1 negative
HLA-ABC major histocompatibility class I antigens 42.0 24.6 moderate
HLA-DR major histocompatibility class II antigens 0.9 0.8 negative
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Fig. 1. Scanning electron micrographs of BioRestore (left; a, c, e, g) and BoneCeramic (right; b, d, f, h????? ????????????
of 20x (a, b), 80x (c, d), 500x (e, f), and 2000x (g, h). Scale bars in the lower right corner of the micrographs.
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Comparison of BioRestore and BoneCeramic 
biomaterials
The hASCs seeded on both BioRestore (Fig. 2) and 
BoneCeramic (Fig. 3) were viable and proliferated steadily 
under control conditions during the whole 14-day culturing 
period as monitored by qualitative Live/dead Cell Viability 
(Fig. 2 and 3) and quantitative CyQuant Cell Proliferation 
(Fig. 4) assays. According to Live/dead assay, BioRestore 
supported cell proliferation more than BoneCeramic. This 
?????????????????????????????????????????????????????????
(Fig. 4a), which showed 1.4-fold higher cell number with 
BioRestore than BoneCeramic in MM (p = 0.026), and 
1.3-fold in OM (p = 0.002) at day 14.
Fig. 2?? ?????????????????????????????????
of viable (green) and dead (red) hASCs on 
bioactive glass (BioRestore) scaffolds at 
3-, 7-, and 14-day time points. Scale bar 
500 μm.
Fig. 3????????????????????????????????????
of viable (green) and dead (red) hASCs on 
biphasic calcium phosphate (BoneCeramic) 
granules at 3-, 7-, and 14-day time points. 
Scale bar 500 μm.
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 The ALP activity of hASCs (Fig. 5) was supported 
equally by both biomaterials in MM, but the induction by 
??? ??? ????????????????????????????????? ????????????
For example, with BoneCeramic the ALP activity was 
enhanced by OM 2-fold when compared to MM, 3-fold to 
BMP-2, 8-fold to BMP-7, and 2-fold to VEGF (p < 0.05 in 
all). In BioRestore, the ALP activity induced by OM was 
higher than with BMP-2 (1.7-fold) and BMP-7 (4.5-fold), 
but not when compared to MM.
 Furthermore, BoneCeramic supported the collagen 
??????????????????????????????????????????????????????
(Fig. 6a). Collagen production by hASCs grown on 
BoneCeramic in MM or MM + growth factors was 
???????????????????? ???????????????? ??????????????????
day 7 and day 14. At day 14, the amount of collagen was 
5-fold higher in BoneCeramic MM than in BioRestore 
MM (p < 0.05). In fact, BoneCeramic combined with 
MM produced comparable collagen levels to that made 
by osteo-induced hASCs grown on BioRestore. Induction 
by OM resulted in increased collagen production on 
both biomaterials at day 14 with the highest levels of 
collagen being produced by hASCs induced in OM on 
BoneCeramic. However, the enhancement of collagen 
production was more intense in the case of BioRestore; OM 
resulted in 5 times more collagen than MM in BioRestore, 
but only a 1.9-fold induction in BoneCeramic – due to the 
high level of collagen present under control conditions. 
When compared to MM control, growth factor treatment 
did not increase collagen production on either biomaterial.
Comparison of OM induction to MM
Overall, OM resulted in higher cell numbers and collagen 
production than MM with both biomaterials. When 
comparing the effect of OM to MM in BioRestore, a 
??????????? ???????????????? ????????? ????????????????? ???
hASCs (Fig. 4a). OM increased the cell number 1.5-fold on 
day 7 and 14 when compared to MM (p < 0.05). Live/dead 
??????????????????????????????????????????????????????
hASCs in BioRestore (Fig. 2). In addition, OM induced 
?????????????????????????????????????????????????????? ??
at day 14 in BioRestore (Fig. 6a). In turn, the ALP activity 
??????????????????? ?????????? ???????????????????????????
in OM than in MM (Fig. 5a).
Fig. 4. Cell number at 3-, 7-, and 14-day time points on BioRestore or BoneCeramic. (A) Growth factors in MM: 
Number of hASCs cultured with MM, OM or growth factors in MM. *p < 0.05 between the indicated groups. **p < 0.05 
with respect to other groups within that time point. (B) Growth factors in OM: Number of hASCs cultured with OM 
???????????????????????????????????????????????????????????????????????????????????????? ?????????????????????
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 In BoneCeramic, the cell number (Fig. 4a) was 
????????????? ??????? ?????? ????? ??????????????? ?????
fold) on day 14. In contrast, Live/dead analysis showed 
slightly higher cell number in OM than MM on day 7, but 
no notable difference between OM and MM on day 14 
in BoneCeramic (Fig. 3). The ALP activity (Fig. 5a) and 
collagen production (Fig. 6a) were induced 1.9-fold more 
with OM than MM in BoneCeramic at day 14 (p < 0.05).
Comparison of growth factor induction to MM
In general, all the growth factors tested in the present study 
supported the viability (Fig. 2 and 3) and proliferation of 
hASCs (Fig. 4a). BMP-2 and VEGF did not increase but 
rather supported similar levels of proliferation as MM 
(Fig. 4a). The result was similar with ALP activity (Fig. 
5a) and collagen production (Fig. 6a), where BMP-2 
and VEGF resulted in comparable levels as MM in both 
biomaterials. In contrast to BMP-2 and VEGF, BMP-7 
resulted in two times lower cell number than MM in 
BioRestore (p < 0.001). Consistently, ALP activity (Fig. 
5a) was three times lower in BMP-7 group than in MM in 
BioRestore (p = 0.002). Equally low amounts of collagen 
(Fig. 6a) were produced by all growth factors and MM in 
hASCs cultured in BioRestore.
 The effects of growth factors in BoneCeramic were 
mostly similar to BioRestore, i.e., no enhancement in 
comparison to MM. However, in BoneCeramic BMP-7 
???? ???? ????????????? ???????? ??????????????? ??? ?????? ????
?????????????????????????????????????????? ?????????????
four times lower values than with MM were detected on 
day 14 (Fig. 5a). Some differences in collagen production 
(Fig. 6a) were detected between the growth factor groups 
??? ???????????? ????????? ????????????????????????????
higher collagen amount than MM and OM (p < 0.05), 
although there was no difference from MM on day 14. 
???????????????????????????? ????????????? ???????????
activity and collagen content than BMP-7 (4.4-fold and 
1.8-fold, respectively), but not higher in comparison to 
MM.
Comparison of OM induction to growth factors
Overall, OM showed superior capacity to induce 
osteogenic differentiation and proliferation of hASCs 
than the growth factors tested in the study. In BioRestore, 
Fig. 5. ALP activity of hASCs at 3-, 7-, and 14-day time points on BioRestore or BoneCeramic. (A) Growth factors 
in MM: ALP activity of hASCs cultured with MM, OM or growth factors in MM. *p < 0.05 between the indicated 
groups. **p < 0.05 with respect to other groups within that time point. (B) Growth factors in OM: ALP activity of 
???????????????????????????????????????????????????????????????????????????????????????????????????????????????
mean absorbance + SD.
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Fig. 6. Collagen production of hASCs at 7- and 14-day time points on BioRestore or BoneCeramic. (A) Growth 
factors in MM: Collagen production of hASCs cultured with MM, OM or growth factors in MM. *p < 0.05 between 
the indicated groups. **p < 0.05 with respect to other groups within that time point. (B) Growth factors in OM: 
?????????????????????????????????????????????????????????????????????????????????????????????????????????????
Results are expressed as mean absorbance + SD.
Live/dead analysis (Fig. 2) showed increased viability 
and cell number by the OM group when compared with 
?????????????????????????????????????? ???? ????????????
by the quantitative analysis of cell numbers (Fig. 4a); OM 
???????? ????????????? ??????? ????? ???????? ????? ???????
factors (1.4- to 2.2-fold) in BioRestore. In a similar way, 
the collagen production was enhanced 6- to 9-fold by OM 
when compared to growth factors in BioRestore (Fig. 6a). 
???????? ????????????????????????????????????????? ?????
BMP-2 (1.7-fold) and BMP-7 (4.6-fold) in BioRestore 
(Fig. 5a). VEGF resulted in comparable level of ALP 
activity to MM and OM in BioRestore. The OM-induced 
ALP activity was donor dependent, and hence was not as 
consistent as the OM-induced collagen production.
 In BoneCeramic, the growth factors supported 
comparable levels of viability to OM and MM (Fig. 3). 
However, according to the quantitative analysis of cell 
??????? ?????????????????? ??????? ??? ????????????????????
numbers of cells on day 14 than the growth factor groups 
(p < 0.05). The effect of OM on ALP activity (Fig. 5a) 
and collagen production (Fig. 6a) in BoneCeramic was 
?????????????????????????????????????????????????????????
In ALP activity, the effects of OM were 2- to 8-fold, and 
in collagen production 1.4- to 2.5-fold in comparison 
to growth factors. In particular, the negative effect of 
BMP-7 was evident in ALP activity of hASCs seeded on 
BoneCeramic (Fig. 5a), as the ALP activity of BMP-7 
group decreased with time (p = 0.006, day 7 versus day 
14).
Combination of growth factors with OM
As osteogenic differentiation was detected mostly with 
OM, in the second part of the study growth factors were 
added to OM to determine whether greater osteo-induction 
could be achieved by their combination. The viability (Fig. 
2 and 3) and cell number (Fig. 4b) of OM + growth factors 
were comparable to that of plain OM, although slightly 
higher than with MM + growth factors. In BioRestore 
the inhibitory effect of BMP-7 on cell number could be 
detected even when combined with OM, but the difference 
???????????????????????????????????
 Overall, combining growth factors with OM did not 
result in enhanced ALP activity or collagen production 
when compared to plain OM. However, in ALP activity, 
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the negative effect detected by BMP-7 (Fig. 5a) was 
rescued when combined with OM (Fig. 5b); in some donor 
cells OM + BMP-7 increased ALP activity on day 7 in 
BioRestore and on day 14 in BoneCeramic, although the 
??????????????????????????????????????????
 When comparing the effects of OM + growth factors 
between the two biomaterials, the results were comparable 
to those obtained with MM + growth factors; BioRestore 
stimulated higher cell number than BoneCeramic, whereas 
BoneCeramic induced higher ALP activity and collagen 
production.
Discussion
Every year, over 2 million bone graft operations are 
carried-out world-wide (Giannoudis et al., 2005). Due to 
the limitations of the traditional bone-grafting, alternative 
approaches such as tissue engineering are emerging in 
order to meet the increasing need for bone substitutes 
(Betz, 2002). To date, much reliance has been put on the 
osteo-inductive effect of BMPs (Garrison et al., 2007; 
Clokie and Sandor, 2008; Mesimaki et al., 2009). However, 
the cost, safety and effectiveness of growth factors have 
been the subject of controversy lately (Alarmo et al., 
2009; Garrison et al., 2010; Zuk et al., 2011). Due to the 
several risks and disadvantages related to the use of growth 
factors, we studied OM as an alternative method to enhance 
osteogenic differentiation of hASCs. OM containing 
???????? ?????????????????????????????????????????????????
hASCs in vitro as well as in vivo. In several in vivo studies, 
the osteogenic commitment of ASCs has been enhanced 
by OM during the in vitro culture prior to implantation 
(Cui et al., 2007; Di Bella et al., 2008; Bohnenblust et 
al., 2009; Schubert et al., 2011). For clinical bone tissue 
engineering it is critical to reduce the total time required 
to regenerate functional bone tissue. The pre-implantation 
expansion of hASCs takes several days to weeks, and 
bone formation after implantation of the construct takes 
from several weeks to months. In this respect, induction 
by OM would be a highly cost-effective way to enhance 
both osteogenic differentiation and proliferation of hASCs 
during the in vitro culture preceding implantation of the 
construct. Although the feasibility of OM-induction has 
been illustrated in several in vivo studies, the effect of OM 
has not been systematically compared to BMP-2, BMP-7 
and VEGF in vitro.
 Consequently, the current study demonstrated 
?????????????????????????????????????????????????????????
by OM over BMP-2, BMP-7 and VEGF treatment in 3D 
culture, when the growth factors were added to MM. In 
fact, MM + BMP-2 or MM + VEGF treatment did not 
enhance the osteogenic differentiation of hASC more 
than MM alone with either biomaterial. In addition, it was 
???????????????? ??????????????????????????????????????????
and ALP activity of hASCs, an adverse effect that was 
detected consistently with both biomaterials. As osteogenic 
differentiation was detected solely with OM, in the second 
part of the study we tested whether OM could sensitise 
hASCs to growth factors in order to yield greater osteo-
induction. However, the combination of BMP-2, BMP-7 or 
VEGF with OM resulted in similar level of osteo-induction 
????????????????????????????????????????????????????????
and that differentiating hASCs may not respond to growth 
factor stimulation. Interestingly, the inhibitory effect of 
BMP-7 was rescued when BMP-7 was combined with OM. 
Hence, OM showed superiority over BMP-2, BMP-7 and 
VEGF added to MM, and these growth factors added to 
OM hold no advantage over plain OM induction in vitro.
 Some studies have suggested that exogenously added 
BMP-2 (Knippenberg et al., 2006; Song et al., 2011), 
BMP-7 (Al-Salleeh et al., 2008) and VEGF (Behr et al., 
2011) could have an osteo-inductive effect on ASCs, but 
in the current study these growth factors did not enhance 
osteogenic differentiation of hASC more than MM with 
either biomaterial. Out of these three growth factors, BMP-
2 is the most studied with ASCs (Knippenberg et al., 2006; 
E et al., 2010; Song et al., 2011; Zuk et al., 2011; Mehrkens 
et al., 2012; Overman et al., 2012). Although BMP-2 
concentrations from 50 to 100 ng/mL have successfully 
induced osteogenic differentiation of ASCs in some studies 
(Song et al., 2011; Knippenberg et al., 2006), Zuk and 
co-workers found no effect with doses in the range of 10-
100 ng/mL (Zuk et al.???????????????????????????????????????
present study and those reported by Zuk and co-workers, 
a recent study showed no effect by BMP-2 with 50 ng/
mL (Mehrkens et al., 2012). However, Mehrkens and co-
workers suggested that a 10 times higher concentration, 
500 ng/mL, is able to stimulate osteogenic differentiation 
of hASCs in vitro (Mehrkens et al., 2012). In turn, this 
is in contrast to two studies, where a short, only 15 min 
treatment with 10 ng/mL BMP-2 was able to support osteo-
induction of ASCs for 14-21 days (Knippenberg et al., 
2006; Overman et al., 2012). Hence, there is no consensus 
on the effect of BMP-2 on osteo-induction of ASCs, and 
further systematic in vitro and in vivo studies are required.
 Several factors may explain the great variation in the 
outcomes of BMP-2 studies, including use of animal-
derived ASCs (Knippenberg et al., 2006; E et al., 2010), 
differential effects of 3D biomaterials (E et al., 2010; 
Overman et al., 2012) to 2D culture, and the use of 
various cell densities and culture media. Nevertheless, 
various explanations have been suggested for the failure 
of BMP induction in ASCs and bone marrow stromal cells 
(BMSCs), including up-regulation of BMP antagonists 
such as noggin and gremlin (Pereira et al., 2000; 
Diefenderfer et al., 2003; Sutherland et al., 2004; Zuk et al., 
2011). On the other hand, the problem may originate from 
???????????????????????????????????????????????????????????
to phosphorylation and nuclear translocation of certain 
Smads, the intracellular target proteins of e.g. BMP-2 
signalling, as proposed by Zuk and co-workers (Zuk et al., 
2011). It is obvious that several aspects of cell signalling 
including timing, dosage, and complex interplay between 
different effectors and inhibitors need further elucidation 
to master the effect of growth factors.
 The expanding literature on in vivo experiments 
conducted with ASCs suggests two critical requirements 
for successful bone formation; firstly, the osteogenic 
commitment of ASCs, and secondly, the presence of 
a mineral component in a scaffold (Scherberich et al., 
2010). The biomaterials used in the current study were 
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chosen because they represent prospective candidates for 
hASC-based bone tissue engineering approaches. As such, 
osteoconductivity and ability to heal bony defects has been 
reported in clinical and in vivo studies for both BioRestore 
(Moimas et al., 2006; Clozza et al., 2012a; Clozza et al., 
2012b) and BoneCeramic (Jensen et al., 2007; Jensen et al., 
2009; Frenken et al., 2010; Rokn et al., 2011). Although 
capable of orthotopic bone formation, BoneCeramic failed 
to form ectopic bone together with BMSCs in subcutaneous 
rodent models (Zimmermann et al., 2011; Mrozik et al., 
2012) indicating a need for enhanced osteo-induction. 
Recently, a similar biomaterial to BoneCeramic, except in a 
porous block format, was shown to increase bone formation 
??? ?????????? ???????? ???????? ???????????????????????
seeded with hASCs than without cells (Choi et al., 2011). 
In a clinical study of 13 patients, BioRestore alone was 
able to induce formation of woven bone in tooth extraction 
sockets, although no mature lamellar bone was detected 
within a 6 months healing period (Clozza et al., 2012b). 
However, the bone formation capacity of BioRestore 
???????????????????????????????????????????????????????
in the future. Promising in vitro results have been reported 
previously for culturing hASCs in BioRestore scaffolds 
under control conditions (Haimi et al., 2009b). Previous in 
vitro studies with BoneCeramic have been conducted with 
???????????????????? et al., 2006), periodontal ligament 
?????????????????? et al., 2012) and BMSCs (Mrozik et al., 
??????????????????????????????????????????????????????????
on BoneCeramic and BioRestore when combined with 
osteo-induction by growth factors or OM.
 The aim of the current study was to compare the 
????????????? ?????????????????????????????????????????????
of hASCs using two clinically prospective biomaterial 
?????????? ????????????? ???? ???????? ????????? ????? ???? ???
biomaterial plays a notable role in hASC behaviour. The 
?????????????????????????????????????????????????????????
BioRestore and BoneCeramic, was detected in their ability 
to stimulate collagen production by hASCs. BoneCeramic 
induced a significantly larger amount of collagenous 
matrix than BioRestore under control conditions, and the 
effect was further enhanced with OM. Although different 
types of collagens are present in several tissues, the onset 
of osteoblastic differentiation is strongly related to the 
formation of organic matrix, mainly consisting of collagen 
type I, which will be subsequently mineralised – a process 
that is in turn facilitated by the accumulation of phosphate 
as a function of ALP enzyme. The differential behaviour 
of hASCs may be dependent on differences between the 
chemistry, topography, or 3D structure of the biomaterials.
 The other major difference between the biomaterials 
was detected in their capacity to support cell proliferation, 
?????????????? ????????? ??? ?? ????????????? ??????? ?????
number than BoneCeramic, an effect likely related to the 
??? ?????????? ??? ???? ??????????????????????? ?????????? ???
BioRestore provides large surface area and allows the cells 
to spread more easily throughout the scaffold, whereas 
the granular format in BoneCeramic provides less contact 
area between the granules, hindering the spreading of the 
cells. This hypothesis was further supported by the viability 
assay, as some BoneCeramic granules were fully populated 
by hASCs whereas other granules in the same well had no 
or very few cells. Based on these results, a larger initial 
cell seeding concentration would be recommended for 
BoneCeramic when considering clinical approaches to 
???????????????????????????????????????????????????????????
over the biomaterial. Although the comparison of these two 
biomaterials is challenging, due to the major differences 
in their 3D structures, based on our results both carriers 
represent viable alternatives for hASC-based bone tissue 
engineering as such, although combined stimulation with 
?????????????????????????????????????????????
 Based on the valuable in vitro????????????????????????
study, a corresponding in vivo study to demonstrate the 
utility of OM over growth factors has been planned. In 
order to reduce the number of animal experiments to be 
performed, it was critical to evaluate the hASCs response 
to growth factors and OM in vitro. For example, based on 
our results, there is no point in testing growth factors with 
?????????????????? ???????????????????????? ?? ????????
factors in comparison to OM alone. Therefore, it is not 
necessary to test all the groups used in the current study in 
vivo. However, in the future in vivo study, effectiveness of 
OM over growth factors in MM should be demonstrated.
Conclusions
??? ?????????? ????? ??? ????????? ?????? ??? ???????????? ?????
OM enhances hASC differentiation towards bone-
???????? ?????? ??? ??????????? ?????????????????? ????? ????
traditionally used growth factors BMP-2, BMP-7 and 
VEGF. Both biomaterials tested in this study, BioRestore 
and BoneCeramic, supported the hASC viability and 
proliferation during 14 days of culture. The most 
significant osteogenic differentiation of hASCs was 
achieved by BoneCeramic combined with OM. In contrast, 
combining growth factors with either biomaterial did not 
increase osteogenic differentiation or proliferation when 
compared to MM. Moreover, BMP-7 consistently inhibited 
proliferation and osteogenic differentiation of hASCs 
in 3D culture. Combining OM with BMP-7 eliminated 
the adverse effect of BMP-7. Otherwise, there was no 
??????????? ??????? ????? ??????? ??????? ???????? ???????
Our results indicate that instead of BMP-2, BMP-7 or 
VEGF, OM should be used to obtain successful osteogenic 
commitment of hASCs in vitro.
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Reviewer I: Fig. 6 compares collagen content among 
different groups, what is the collagen normalised to among 
different groups?
Authors: Fig. 6 shows the absolute values obtained as 
absorbance; hence the results have not been normalised. 
Absorbance is directly proportional to the amount of 
collagen in the samples; therefore, a reliable comparison 
among different groups can be obtained using absolute 
values. Unfortunately, with the collagen assay, it was not 
possible to determine cell number from the same samples.
Reviewer I: Authors need to provide in vivo data to 
demonstrate that ADSC preconditioned in osteogenic 
medium are better at forming bone in vivo than ADSCs 
exposed to BMP-2 or any other growth factors. Results 
from these studies would enhance the data being reported.
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Authors: The authors agree that in vivo study is important 
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2, BMP-7 and VEGF. However, the authors feel that 
the present study in its current form provides valuable 
information on the effects of BMP-2, BMP-7, VEGF and 
OM on hASC proliferation and osteogenic differentiation 
in 3D scaffolds, and behaviour of hASCs in two clinically 
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utilised to better plan the corresponding in vivo study. In 
order to reduce the number of animal experiments to be 
performed, it is critical to evaluate the hASCs response to 
growth factors and OM in vitro. For example, based on 
our results, there is no point in testing growth factors with 
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factors in comparison to OM alone. Therefore, it is not 
necessary to test all of the groups used in the current study 
in vivo. However, in the future in vivo study, effectiveness 
of OM over growth factors in MM should be demonstrated. 
It is clear that systematic in vitro data is of fundamental 
importance before it is reasonable to conduct in vivo 
studies. The in vitro results also facilitate the correct 
interpretation of the in vivo results.
Reviewer I: The present report concludes that osteogenic 
medium is superior in enhancing adipose derived stem 
cells differentiation toward osteogenic lineage than bone 
morphogenetic proteins. Although, the data reported is 
valid, use of osteogenic medium to assess osteogenic 
differentiation is an established protocol. There are 
controversies regarding response of adipose derived stem 
cells to BMP-2 to induce osteoblasts differentiation; some 
reports have shown positive response others have shown 
?????????????????? ??? ???????????????????????? ??????????
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Authors: We would like to note that the OM used in 
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?????????? ??????????????????????????????? ????????
(5 nM) and high AsA2-P (250 μM) concentration used 
in this study may have contributed to the superior effect 
of the OM over the tested growth factors. Because the 
traditional OM with high Dex (100 nM) and low AsA2-P 
(50 μM) was originally developed based on studies with 
BMSCs (Jaiswal et al., 1997, additional reference), it 
has been reported that OM with lower Dex and higher 
AsA2-P is more optimal for ASCs (De Girolamo et al., 
2007, text reference; Kyllönen et al., unpublished results). 
??????????????????????????????????????????????? ???????
OM over the traditional OM has been reported, is under 
submission (Kyllönen et al., unpublished results). This 
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osteo-induction of hASCs previously (Tirkkonen et al., 
2011, text reference). Although several studies have 
been conducted with BMP-2, there is still no consensus 
on the effect of BMP-2 on osteo-induction of hASCs. In 
addition, the effects of BMP-7 and VEGF have been even 
less reported on hASCs than BMP-2. Furthermore, in the 
present study, these growth factors were systematically 
compared in control medium and OM.
Additional Reference
 Jaiswal N, Haynesworth SE, Caplan AI, Bruder SP 
?????????????????? ???????????????? ??? ????????? ????????
expanded human mesenchymal cells in vitro. J Cell 
Biochem 64: 295-312.
   
  
PUBLICATION 
II 
Engineering pre-vascularized bone grafts with adipose stem cells and 
supercritical carbon dioxide processed composites  
Pitkänen S., Paakinaho K., Vuornos K., Poot A., Leijiten J., Grijpma D., Seppänen-
Kaijansinkko R., Kääriäinen M., Kellomäki M., Miettinen S., Kyllönen L.*, Haimi 
S*. 
Submitted 
 
  
  
 
 
 
 
 
 
 PUBLICATION 
III 
Characterisation and in vitro and in vivo evaluation of supercritical-CO2-
foamed β-TCP/PLCL composites for bone applications  
Pitkänen S., Paakinaho K., Pihlman H., Ahola N., Hannula M., Asikainen S., 
Manninen M., Morelius M., Keränen P., Hyttinen J., Kellomäki M., Laitinen-
Vapaavuori O., Miettinen S. 
European Cells and Materials vol(38), 35-50 
(https://doi.org/10.22203/eCM.v038a04) 
Publication reprinted with the permission of the copyright holders. 
 
  
  
 
 
 
 
 
 
S Pitkänen et al.                                                                      ScCO2?????????????????????????????????????????????
35 www.ecmjournal.org
Abstract
??????????????? ???? ????????????????? ???????? ??????????????? ?? ?????????? ?????????????? ??????????????????????
????? ????????? ?????????????????????????????????????? ?????????? ????????????????????????????????? ?????? ?
??? ?????????????? ????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????2??????????
????????????????????????????????????????????? ??????????????????????????????????????????????????????????????
??????????????????????????????? ????????????? ????? ??????? ????????????????????????????????????????????
????????????????????????? ???????????????????????? ??? ???????? ????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????? ?????????? ?????????????????????????????????????????in vitro and 
in vivo?????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????? ???????????????????????????????????????In vitro????????
???????????????????? ???????????????????? ??????? ????????????????????? ???????????????????????????????
??? ???? ????????????????????? ????????????????????????????????? ?????????? ????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????????????????
???????????????? ??????????????????????
Keywords?????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????
*Address for correspondence?????????????????????????????????????????? ???????????? ??????????????????
????????????????? ????????????????????????????
???????????????????????????????????????????????????????????????
Copyright policy??????? ???????? ??????????????? ???????????????????????????????????????????????????????
????????????????????????????????????????????????
????????? ????????? ????????? ????????????????????????????????????????????????????????????????????????????????????????????
CHARACTERISATION AND IN VITRO  AND IN VIVO EVALUATION 
OF SUPERCRITICAL-CO2??????????????????????????????
FOR BONE APPLICATIONS
????????????????????????????????????? ?????? ????? ?? ????3?? ?? ???????????? ??????????? ?? ?????????
??? ?????????????????????????? ????????? ???????????3?? ?????????????????????????????? ??????????
?????????????????? ?????????????????????????????? ???????????? ?????????????????????????? ???????????
????????????????
2 ?????????? ?????????????????????????????????????????? ?????????? ?????????????????????????
3 ???????????????????????????????????? ?????????????????????????????? ???????????? ??????????????????
???????? ???????????????????????????
???????? ??????????? ????????? ????????????????
????????????????????????????????? ?? ??? ??????????????????????????????? ?????????
?????????????? ????????? ????????????????
??????????????????????????????????????? ?????????????????????????????? ???????????? ??????
???????????????????? ???????????????????????????
?????????????????????????????? ?????? ?????????????????????????? ??????????????????????????
?????? ?????????????????????????
Introduction
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????????? ???????????????? ????????????????????????
????????????????????????????????????????????????????
???????????????????? ???????????????? ????????????
????????????????????????????????????????????????
??????? ????????????????? ??????????????????????????
????????????????????????????????????????????????????
??????????????????? ???????????????????????????????????
???????? ???????????????? ????????????????????????????
?????????????? ??? ??????????????????? ???? ??????????
????????????? ??????????????????????????? et al.??
??????????????????????????????????????????????? ???
????????????????????????????????????????? ????????
?????????? ??????????????? ??????????????????? ????????
??????????????????????????????????????????????????? 
et al.????????? ????????? ???? ????????????????? ???????
????????????????????????????????????????? ????????????
??? ?????????????????????????????????????????????
??????????????????????????????????????????????????????
?????????? ?????? ????? et al.?? ?????? ???????? ????
????????????????? ??????????????????????????????????
???????? ???????????????????????? ????????????????????
??????????????????????????????
? ????? ??????? ???????? ????????????? ????? ?????
????????? ???? ????? ????????????? ???? ?????? ????
???????????? ??? ?????? ??????????? ????? ???????
?????????? ??? ????????? ????????????? ???????????? et 
al.?? ??????? ??????? ?? ????? ??????????? ???? ??????? ??
??????????????????????????????????????????????????????
?????????????????????in vitro and in vivo????????????
?????????????? ????????????????????????????????????????
????????? ??? ???? ???????????????????? ???? ??? ????
????????????? ????????????? ??????? ?????????? ???????
???????????????????? ???? ?????????????????????????
data ? ???????????? ??????????????????????????????????
??????????????????????????????????? ???????????????
??????????????????????????? et al.???????????????????
???????? ????????????????????????????????????????????
????????????????????????????????? et al.???????? ??????? 
et al.?? ?????? ????????? ?????? ???? ????????????????
????????? et al.?????????????????????? ???? ? ??????
??????????? ??????? ???? ????????????????????? ???????
????????????? et al.?????????????????????? ??????????????
?????????????????????????? ??? ????? ???????????????
?????????????????????????????????????????????????
? ?????????? ????? ??? ??????????????? ???? ??????
???????????????????? ???? ??????? ????????????????
????? ??????? ????? ??????????? ?????????????????????
?????????? ????? ????????????????????? ???? ?????????
?????? ????? ??????????????? ????????????????????
???????????????????????????????????????????????????
?????????? ??? ??? ???????? ????? in vivo? ??? ?????????
?????????????????? ?????????? et al.?? ?????????? et 
al.?? ?????? ????? ????????????????????? ?????????? ????
???????? ????????? ????? ????????????????? ????????
?????? ???? ????? ??????????? ???????? ??????????? ????
???????????????????????????????????????????????????
????? ??????????? ????? ?????????? ??? ???? ????????
?????????????????? ???????????????????? ????????????
???? et al.?? ???????????????????????????????????
???? ????? ???? ???????????????? ????? ?????????? ???
?????? ????????????????? ???? ????????? ??????????
????????????????????????????????????????????????????
?????????????????????????????????????? ?????????????
???????????? ?????????? ?????????????? ?????????????in 
vitro ???????? et al.????????????? et al.?????????????? 
et al.?? ?????????? et al.?? ???????????????????????????
??????????????????????????????????????? ?????????????
??????????????? ???? ?????? ????????????????????????????
???? ?????? ????????????????????? ??????????? ????????????
?????????? ????????????????????????? ????? ?????????
????????????????????? ??? et al.???????? ??? et al.??
???????????????????????????????????????????????????
????????????????????????? ?????????????? ???????????
????????????????????????????????????????????????????????
????????????????????????? ??? ??????????????????in vitro 
or in vivo??????? et al.???????? ??? et al.????????? ?? ?????
?????????????? ?2??????2????????????????? ????????????
??? ??????? ????????????????????? ????????????? ????
?????????? ????????????????? ?????????2????????? ???
???????????????????????????????????????????????????????
???????????????????????????????????????????????????
??????????????????????????????????????????????? ????
?????????? ????? ?????? ???? ?????? ???????????? ?????????
??2???????????????????????????????????? ?????????????
???????????? ???? ????????? ??????? ???? ????? ??????
?????????????????????????????????????????????????????
?????????? ?????????????????????????????????2??????
??????? ??????????? ??????????????????????????? ?2 gas 
????????????????????????????????????? ?????? ??????
???????????????????????????????????????????????? et 
al.????????
? ????????????????????????????????????? ????????
???????????????????????????????????????????????????
?????????????????????? ??????? ???????????????????????
in vitro ????????? et al.????????????????? et al.?????????
???????? et al.???????? ???????? et al.???????? ???????? 
et al.????????????in vivo?????? et al.???????? ????? et al.??
?????????????????????????????????????????????????????
?????????????? ???? ????????????????????? ????????????
???????????????????????????????? ???????????????????????
??????????????????????????in vitro?
? ?????? ???? ???? ???????? ?????????? ????????????
???????????? ??????????????????????????????????????
???????????????????? ??? ???????? ??? ????????? ???????
???????? ?????????????? ????????????????????????
????? ?????????? ???? ????? ????????????? ??? ??????
????2??????????????????????????????????in vitro and in 
vivo????????????????????? ? ?????????????????????????
?? ??????????? ?????????? ?????????? ????????????????
?????????????????????????????????????????????????????
????????????????????????????????????????????????????
?? ?????? ??????????????????2?????????????????????
??????????????? ?????? ???????????????????????? ????
?????????????? ??????????? ???????????????????????
??????????? ?????????????????????????????????????
????????????? ??? ???? ??????????? ???? ??????????????
?????????? ???????????? ??????????? In vitro? ????????
????????????????????????????? ??????????????????
???????????????????????????????????????? ????????????
????????????????????????????????????????????????????
????????? ??????????in vivo??????????????????? ??????
??????
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Materials and Methods
Composite manufacturing and characterisation
????????????????????????????? ???????????????
????????????? ??????????? ????????? ?????????
???????? ?????? ?????????????? ??????????? ????
??????????????????????????????????????????????????
?????????????????????????????????????????????????
????????????????????????????????????????????????
????2?????????????????????????????????????? ????????
????????????????????????????????????????????????????
???????????????? ?????? ????? ??? ????? ????????????
???????????????? ????????????????????? ??? ????
???????????????????????? ??????????????? ???????
????????????? ????????????? ?????? ?????? ?????????????
discs for in vitro??????????????????????????? ??? ??????
????????????????? ??????????????? ???? in vivo? ????????
???????????????????? ????????????????????????????
??????????????? ???????????????????? ??? ?????? ????
????????????????????????????????????????????????????
???? ??????????????????
? ?????????in vitro and in vivo???????????????????????????
?????????????????????????????????????????????????
??????????????????????????????????????????????????
?????? ?????? ??? ??????? ???? ???????????? ?????????
??? ????????????????????????????? ????????????????
??????????????????????????????????????????????????
???? ?????? ???????????? ?????? ????????????? ????
????????????????????????????????????????? ??????????
?????? ??????? ???? ?????? ???? ???????????? ???????????
??????????? ???? ????? ??????????? ??????????? ?????
??????????????? ??????????? ?????? ????????????
???????????????? et al.?????????????????????????? et al.??
?????????????? ?????????????????????????????????????
????? ??????????????????????????????????????????????
Mechanical testing of composites
??????????????????? ??? ????????????? ???????????????
?????????????????????????????? ??? ????????????? ????
??????????????????????????????????????????????????
???????????????????????????????????????????????????
?????? ??????????????? ???? ??? ????????????
???????????????????? ?????? ?????????? ???????? ???
????????? ???????????????????? ????????????????????
?????????????????????????? ??????????????????????
???????????????????? ??????????????????????????? ???????
????????? ????????
Hydrolytic degradation of composites in vitro and 
in vivo
?????????????????????????? ??????????? ???????????
in vitro????????????????????????????????????????????
??? ??????????????? ????????? ?n? ?? ??? ???? in vivo as 
?????????????? ????????????? ??? ?????????? ??? ????
?????????????? ???????n????????????????? ??????n?????
??????????????????????????????????????????????????
???????????? ???????? ???????? ??????????????????
??????????????????????????????????????????????????
??????????????????????????????????????????? ??????
?????????????????????????????????? ??????????????
?????????? ????????????? ????????? ?????????????????
?????????????????????????? ???????????????????????
????????????? ??????????????????????????????????????
???? ?????????????? ????????? ????????n??? ??????
?????????????????????????????????????????????????
??????????????? ???????????????????????????????????
???????????????????????????? ??????????????????????
???????? ?????????? ??? ?? ????? ????? ??? ??????????
???????? ?????????????????????????????????????????
?????????????????????? ???? ????????????? ?????? ???
???? ??
Isolation, characterisation and seeding of hASCs 
in vitro
??????????? ????????? ????????????? ??????? ????????
??????????????????????????? ??????????????? ??????????
?????????????????????????????????????????????????
??? ???????????????? ??????? ?????????? ??????????????
????????? ??????????????????? ????????? ?????????????
??? ???????????????? ???? ????????????????? ??? ????
?????????? ???????? ??????????????????????????
? ?????????? ??? ?????????? ?????????? ?????? ??
??????????? ???? ?????????? ????????? ??? ??????????
??????????? ????????? et al.?? ??????? ???????????????
????? ????????? ???????????????? ????? ???????????
???????????????????????????????????????????????
???????? ????? ??????????? ?? ?? ??? ???????????????
?????????????? ??????????????????????????? ????????
??????????? ?????????????????? ???????????????????? ?
??? ?????????????? ??????? ???? ???? ????????????
?????????? ??? ??????????????? ????????????? ??????
???????????????????????????? ???2????? ?????? ???
???????? ?????? ?????????????????????????????????
???????????????????? ?????????????? ????? ????? ????
?????????????????????????
? ?????????? ???????????????? ?????????? ???? ???????
??????????????? ??????????????????????????????? ??
????????????????????? ????????????????????????????????
???????????????????????????????????????????????????
????????? et al.????????? ?????????????????????????????
????????????? ???????????? ??????????? ????
?????????????????????????????????????????????
?????? ?????????????? ????????????????????? ????
???????????????????????????????????????????????
???? ?????????? ??? ??????? ?????? ???? ??????? ????
???????????????????????????????????????????????
???? ???? ??????????? ????????????????? ???????? ????
?????????????????????????????????????????????????
?????? ???????????????????????????????????????????
????? ???? ?????? ?????????? ??????????? ????????
????????????? ????????? ???? ????? ??? ?????????
???????????????????????????????? ???????????????????
?????????????????????? ?????????????????????????
??????????????? et al.????????
? ?????????????????????????????????????????????????
??????????? ?????????? ?????????? ???? ????? ??????
??? ??? ??????????????? ??????? ??? ?? ?????????????
?????????????????????????????????3????????????????????
?????? ?????????????????????????????????????????????
??? ?????? ?????????????????? ?????????? ???????
???????????????????????? ???????????????? ???????
?????????????????????????????????????????????????
?? www.ecmjournal.org
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??????????????????? ???????????????? ???? ?? ???
??????????????????????????????? ???????? ?????????
???????????????????????????????????????????????????????
???????????? ?? ?? ?? ?? ??????????????? ????????????
?????????? ????????
Cell viability and proliferation
????? ????????? ???????????????????????????????????????
?????????????????????? ??????????????????????????
??????????????????????????????????????????????? ????
????????????????? ????????? ?????? ?????????????????
???????????????????????????????????????????????????
????? ??????????? ????? ???????????????? ????????
??????? ??? ??????? ?????? ??????? ?????????????? ????
????? ?????? ??????????????????????? ???????????????
??????????? ??????????? ?????????????????????????
?????????????????????????????????????????????
??????????
? ???????????? ????????????????????????????????????
???????????????????????????????????????????????? ???
??? ??????? ???? ????????????? ????? ??????????????
????????? ?????????? ???????????????????????????? ???
????????? ??????????????????? et al.??????????????????
????? ????????? ?????? ???? ???????????? ??????? ????
????????????????????????? ??? ???????????????? ??
???????????????????????????????????????????????????
????????????????????????
????????????????????????????????????? in vitro
????????? ?????????????????????????? ??? ??????????
??????????????????? ????? ????????? ??????????????????? 
et al.?????????? ???????????? ???????????????????????
???????????????????????????????????????? ??????????
???? ????????????????????????????????
? ?????????????????????????????????????????????????
????????????????????????????????????? ? ???????????
??????????????? ????? ??? ?????????? ???????????
?????????? et al.?? ??????? ????????? ?????????????
???????????????? ????????? ???????? ?????????????????????
??????????????? ????? ??????????????????????? ?????
???????????????? ??????????????? ?????????? ???? ????
????????????????????? ????????????????????????????
?????????????????????????????? ???????????????????????
????????? ????????????? ??????????????????????? ??????
????????g ???????? ????????????? ??????? ???? ??????
????? ??????? ??? ????????????????????????????????
?????????????????? ???????? ??????? ??????????????? ???
????????g??????????????????????????????????????????
??????? ???????????????????????????????? ?????????????
????????????????????????????????? ?????????????????
????????? ??????? ???????? ??? ?? ?????????????? ???????
???????? ???????????????????????????????
? ??????????????????? ???????? ??? ????????? ???? ??
????????????????????????????????????????????????????
????????? et al.?????????????????????????????????????
?????????????????????????????????? ????????????????
???????? ???? ????????? ???????????????????????????????
????????? ??????????????????????? ????????????????
??????? ???????? ??????????????? ????????????????
???????????????????????????????????????????????????
???????????????????????????? ???? ??????????? ???
?????????????????????
? ????????????? ?????????? ???????? ??????????????
?????????????????????????????????????????????????
???????????????????????????????????????? ?? ??????????
???????????????????????? ????????????????????????
?????????????????????????????????????????????????
??????????????? ??? ???? ???????? ?????????????????
?????????? ??? ????????????????????????????? ???????
???????????? ?????????????????????????? ??? ?????
???? ????????????????????????????????????????????
??????????????????????????????????????????????????
?????????????????????????????????????????????????
?????????? ???????????????????? ???hRPLP0??? ?? ???
?????????? ?????????????????????? ????RPLP0 and 
osteogenic genes RUNX2a??OSTERIX and DLX5 are 
??????? ????????? ??????????????????????? ??????????
????????? ??????????????????????????????????
????????????????????????????????????? ??????????
????? ??? ????®??????????????? ???????????????????
????????????????????????????? et al.??????????????????
?????????????????????????????®? ????? ?????????
???????????????????????????????????????????????
? ??????????? ?????? ????????????????????????????????
???? ????????????????? ???? ???????? ????????????????
? ?????????????????????????? ??????? ????????????
Table 1. Surface marker expression of hASCs at passage 1. ??????????????????????????????????????????
????? ????? ?????????????????????????
Surface marker mean ??SD expression
???? ???????????????????????????????????????? ????????? ????????
???? ??????????????????????????????????????????? ????????? ????????
???? ????????????????????????? ??????? ??????????? ????????
???? ???????????????????????? ????????? ????????
???? ???????????????????? ?????????? ????????
???? ??????????????????????????????????? ?????????? ????????
????? ?????????????? ?????????? ????????
?????? ?????????????????????????????????????????? ????????? ????????
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?????????????? ????????????? ?????®? ???????????
???????????????? ??????????????????? ??????????
? ??????????????????????????????????????????????
?????????? ???? ?????? ???????? ?????????????? ???????
???????????????????????????????????????????????
?????? ???? ???????? ??????????? ?????????????????????
??????????????? ???? ??????????????? ??? ??????
??????????????????? ???????? ???? ????????? ????????????
???? ????????? ????????? ???????????? ???? ?? ??????
???????????????? ????????????????????? ??????????
???????????????????? ???????????
? ???? ???????????????? ??????? ?? ????? ?????????????
?????????????????????????????????????????????????
???? ???? ?? ?? ??? ??? ??????????? ???????????
????? ????????? ???????? ??? ??????????? ????? ??? ????
?????? ????????????????????? ???? ???? ?? ?? ??????
????????? ?????????????????????????????????????????
??????????????????????????????? ?????? ????????® 
????????? ????????????? ???? ????? ??? ????????
???? ????????? ?????? ??? ????????????????? ?????? ????
??????????? ???????????????????????? ?????????????
???????????????????? ???????????????????????? ??
????????? ?????? ????????????????????????????
????? ????????? ?????®??? ???????????? ??????????
????????? ??????????????????????????????????? ?????????
????????????? ??? ?? ????? ????? ???? ???????? ?????? ????
????????????? ?????? ??? ?? ??????????????????????????
???????????????? ?????????????????ad libitum??????
??????? ???? ?????????? ????????? ??????????????????
????????????????????????????????????????????????????
?????????????????????????????? ????????????????????????
???????
? ??????????????? ????????????? ?????????? ?????? ??
????? ???????????????????????????????? ???????????????
????????????????????????????????????? ????????????
????? ?????????? ???????????? ?????? ???????????? ??
??????????????????????? ?? ?????????????????? ??????????
???????®???????? ??????????????????????????????
?????????? ?????????????????? ??????? ??????????????
?????????????????????
? ???? ????????? ??????????????? ??????? ????
????????????? ???? ?????????????? ???????? ?????????
???????????? ????????? ?????? ??????????????????
???????????????? ????????????????????????????????
??????? ???????????? ??????? ????????? ???? ???????
???????????????? ??????????????? ?????????????? ?????
????????????? ???????????????????????????? ??????
???????????????????????????? ?????????????????????
?????????????????????? ???????????? ?? ??????????????
?????????????????????????????????????????????????
??????? ???? ???????????? ? ??????????????????????
??????????????? ???????????????????????? ? ??? ???????
???????? ????????????????????????????????? ???????
????????????????????????????????????? ??????????
?????????????????????????????????????????????????????? ?
???? ?????????????????????????????? ?????? ??? ?????
?????????????????????????????????????????????????
????????????????????????????????????????? ????????
?????????????? ????????????????????????? ???? ??????
????? ??????????????????????????????????????????
???????????????????????????????????????????????
?????????????? ??????????? ???????????? ???????
????? ???????????????????????????
Animal experiments
??? ? ? ??? ? ?? ? ?? ??? ? ? ????? ???? ? ? ??? ???
??????????????????????????? ????????? ???? ???????
????????????????????????????????????????????????
?????????????? ?????????
? ???????????? ???? ???????? ??? ?????????????
?????????? ?? ???????????? ?????? ??????? ??®????? ??
???? ??????? ??????? ????? ???????? ??? ????????????
????? ?????? ??????®??? ?????? ???????????? ??????
?????????? ???????????? ????????? ???????? ????????
???????????????????? ?????? ??????????????????????
??????? ?????????? ????????? ?????? ??????????? ???
????? ????????????????? ?????? ??????????? ???????® 
???? ??????????????????????????????????? ?????????
???????????????????????????????????????????????????
??????????????? ??????? ?????????????????????? ??
???? ????? ®???????? ??????????????????????????????
????????????? ???????????? ?????????????????????????
????????????? ???????????? ??????????? ??????????
????????®??????????????????????????????????????
Table 2. Primer sequences and accession numbers of genes analysed by qRT-PCR.
Name Full name
Accession 
number  Sequence
Product 
size (bp)
hRPLP0 ???????????????????????????? ?????????
??????? ??????????????? ???????????????
??
??????? ?????????????????????????????
hALP ???????????????????? ???????????
??????? ????????????????????????????????
??
??????? ??????? ??? ??? ??? ?????????????
hRUNX2A ????????????????? ??????????????
??????? ??????????????????????? ???????????
??
??????? ??????????????? ??? ??????? ?????
hOSX ??????? ?????????
??????? ??????? ??? ??? ??????????? ???
??
??????? ??????? ??? ??? ??????? ?????
hDLX5 ?????????????????????? ???????????
??????? ??????? ??????????? ??? ????????
??
??????? ??????????????? ??????? ??? ?????
?? www.ecmjournal.org
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??????? ????????????? ????????????? ????? ???????? ???
???? ??????????????????? ????? ?? ?????????????? ????
????? ???????? ??????????????????????? ??????????? ??
????? ?? ??????????? ?????????? ?? ???????? ???????????
????? ?????????????? ????? ???? ???????????????
???????????????? ?????????? ?????????????????????
??????????????????????????????????????? ????????
??????????????????????????????? ???? ???????? ?????????
????? ?????? ??? ????? ????????? ????????? ?????????
???????????? ???????? ?????????? ???????? ??????? ????
???????????????????? ????????????? ????????????
???????????????????????????????????????????????
?????? ???????????????????????? ?????????? ??????
????????? ?????????????
Statistical analysis
????????????????????? ??? ????????? ????????? ???????
????????? ??????? ???????????????????? ????????????????
Fig. 1. ?????????? composite characteristics before and after pre-compression treatment.??a?? ??????????????
???????????????????? ??? ????????????? ??????? ?????????????? ????????? ???????????????????????? ????????
?????????????????????????????????? ???????????????????????? ???????b?????????????????????????????????? ?
??????? ?????????????????????????????????????????????????????????????c?? ??????? ??????????????????????
????????????????????????????????????????????????????????????????????????????a p?????????n???????
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Fig. 6. Relative gene expression of osteogenic genes in hASCs in ?????????? composites.??a??ALP???b??
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ABSTRACT: The local delivery of Cu2+ from copper-doped bioactive
glass (Cu-BaG) was combined with 3D printing of polycaprolactone
(PCL) scaﬀolds for its potent angiogenic eﬀect in bone tissue
engineering. PCL and Cu-BaG were, respectively, dissolved and
dispersed in acetone to formulate a moderately homogeneous ink. The
PCL/Cu-BaG scaﬀolds were fabricated via direct ink writing into a cold
ethanol bath. The architecture of the printed scaﬀolds, including strut
diameter, strut spacing, and porosity, were investigated and charac-
terized. The PCL/Cu-BaG scaﬀolds showed a Cu-BaG content-
dependent mechanical property, as the compressive Young’s modulus
ranged from 7 to 13 MPa at an apparent porosity of 60%. The ion
dissolution behavior in simulated body ﬂuid was evaluated, and the
hydroxyapatite-like precipitation on the strut surface was conﬁrmed.
Furthermore, the cytocompatibility of the PCL/Cu-BaG scaﬀolds was assessed in human bone marrow stem cell (hBMSC) culture, and a
dose-dependent cytotoxicity of Cu2+ was observed. Here, the PCL/BaG scaﬀold induced the higher expression of late osteogenic genes
OSTEOCALCIN and DLX5 in comparison to the PCL scaﬀold. The doping of Cu2+ in BaG elicited higher expression of the early osteogenic
marker gene RUNX2a but decreased the expression of late osteogenic marker genes OSTEOCALCIN and DLX5 in comparison to the PCL/
BaG scaﬀold, demonstrating the suppressing eﬀect of Cu2+ on osteogenic diﬀerentiation of hBMSCs. In a coculture of hBMSCs and human
umbilical vein endothelial cells, both the PCL/BaG and PCL/Cu-BaG scaﬀolds stimulated the formation of a denser tubule network,
compared to the PCL scaﬀold. Meanwhile, only slightly higher gene expression of vWF was observed with the PCL/Cu-BaG scaﬀold than
with the PCL/BaG scaﬀold, indicating the potent angiogenic eﬀect of the released Cu2+.
KEYWORDS: 3D printing, tissue engineering scaﬀold, angiogenesis, polycaprolactone, copper-doped bioactive glass, gradient porosity,
coculture of mesenchymal stem cells and endothelial cells
■ INTRODUCTION
Synthetic bone grafts that resemble the architecture and
composition of the bone extracellular matrix are always sought
by biomaterial scientists and surgeons to overcome the
limitations of bone autografts and allografts in the treatments
of large bone defects in patients.1−3 The application of tissue
engineering (TE) scaﬀolds has emerged as a strategic approach
for bone reconstitution, as it combines the engineered
biomaterial structure, soluble/mechanical factors (e.g., release
of stimulating bio(macro)molecules/ions), and regenerative
cells to provide a structural and physiological support to the
spatial tissue growth.4,5
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As the ﬁrst man-made biomaterial capable of forming
chemical bonding to bone,6 bioactive glasses (BaGs) have
been extensively explored during the past several decades in
bone TE because of their osteostimulative capability to guide
and stimulate the bone growth.7−9 However, successful
neovascularization (the sprouting of blood vessels) in the
bone TE constructs remains challenging.10,11 Several well-
established compositions of silicate BaGs, such as 45S5 and
S53P4, are capable of inducing angiogenic diﬀerentiation of
mesenchymal stem cells (MSCs).12,13 This is attributed to their
ionic dissolution products of soluble Ca, Si, and P that can
upregulate the genes related to angiogenesis, such as those
encoding vascular endothelial growth factor (VEGF) and basic
ﬁbroblast growth factor (bFGF).13,14 Moreover, the essential
participation of Cu2+ in angiogenesis has been acknowledged:
Cu2+ in a proper dosage has a clear proangiogenic function by
activating a group of proangiogenic growth factors, including
VEGF and platelet-derived growth factor (PDGF), therefore
promoting endothelial cell proliferation and tubule forma-
tion.15−17 At present, the local delivery of Cu2+ from the Cu-
doped BaG to induce angiogenesis has been investigated in
various forms, e.g., porous scaﬀold of Cu-doped mesoporous
BaG,18 composite hydrogel containing Cu-doped mesoporous
BaG,19 functional coating of Cu-doped BaG nanoparticles and
electrospun nanoﬁbers of Cu-doped BaG.20−22 Strategically, the
incorporation of Cu-doped BaG in bone TE scaﬀolds may oﬀer a
straightforward approach to address the neovascularization
challenge in bone tissue regeneration.
The critical aspects to be taken into consideration when
designing a bone TE scaﬀold are the selection of suitable
biomaterials to support cell adhesion and proliferation as well as
the deﬁnitive structural parameters of the scaﬀold to mimic the
native bone tissue. Polycaprolactone (PCL), a bioresorbable
polymer extensively used in various biomedical applications,
oﬀers excellent material properties and cytocompatibility.23 The
extrusion-based 3D printing (3DP) techniques oﬀer a high-level
control of the scaﬀold architecture, including pore size,
distribution, and interconnectivity.24 Previously, the TE
scaﬀolds for bone regeneration manufactured by the 3DP
using PCL or its composites with inorganic minerals such as the
microparticles of tricalcium phosphate,25 hydroxyapatite, and
calcium polyphosphate have been studied.26,27 Conventionally,
the melted PCL is used as the carrier phase for the mineral
microparticles, and the printed constructs keep the shape ﬁdelity
through fast cooling after being extruded through the nozzle in
3DP.
In the current study, a solvent-based approach was proposed
to prepare the well-dispersed BaG microparticles of Cu-doped
S53P4 (S53P4−Cu1) in PCL solution (in acetone) as a
homogeneous ink fed in the direct ink writing (DIW), and the
printed struts solidiﬁed rapidly in the cold ethanol due to the
solubility change of PCL, thus facilitating the fabrication of the
PCL/Cu-BaG composite scaﬀolds. This method oﬀers a facile
printing as no heating is needed and also extends the possibility
to incorporate other bioactive molecules, such as growth factors,
within the scaﬀold during the printing process. Then, the ion
dissolution behavior and bioactivity (in terms of supporting the
hydroxyapatite precipitation) of the composite scaﬀolds were
evaluated in simulated body ﬂuid (SBF). Furthermore, the
cytocompatibility of the composite scaﬀolds as well as the
impact of the ion release on the early osteogenic diﬀerentiation
of human bone marrow stem cells (hBMSCs) were evaluated in
vitro. Finally, we studied whether the Cu2+ released from the 3D
scaﬀolds could promote the angiogenesis in a coculture of
hBMSCs and human umbilical vein endothelial cells (HU-
VECs). The observations are indicative for utilizing the Cu-
doped BaG aiming at enhancing the vascularization in TE
scaﬀolds.
■ MATERIALS AND EXPERIMENTAL
Glass Melting of BaGs (S53P4 and S53P4−Cu1) and
Preparation of BaG Microparticles. Two BaGs, S53P4 (53%
SiO2−4%P2O5−20%CaO−23%Na2O wt %) and S53P4−Cu1 (53%
SiO2−4%P2O5−19%CaO−23%Na2O−1%CuO wt %), were prepared
using the melt-quenching method. The batches consisted of analytical
grade reagents Na2CO3, CaCO3, CaHPO4·2H2O, Cu(NO3)2·2.5H2O
(all purchased from Sigma-Aldrich), and Belgian glass quality quartz
sand (0.32 mm, Varnia Oy). The batches were melted in a Pt crucible at
1360 °C for 3 h, cast, annealed, crushed, and remelted to ensure the
homogeneity. The annealed glass block was crushed and gradually
fractionated with a set of woven wire mesh sieves with #mm from 500
μm down to 45 μm (laboratory test sieves, Retsch GmbH) to give
several powdered fractions. The ﬁnest powder fraction, which could
pass through the #mm = 45 μm sieve, was further milled for 10 min
using a benchtop planetary ball mill (MinMill, Philips) to obtain the
ﬁne particles of BaG for the DIW ink formulation.
Scaﬀolds Fabrication via DIW. A 30 g portion of PCL (Mw =
80 000, Aldrich) was dissolved in 100 mL of acetone overnight in a 50
°C water bath to obtain a viscous solution, which was then used as the
carrier phase for the BaG particles in the ink formulation. The BaG
particles were homogeneously dispersed into the viscose PCL solution
using a planetary centrifugal mixer (ARE-250, Thinky Corporation) at a
rotation speed of 2000 rpm. The compositional ratio between the PCL
and BaG was adjusted to 4:1, 2:1, or 1:1, according to the content of
PCL and BaG in wt %.
The scaﬀold fabrication via DIW was carried out using an adapted
Korean Institute for Machinery andMaterials (KIMM) Bioplotter. The
KIMM Bioplotter software was used to produce a G-code tooling path
for printing. Square block models (x = 10 mm, y = 10 mm, and z = 1, 2,
or 4 mm) were designed with the Bioplotter software, and the strut
spacing (SS) was deﬁned as either 400 or 800 μm between the center of
the struts. For the scaﬀolds with a gradient porosity, the SS was
decreased from the center to the edge of the scaﬀold, from 800 to 200
μm. The viscous ink as formulated was loaded into a ﬂuid dispensing
system (Optimum by Nordson EFD), with the syringe barrel installed
onto the KIMM printer and connected to an air pressure regulator. A
precision tip made of stainless steel (25GA, Nordson EFD) was used as
the dispensing nozzle. The scaﬀolds were printed layer-by-layer through
extruding the ink into a cold ethanol bath. The feed rate was kept
constant at 2 mm s−1, and the extrusion pressure was then manually
adjusted in the range 1.5−3.0 bar according to the viscosity of the ink
for an optimal printing process. The scaﬀolds were then soaked in
absolute ethanol for 24 h, and the ethanol was replaced every 8 h to
complete the phase exchange of PCL from acetone to ethanol. Finally,
the scaﬀolds were collected and dried in air before further character-
izations.
Scaﬀold Imaging with Optical Microscopy, Scanning
ElectronMicroscopy (SEM), andMicro Computed Tomography
(μ-CT). The microscopic features of scaﬀolds were observed by using a
LEICA M205A optical microscope. The reported strut diameter and
strut spacing were assessed in triplicate (n = 3). The morphological
features of the scaﬀold strut were characterized by using SEM. To assess
the macroporosity, μ-CT was used to analyze the inner structure of the
scaﬀolds. The imaging was performed with an Xradia MicroXCT-400
(Zeiss, Pleasanton, CA) device: 1600 projections were taken with a
pixel size of 19.70 μm. The source voltage was set to 80 kV, and the
source current was 125 μA. To achieve the desired image quality, a 3 s
exposure time was used. The device manufacturer’s XMReconstructor
software was used to reconstruct the 3D volumes. Image segmentation
was done with Avizo software (Thermo Fisher Scientiﬁc, Waltham,
MA) using manual thresholding. Approximately 8.2 × 8.2 × 2.4 mm
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volumes were selected, and the porosity, strut size, and pore size of the
3D scaﬀolds were calculated with the BoneJ plugin in the Fiji program.
Thermogravimetric (TG) Analysis. TG analysis of the scaﬀolds
was performed using a diﬀerential thermal analysis instrument (Netzsch
STA 449F1) in the gas ﬂow of synthetic air at a speed of 100 mLmin−1.
The temperature ramped up to 850 °C at an elevating rate of 10 °C
min−1. The BaG wt % of the scaﬀold was determined as relative to the
residue content in the TG analysis.
Mechanical Tests. The compressive response of the printed
scaﬀolds was measured with a Shimadzu EZ-L Universal Mechanical
Tester. Scaﬀolds were compressed at 1 mm min−1 and a maximum
loading of 500 N was applied. When calculating the strength, the
dimensions along the x, y, and z-axes measured with a digital caliper
were used. Strain was registered as a function of stress for an applied and
increasing force and the measurements were conducted in triplicate to
elaborate the compressive modulus based on the stress vs strain curves.
Ion Release Study of PCL/Cu-BaG Scaﬀolds in SBF. The SBF
was prepared according to the protocol of Kokubo, and the exact
composition is presented in the Supporting Information S1.28 The 3D
scaﬀolds were immersed in 10 mL of SBF in airtight polyethylene
containers that were placed in an incubating orbital shaker held at 37 °C
and agitated at 100 rpm. The samples were incubated for a total period
of 30 days and sampled at intervals of 6 h, 24 h, 3 days (3 d), 7 d, 14 d, 22
d, and 30 d. At each time point, 0.5 mL of the immersion solution was
sampled, and 0.5 mL of fresh SBF was additionally replenished for a
continued immersion. The ionic concentrations of Ca, P, Si, and Cu
ions in the sampled solution were analyzed with an inductively coupled
plasma optical emission spectrometer (ICP-OES) (Optima 5300 DV,
PerkinElmer, Shelton, CT). For the ICP-OES measurements, the
sampled aliquots were diluted 10 times with deionized H2O. At the end
of the immersion test, the scaﬀolds were carefully collected, washed
extensively with ethanol, and dried in the air. The surface morphology
and elemental analysis of the scaﬀolds were characterized with an SEM-
EDXA instrument (EDXA, LEOGemini 1530 with a Thermo Scientiﬁc
UltraDry Silicon Drift Detector, X-ray detector by Thermo Scientiﬁc).
Isolation and Characterization of hBMSCs and HUVECs. The
hBMSCs were isolated from a bone marrow aspirate sample obtained
from a surgical procedure at the Department of Orthopedics and
Traumatology, Tampere University Hospital, with the patient’s
consent. The hBMSCs used in the study were harvested from a female
donor of 80 years of age. The study was conducted in accordance with
the Ethics Committee of the Pirkanmaa Hospital District, Tampere
(R15174). hBMSCs were isolated using centrifugation through a Ficoll
gradient. First, the bone marrow aspirate was suspended in Dulbecco's
phosphate buﬀered saline (DPBS), and the solution was pushed
through a 100 μm cell strainer. The bone marrow aspirate solution was
centrifuged, and the fat layer was removed. Thereafter, the bone
marrow aspirate solution was pipetted carefully on top of a Ficoll
gradient (Histopaque-1077; 1.077 g mL−1; Sigma-Aldrich; St. Louis,
MO). A 2.6 mL portion of Ficoll (Histopaque; Sigma-Aldrich) per 1
mL of bone marrow aspirate sample was used. The bone marrow
aspirate solution was centrifuged for 20 min at 800g, and the
mononucleated hBMSCs were harvested from an interphase between
the Ficoll and plasma phases. The cells were washed twice with 5 mL of
MEM Alpha medium (Thermo Fisher Scientiﬁc, Waltham, MA) per 1
mL of collected interphase, and the suspension was centrifuged for 15
min at 400g. The cell pellet was suspended in basic medium (BM)
consisting of MEM Alpha medium (Thermo Fisher Scientiﬁc), 5%
human serum (HS; BioWest, Nuaille,́ France), and 1% antibiotics (100
U mL−1 penicillin; 100 U mL−1 streptomycin; Lonza, Basel,
Switzerland) with 5 ng mL−1 human FGF-2 (Miltenyi Biotec; Bergisch
Gladbach, Germany). Isolated hBMSCs were expanded in BM at 37 °C
in 5% CO2, and medium was changed twice per week. Cells were
detached with TrypLE Select (Thermo Fisher Scientiﬁc). The
experiments were carried out at passage 3.
HUVECs were extracted from the umbilical cord acquired from
scheduled Cesarean section at the Department of Obstetrics and
Gynecology, Tampere University Hospital, with the donor’s consent
according to Hamilton et al.29 The study was conducted in accordance
with the Ethics Committee of the Pirkanmaa Hospital District,
Tampere (R13019). Brieﬂy, the cord was separated from the placenta;
the umbilical vein was cannulated with a 20G needle, and the needle
was secured by clamping the cord over the needle with a clamp. The
vein was perfused with PBS to wash out blood, and then, the opposing
end of the umbilical vein was clamped. Subsequently, the vein was
infused with collagenase II (Sigma). The umbilical cord was incubated
in a water bath at 37 °C for 15 min. After incubation, the collagenase
solution containing HUVECs was ﬂushed from the cord into a 50 mL
polypropylene tube. The cells were centrifuged at 1200 rpm for 6 min
and resuspended in EGM-2 BulletKit (Lonza) medium supplemented
with 2%HS and seeded into 25 cm3 ﬂasks. The HUVECs were cultured
at 37 °C in 5%CO2, and the mediumwas changed twice per week. Cells
were detached with TrypLE Select (Thermo Fisher Scientiﬁc). The
experiments were carried out at passage 3.
To verify the mesenchymal origin of the hBMSCs and the
endothelial phenotype of HUVECs, surface marker expression was
characterized by ﬂow cytometry (FACSAria; BD Biosciences,
Erembodegem, Belgium) as described previously, as documented in
Supporting Information S2.30
Cell Seeding and Culture on Scaﬀolds. In the cell culture study,
the PCL scaﬀolds were used as a control to the composite scaﬀolds; the
scaﬀolds PCL/S53P4 were also included as a Cu-free control to the
scaﬀolds of PCL/S53P4−Cu1. All the tested scaﬀolds (10 mm × 10
mm × 1 mm) were sterilized by incubating the scaﬀolds 2 × 10 min in
70% ethanol, and then, the scaﬀolds were left to dry for 2 h in a biosafety
cabinet. Thereafter, the scaﬀolds were incubated in BM for 48 h prior to
cell seeding.
All scaﬀolds’ ability to support hBMSC viability, proliferation, and
early osteogenic diﬀerentiation was evaluated in hBMSC culture.
hBMSCs were seeded, 50 000 per scaﬀold, in a 50 μL OM (BM with
200 μM ascorbic acid 2-phosphate (Sigma-Aldrich), 10 mM β-
glycerophosphate (Sigma-Aldrich), and 5 nM dexamethasone (Sigma-
Aldrich)) drop on to the scaﬀolds. Cells were allowed to attach for 3 h
before adding 2 mL of OM per well. The medium was changed to a
fresh one twice per week during the experiment.
The scaﬀolds’ ability to support vascularization was assessed in the
coculture experiment with hBMSCs and HUVECs. Only PCL, PCL/
S53P4 = 4:1, and PCL/S53P4−Cu1 = 4:1 scaﬀolds were used in the
coculture experiment due to the observed cytotoxicity of higher
S53P4−Cu1 content with the other compositional ratios. The
originally printed scaﬀolds (10 mm × 10 mm × 1 mm and d = 400
μm) were cut into four quarters for further use. hBMSCs were seeded,
20 000 per scaﬀold, and cultured for 6 d before seeding an equal amount
of HUVECs. After seeding the HUVECs, the medium was changed to
EGM-2 (Lonza, Basel, Switzerland). hBMSCs alone were used as a
control group and cultured in OM throughout the experiment.
Cell Viability and Proliferation. Cell viability was evaluated
qualitatively by staining the hBMSCs with ﬂuorescent live/dead-
staining probes (Thermo Fisher Scientiﬁc) after 1 d and 14 d of culture.
The samples were incubated for 45 min at room temperature in a
mixture of 0.5 μM calcein-AM and 0.25 μM ethidium homodimer-1.
Images of viable cells (green ﬂuorescence) and dead cells (red
ﬂuorescence) were taken using an Olympus IX51 phase contrast
microscope with ﬂuorescence optics and Olympus DP30BW camera
(Olympus, Tokyo, Japan).
Cell viability was quantitatively analyzed by a lactate dehydrogenase
(LDH) activity assay (Abcam, Cambridge, UK). The LDH reduces
NAD to NADH, which then interacts with a speciﬁc probe to produce a
color. Themedium samples were collected at everymedium change and
stored at −20 °C until analysis. The analysis was conducted according
to the manufacturer’s protocol. After 30 min of incubation at room
temperature, the absorbance, i.e., the intensity of the color, was
determined at 450 nm with a microplate reader (Victor 1420Multilabel
Counter; Wallac; Turku, Finland).
Cell number was determined quantitatively after 7 d and 14 d of
hBMSC culture by analyzing the total amount of DNA by a CyQUANT
cell proliferation assay kit (Thermo Fisher Scientiﬁc) as reported
previously.31 CyQUANT GR dye emits ﬂuorescence when bound to
nucleic acids. Samples were analyzed after two freeze−thaw cycles, and
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ﬂuorescence was measured at 480/520 nm with a microplate reader
(Victor 1420, Wallac).
Cu2+ Concentration in Culture Medium of hBMSCs. In the
culture of hBMSCs, the medium samples were collected from 3 parallel
wells at 2 d, 6 d, and 13 d while the medium was changed and pooled as
one sample per time point. The concentration of Cu2+ in the sample was
analyzed by the ICP-OES analysis using the same protocol as described
in the earlier Ion Release Study of PCL/Cu-BaG Scaﬀolds in SBF
section.
Alkaline Phosphatase Activity. Alkaline phosphatase (ALP)
activity was determined after 7 d and 14 d of hBMSC culture as
described previously.31 The ALP activity was determined from the same
cell lysates as the total DNA content. Absorbance was measured at 405
nm (Victor 1420, Wallac).
Quantitative Real-Time PCR. The relative expression of
endothelial marker genes PECAM and vWF was evaluated with
quantitative real-time reverse transcription polymerase chain reaction
(qRT-PCR) at 6 d (hBMSCs only), 11 d, and 20 d (hBMSCs only and
hBMSCs+HUVECs coculture) time points as previously described.32
The relative expression of osteogenic genes RUNX2a, OSTEOCAL-
CIN, and DLX5 was analyzed with qRT-PCR at 11 d and 20 d time
points (hBMSCs only and hBMSCs+HUVECs coculture). The data
was normalized to the expression of a housekeeping gene RPLP0
(human acidic ribosomal phosphoprotein P0), and the calculations
were conducted using a previously described mathematical model.33
For vWF and PECAM, the QuantiTect primer assays were used
(Qiagen, Hilden, Germany). The primer sequences and accession
numbers for RPLP0 and osteogenic genes RUNX2a, OSTERIX, and
DLX5 are listed in Table 1. The qRT-PCR mixture contained cDNA,
primers, and SYBR Green PCRMaster Mix (Applied Biosystems). The
reactions were carried out with an ABIPRISM 7300 sequence detection
system, and the results were analyzed with AbiPrism 7300 sequence
detection system software (Applied Biosystems).
Immunocytochemical Staining. The expression of endothelial
marker proteins vWF and CD31 (the product of the PECAM gene) was
characterized with immunocytochemical staining after 13 d and 20 d of
culture (hBMSCs only and hBMSCs+HUVECs coculture). The
protocol was conducted as previously described.32 The following
primary antibodies were used: CD31 monoclonal mouse antihuman
antibody (dilution 1:20, Dako, Agilent, Santa Clara, CA) and rabbit
polyclonal anti-vWF antibody (dilution 1:100, Abcam). The primary
antibodies were incubated overnight at +4 °C. The secondary
antibodies goat antimouse Alexa Fluor 488 (for CD31 staining;
dilution 1:200; Thermo Fisher Scientiﬁc) and goat antirabbit Alexa
Fluor 568 (for vWF staining; dilution 1:500; Thermo Fisher Scientiﬁc)
were incubated for 1 h at room temperature. The images were acquired
with an Olympus IX51 phase contrast microscope with ﬂuorescence
optics and Olympus DP30BW camera.
Statistical Testing. Statistical testing was conducted with SPSS
version 23 (IBM, Armonk, NY) using a nonparametric test due to small
sample size. The eﬀects of the scaﬀolds on cell viability, cell amount,
ALP activity, and gene expression were compared using the Kruskal−
Wallis test with Mann−Whitney U post hoc test and Bonferroni
correction. The results were considered signiﬁcant when p < 0.05. The
cell culture experiments were repeated with 1 donor line with 3 or 4
parallel samples (n = 3 or n = 4). However, most likely due to the small
sample size, no signiﬁcant diﬀerences between the test groups were
detected.
■ RESULTS
Scaﬀolds Fabrication via DIW and Morphological
Features. In this work, we used a viscous solution of PCL
dissolved in acetone as the carrier phase to disperse the BaG
microparticles to formulate a homogeneous ink. Up to 50% of
BaGs calculated as the dry weight in PCL/BaG could be mixed
into the ink with the aid of orbital mixing. In DIW, the printing
nozzle was immersed in a cold ethanol bath, and the printed
struts solidiﬁed as extruded due to the solubility change of PCL
in acetone (soluble) and in ethanol (insoluble).
Figure 1 presents the optical and morphological images of the
PCL/S53P4−Cu1 scaﬀolds with various compositional ratios at
4:1, 2:1, or 1:1 (wt %). Overall, the well-deﬁned layouts of the
struts were obtained in all the scaﬀolds, as seen in the ﬁrst two
columns. After the solvent exchange and drying, the printed
scaﬀolds shrank compared to the designed model, more in the z-
axis than the x- and y-axes (Table 2). The gravitational force was
Table 1. Primer Sequences and Accession Numbers of Genes Analyzed by qRT-PCR
name 5′-sequences-3′ product size (bp) accession number
hRPLP0 Frw AATCTCCAGGGGCACCATT 70 NM_001002
Rev CGCTGGCTCCCACTTTGT 70 NM_001002
hOSTEOCALCIN Frw AGCAAAGGTGCAGCCTTTGT 63 NM_000711
Rev GCGCCTGGGTCTCTTCACT 63 NM_000711
hRUNX2a Frw CTTCATTCGCCTCACAAACAAC 62 NM_001024630.3
Rev TCCTCCTGGAGAAAGTTTGCA 62 NM_001024630.3
hDLX5 Frw ACCATCCGTCTCAGGAATCG 75 NM_005221.5
Rev CCCCCGTAGGGCTGTAGTAGT 75 NM_005221.5
Figure 1. Optical images (column i) and SEM images of the scaﬀolds
(column i and column ii) of PCL (d = 400 μm) (row a), PCL:S53P4−
Cu1 = 4:1 (d = 400 μm) (row b), PCL:S53P4−Cu1 = 2:1 (d = 400 μm)
(row c), and PCL:S53P4−Cu1 = 1:1 (d = 400 μm) (row d). Scale bars:
2 mm (i), 200 μm (ii), 2 μm (iii).
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assumed to cause the higher compaction along the z-axis during
the solidiﬁcation. Also, the content of S53P4−Cu1 in the
composite aﬀected the shrinkage rate. As seen from Table 2, less
shrinkage occurred in the composite containing more BaG
microparticles since the shrinkage is mainly caused by the
condensation of PCL polymer after the removal of organic
solvent. The shrinkage decreased from 13% to 14% for the PCL
scaﬀold to 4% for the composite scaﬀold of PCL/S53P4−Cu1 =
1:1 on x- and y-axes while for the z-axis the diﬀerence in the
shrinkage was from 20% compared to 12%. The strut diameter
and strut spacing were conﬁned within the range 200−230 μm
and 300−340 μm, respectively, after the shrinkage upon
solidiﬁcation. As the content of S53P4−Cu1 in the composites
increased, the composites showed a coarser surface morphology
as revealed by the SEM images (Figure 1). The increased surface
roughness in the composites containing more S53P4−Cu1
microparticles was probably due to the presence of more BaG
microparticles that protruded the PCL matrix to a larger extent.
In the scaﬀolds of PCL/S53P4−Cu1 = 2:1 and 1:1, small
cavities and even microcracks were seen on the surface,
indicating a disruption to the continuous phase of PCL in the
struts.
TG analysis conﬁrmed the compositional ratio of S53P4−
Cu1 in the composite scaﬀolds, as displayed in Supporting
Information S3 as well as listed in Table 2. The residual content
was highly consistent with the inorganic content of BaG in the
ink dispersion. Also, the cross-section image of the PCL/
S53P4−Cu1 = 2:1 scaﬀold revealed a moderately homogeneous
distribution of BaG microparticles through the PCL matrix (as
seen in the SEM image in Supporting Information S3). This
indicates that the dispersion of BaG microparticles in viscous
PCL solution was rather homogeneous, which consequently
facilitated theDIW fabrication of the scaﬀolds with good textural
integrity and high resolution.
Compressive Response of the 3D Scaﬀolds of PCL and
PCL/S53P4−Cu1. In a compressive mode, the mechanical
responses of the PCL and PCL/S53P4−Cu1 scaﬀolds were
analyzed. The stress−strain response curves for the scaﬀolds of
PCL and PCL/S53P4−Cu1 = 4:1 and 2:1 with the SS = 400 μm
are displayed in Figure 2a. The observed stress−strain response
of the scaﬀolds is typical for the highly porous PCL-based
scaﬀolds reported elsewhere.26,34,35 Their stress−strain curves
are characterized by three diﬀerent regions: a linear region at
lower strain values, suggesting an initial rigid mechanical
response, associated with elastic behavior of the scaﬀolds; a
region with lower stiﬀness; and lastly, a region where a rise of
stress with increasing strain is recorded, which is related to
densiﬁcation of the porous structure. Compared with the PCL
scaﬀold, all the composite scaﬀolds exhibited reinforced
mechanical properties as the strains were yielded at higher
stress values. The compressive Young’s moduli E of the scaﬀolds
calculated from the slope of the stress−strain curves are
displayed in Figure 2b with respect to the compositional ratio
between the PCL and S53P4−Cu1. The PCL scaﬀold showed
an E value of 5.9MPa and a yield stress σy (at 0.2% strain) of 0.64
MPa. Among the compositional ratios at 4:1, 2:1, and 1:1 for
PCL/S53P4−Cu1, the scaﬀold of PCL/S53P4−Cu1 = 2:1
exhibited the highest E value of 12.5 MPa and yield stress σy (at
Table 2. Structural Parameters of 3D Printed Scaﬀolds of PCL/S53P4−Cu1
scaﬀold
dimension
(mm × mm × mm)
mean ± SEM axial shrinkage (%)
strut diameter
(μm) mean ± SEM
spacing between struts
(μm) mean ± SEM
BaG content in composite
as revealed by TGa
PCL 8.65 (±0.03)
× 8.72 (±0.02)
× 3.20 (±0.03)
13−14% on x- and y-axes;
∼20% on z-axis
229 (±16) 297 (±9)
PCL:S53P4−Cu1 = 4:1 8.86 (±0.07)
× 8.88 (±0.05)
× 3.28 (±0.06)
∼11% on x and y-axes;
∼18% on z-axis
207 (±8) 339 (±6) 20.2%
PCL:S53P4−Cu1 = 2:1 9.20 (±0.03)
× 9.21 (±0.03)
× 3.41 (±0.14)
∼8% on x and y-axes;
∼15% on z-axis
232 (±20) 323 (±12) 32.0%
PCL:S53P4−Cu1 = 1:1 9.58 (±0.01)
× 9.61 (±0.01)
× 3.49 (±0.01)
∼4% on x and y-axes;
∼12% on z-axis
231 (±3) 337 (±4) 57.4%
aDetermined from the weight loss in the TG analysis curves as shown in Supporting Information S3.
Figure 2. (a) Stress−strain curves for the 3D scaﬀolds. (b)
Compressive Young’s modulus vs the compositional ratio of PCL/
S53P4−Cu1 in the scaﬀold. Error bar: SEM.
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0.2% strain) of 1.54 MPa, more than 2 times higher than the
PCL scaﬀold of similar porosity. As revealed by the μ-CT
measurements, all the scaﬀolds printed with SS = 400 μm gave a
volume fraction of approximately 0.39 as well as an apparent
porosity of 60%. The scaﬀold of PCL/S53P4−Cu1 = 4:1
demonstrated a similar compressive modulus to the PCL
scaﬀold with an E value of 6.29 MPa, while the scaﬀold of PCL/
S53P4−Cu1 = 1:1 demonstrated an E value of 7.19 MPa, which
is lower than that of the scaﬀold of PCL/S53P4−Cu1 = 2:1. The
reduction in mechanical properties of the scaﬀold of PCL/
S53P4−Cu1 = 1:1 can be attributed to the formation of BaG
agglomerates, which may result in a heterogeneous dispersion of
the inorganic ﬁllers in the PCL matrix, as observed in the SEM
images (Figure 1d,iii).
Porosity Control on the Printed Scaﬀold in DIW. As
revealed by the μ-CT measurements, the scaﬀolds printed with
SS = 400 μm gave a volume fraction of about 0.393 as well as an
apparent porosity of 60.64%. To demonstrate the precision
control of the DIW process over the scaﬀold porosity with the
developed ink system, the scaﬀolds with the SS = 800 μm
(shown in Figure 3A) or with a dense outward gradient porosity
(shown in Figure 3B) were, respectively, printed using the ink of
the compositional ratio at PCL/S53P4−Cu1 = 2:1. It showed
that, after solidiﬁcation, the scaﬀolds with SS = 800 μm had the
same strut diameters of 232 μm as the scaﬀolds with SS = 400
μm, but the SS remained around 610 μm. The μ-CT
measurements gave a volume fraction of 0.274 with an apparent
porosity of 72.53%. In the design of dense outward gradient
porosity, the strut spacing was set with a linear change from edge
to center on both x- and y-axes. As displayed in Figure 3B, this
resulted in an almost linear change of the SS value from 165 to
663 μm in the scaﬀold after shrinkage.
Figure 3. (A) Optical images of the scaﬀold of PCL/S53P4−Cu1 = 2:1 with strut spacing at d = 800 μm. (B) Optical images of the scaﬀold of PCL/
S53P4−Cu1 = 2:1 with a dense outward gradient porosity. (C) μ-CT images of the scaﬀolds with diﬀerent porosity parameter. (D) Young’s modulus
with respect to various porosity in scaﬀolds of PCL and PCL/S53P4−Cu1 = 2:1.
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For the scaﬀolds with diﬀerent porosity parameters, the μ-CT
image on the left in Figure 3C demonstrates the 3D spatial space
inside the printed scaﬀolds, and the image on the right presents
the 2D distribution of struts in the scaﬀolds. In general, the 3D
reconstruction of the scaﬀolds displayed as the “replicates” in
accordance to the CAD designs, indicating good controllability
of the developed DIW process. The pore architecture
parameters in these scaﬀolds are summarized with respect to
the varied porosity in Table 3. The Young’s moduli of these
scaﬀolds were also compared with respect to the porosity in
Table 3. Pore Architecture Parameters in the Printed Scaﬀold of PCL/S53P4−Cu1 = 2:1
scaﬀold
PCL:S53P4−Cu1 = 2:1
strut diameter (μm)
mean ± SEM
spacing between struts (μm)
mean ± SEM
volume fraction measured by
μ-CT
porosity measured by
μ-CT (%)
d = 400 μm 232 (±20) 323 (±12) 0.393 60.64
d = 800 μm 232 (±20) 610 0.274 72.53
gradient porosity 232 (±20) gradient change 0.261 73.92
Figure 4. (A) SEM image of the strut surface in the scaﬀold of PCL/S53P4−Cu1 = 4:1 after 30 days of immersion in SBF in various resolutions. (B)
SEM image of the strut surface in scaﬀold PCL/S53P4−Cu1 = 2:1 after 30 days of immersion in SBF in various resolutions. (C) SEM image of the strut
surface in scaﬀold of PCL/S53P4−Cu1 = 1:1 after 30 days of immersion in SBF in various resolutions. (D) SEM image of the strut surface in scaﬀold of
PCL/S53P4−Cu1 = 2:1 at various immersion time points. (E) EDXA performed on the precipitates on the strut surface in scaﬀold of PCL/S53P4−
Cu1 = 2:1 after 30 days of immersion in SBF.
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Figure 3D. Compared with the scaﬀold with SS = 400 μm, the
compressive modulus decreased for both the scaﬀold with SS =
800 μm and the one with a gradient porosity, as the porosity in
both types of scaﬀolds increased to ∼73%. An increase of the
total porous volume from 10% to 20% may result in a factor of 4
decrease in the mechanical strength.36
Ion Dissolution Proﬁles and Bioactivity of PCL/Cu-BaG
Scaﬀolds in SBF in Vitro. The bioactivity and ion dissolution
behaviors of the scaﬀolds of PCL/S53P4−Cu1 (SS = 400 μm) at
various compositional ratios were evaluated in SBF for a total
duration of 30 d. Figure 4A−C, respectively, displays the strut
surface morphology in the scaﬀolds of PCL/S53P4−Cu1 = 4:1,
2:1, and 1:1 after static immersion in SBF for 30 d. In the scaﬀold
of PCL/S53P4−Cu1 = 4:1, only small aggregates of calcium
phosphate phase (CaP) decorated on the strut surface (Figure
4A), whereas heavy precipitation of CaP formed layers covered
the strut surface in the scaﬀolds of both PCL/S53P4−Cu1 = 2:1
and PCL/S53P4−Cu1 = 1:1 (Figure 4B,C). The CaP
precipitate demonstrated a characteristic cauliﬂower-like
morphology consisting of numerous nanoﬂakes and gave a
Ca/P = 1.56 as measured by the EDXA (Figure 4E), which was
close to the Ca/P ratio of 1.67 in natural bone minerals,
hydroxyapatite. Figure 4D reveals the morphological change of
the strut surface in the scaﬀold of PCL/S53P4−Cu1 = 2:1 at
various time points during the SBF immersion. Notable
precipitation of the CaP phase on the strut surface was only
observed after 7 d of immersion.
By analyzing the ion concentrations in SBF at various time
points, the ion dissolution proﬁles of the scaﬀolds were acquired.
Figure 5 displays the ion dissolution proﬁles for PCL/S53P4−
Cu1 scaﬀolds with compositional ratios at 4:1, 2:1, and 1:1, all
with dimensions of 10 mm (x) × 10 mm (y) × 2 mm (z) and SS
= 400 μm deﬁned in DIW. With respect to the dissolution of Si,
in all three types of scaﬀolds a burst release was initially detected
within 3 d of immersion, which was most likely associated with
the initial dissolution of Cu-BaG particles exposed on the most
outer surface. After 3 d, the Cu-BaG dissolution slowed down
when the ion diﬀusion from the inner of the particles might have
been hindered by the formed silica-rich layer. Overall, a rather
low amount of Si was detected for the scaﬀold of PCL/S53P4−
Cu1 = 4:1 due to the low content of S53P4−Cu1. For the
scaﬀold of PCL/S53P4−Cu1 = 2:1, a continuous release of Si at
an almost constant rate was detected for the rest of the
immersion period, whereas the Si released from the scaﬀold of
PCL/S53P4−Cu1 = 1:1 reached a saturation level at ∼60 mg
L−1 in SBF after 7 d of immersion. With respect to the
dissolution of Cu, in general the release trend was similar to that
of Si. A higher concentration of Cu2+ was observed in SBF from
the scaﬀold of PCL/S53P4−Cu1 = 1:1 due to the highest burst
release in the initial dissolution. The ion concentration proﬁles
of Ca and P in SBF are reﬂected both by the ion dissolution from
the scaﬀold and by the precipitation of CaP phase on the strut
surface. For the scaﬀold of PCL/S53P4−Cu1 = 4:1, apparent
precipitation of CaP was only seen after 14 d of immersion due
to the low concentration of Ca2+ accumulated in SBF, as
indicated by the steep ramp in P concentration. For the scaﬀolds
of PCL/S53P4−Cu1 = 2:1 and PCL/S53P4−Cu1 = 1:1, the
CaP precipitation was readily indicated after 1 d of immersion by
the steep ramp of P concentration in SBF as shown in Figure 5.
Figure 5. Ion concentration proﬁles of Ca, P, Si, and Cu ions in SBF with static immersion of PCL/S43P4-Cu1 scaﬀolds at various compositional
ratios.
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hBMSC Culture on the Scaﬀolds. To determine the
viability of hBMSCs on the scaﬀolds, a qualitative live/dead
staining as well as a quantitative LDH activity assay were
conducted. As made evident in Figure 6A, the cells were viable
on all the materials after 14 d of culture, and the number of dead
cells was negligible. Increasing the content of S53P4 in the
composite seemed to induce hBMSC proliferation more in
comparison to the PCL control. However, apart from the
scaﬀold of PCL/S53P4−Cu1 = 4:1, the high content of S53P4−
Cu1 had a clear negative eﬀect on the cell amount.
Cells release LDH enzyme to the culture medium upon cell
death associated membrane rupture, making LDH a good
quantitative indicator of cell viability. Figure 6B shows the LDH
activity levels of the culture medium after 2 d, 6 d, 9 d, and 13 d
of culture. Since the medium was changed at each of these time
points, the LDH activity values are not cumulative. In general,
the LDH activities remained at a relatively low and constant level
with all the scaﬀolds until 9 d, indicating low cytotoxicity of the
studied scaﬀolds. At 13 d the values increased slightly, which is
likely due to the high cell density at this point, as observed in the
live/dead staining (Figure 6A). Unexpectedly, the amount of
Cu2+ released from the scaﬀolds of PCL/S53P4−Cu1 = 2:1 and
PCL/S53P4−Cu1 = 1:1 did not induce elevated LDH levels in
the culture medium, as expected based on the live/dead staining.
Still, cell amount in the S53P4−Cu1-containing scaﬀolds was
clearly less than that in the other samples, thus possibly
explaining this observation.
The cell proliferation was quantitatively evaluated at time
points of 7 d and 14 d as shown in Figure 6C. The integration of
S53P4 in the composite showed an increasing eﬀect on the
hBMSC proliferation at both time points and with all the studied
BaG contents. Regarding the role of Cu2+ released from S53P4−
Cu1, the cell proliferation assay was in line with the live/dead
staining, indicating the inhibitory eﬀect of the increased
concentration of Cu2+ on the growth of hBMSCs. Still, despite
the very low cell amount on the scaﬀold of PCL/S53P4−Cu1 =
Figure 6. Results concerning viability and proliferation of hBMSCs in scaﬀolds. (A) Representative images of live/dead staining at the 14 d time point.
Live cells are stained green and dead cells red. Scale bars: 500 μm. (B) LDH activity results at 2 d, 6 d, 9 d, and 13 d time points (n = 3, mean + SD). (C)
Total DNA amount in samples at 7 d and 14 d time points, indicating hBMSC proliferation (n = 4, mean + SD). (D) ICP-OES analysis results on Cu2+
concentration in culture medium at 0 d, 2 d, 6 d, and 13 d time points (n = 1).
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4:1 at 7 d, the cell amount at 14 d was comparable to that in the
scaﬀold of PCL/S53P4 = 4:1. The Cu2+ concentration in the
culture medium at time points of 0 d, 2 d, 6 d, and 13 d was
further analyzed by ICP-OES, which are presented in Figure 6D
with respect to the compositional ratio. During the preincuba-
tion in BM for 48 h (0 d at cell seeding), the concentration of
Cu2+ in the culture medium, respectively, reached 35, 70, and
117 μΜ released from the scaﬀolds of PCL/S53P4−Cu1 = 4:1,
2:1, and 1:1. As seen in Figure 6C, the proliferation of hBMSCs
on the scaﬀold of PCL/S53P4−Cu1 = 4:1 was ﬁrst inhibited at
the early time point of 7 d. When the concentration of Cu2+
decreased to 20 μΜ after the culture medium was changed
several times, and the dissolution rate of Cu slowed down after
the initial burst, the hBMSCs were able to retain their
proliferative capacity at the later time point of 14 d, which was
comparable to that on the scaﬀold of PCL/S53P4 = 4:1.
However, at both time points of 7 d and 14 d, the proliferation of
hBMSCs was restricted on the scaﬀolds of PCL/S53P4−Cu1 =
2:1 and PCL/S53P4−Cu1 = 1:1 due to the high concentration
of Cu2+ in the culture media at these time points. Apparently, the
concentration of Cu2+ is critical for retaining the proliferative
capacity of hBMSCs.
To evaluate the early osteogenic commitment of hBMSCs on
the scaﬀolds, ALP activity was quantitatively determined after 7
d and 14 d of culture. As seen in Figure 7, the ALP activity
increased on all the materials from 7 d to 14 d, indicating that all
the scaﬀolds supported the early osteogenic diﬀerentiation. On
one hand, the ALP activity decreased with increasing the BaG
content (both for S53P4 and S53P4−Cu1), and the highest
values were detected on the PCL control. On the other hand, a
higher ALP activity was observed in the scaﬀold of PCL/
S53P4−Cu1 = 4:1 in contrast to the scaﬀold of PCL/S53P4 =
4:1.
hBMSCs and hBMSCs+HUVECs Coculture on the
Scaﬀolds. The ability of the PCL/BaG and PCL/Cu-BaG
scaﬀolds to support the vascularization in both hBMSC culture
and hBMSC+HUVEC coculture was analyzed by immunocy-
tochemical staining of the endothelial proteins CD31 and vWF
after 13 d and 20 d of culture. Moreover, the expression of these
two markers was also evaluated in gene level with the qRT-PCR
after 6 d, 11 d, and 20 d of culture. Due to the observed
inhibitory eﬀect of the scaﬀold of PCL/S53P4−Cu1 = 2:1 and
PCL/S53P4−Cu1 = 1:1, only the scaﬀold of PCL/S53P4−Cu1
= 4:1 was chosen for the coculture experiments, along with the
PCL scaﬀold as a control to the composite scaﬀold and the
PCL/S53P4 = 4:1 scaﬀold as a Cu-free composite control. As
seen in Figure 8A,B, elevated production of CD31 protein was
observed on all the scaﬀolds in the coculture. Importantly,
extensive tubule formation was clearly visible. On the PCL
scaﬀold, the tubular structures were thick but relatively sparse,
whereas a denser network of thinner tubules was formed on the
S53P4-containing scaﬀolds. However, the scaﬀold of PCL/
S53P4−Cu1 = 4:1 did not stimulate tubule formation to a higher
extent when compared with the Cu-free scaﬀold of PCL/S53P4
= 4:1. Notably, S53P4 in the composite scaﬀolds also stimulated
the CD31 production in the hBMSC culture without HUVECs,
although no tubular structures were detected. On the gene level,
PECAM was notably upregulated in the coculture when
compared with the hBMSC culture, but no clear diﬀerences
among the material groups could be detected (Figure 8C). Still,
in the coculture model, the expression increased from 11 d to 20
d in all the groups.
Figure 7. Alkaline phosphatase activity results of hBMSCs in scaﬀolds
at 7 d and 14 d time points. Results are normalized to cell amount (n =
4, mean + SD).
Figure 8. Immunocytochemical staining of endothelial marker protein
CD31 (stained green) in hBMSCs and hBMSCs+HUVECs cultured in
scaﬀolds at (A) 13 d and (B) 20 d time points. Nuclei are stained blue;
scale bars: 500 μm. (C) Gene expression results of endothelial marker
gene PECAM in hBMSC and hBMSC+HUVEC cultures at 6 d, 13 d,
and 20 d time points. Results are expressed relative to hBMSCs cultured
for 6 days on PCL scaﬀold (n = 3, mean + SD).
ACS Biomaterials Science & Engineering Article
DOI: 10.1021/acsbiomaterials.9b00105
ACS Biomater. Sci. Eng. XXXX, XXX, XXX−XXX
J
The production of vWF was in line with the immunological
staining of CD31 asmade evident in Figure 9. Tubular structures
were evident in the coculture on the scaﬀold of PCL and the
scaﬀold of PCL/S53P4 = 4:1 at 13 d (Figure 9A), and their
amount had clearly increased at 20 d especially on the scaﬀold of
PCL/S53P4 = 4:1 (Figure 9B). Still, the Cu2+ released from the
scaﬀold of PCL/S53P4−Cu1 = 4:1 did not stimulate the vWF
production or the tubular structure formation. There was a low
level of vWF production also in the culture of hBMSC alone, but
no tubular structures were observed. The relative vWF gene
expression followed a highly similar pattern as PECAM; elevated
expression levels were observed in the coculture, but the
diﬀerences among the material groups were minimal (Figure
9C). In the coculture, the vWF gene expression increased from
11 d to 20 d, and at both time points the expression level was
slightly higher in the scaﬀold of PCL:S53P4−Cu1 = 4:1 when
compared with the other groups.
The eﬀect of PCL, PCL/S53P4 = 4:1, and PCL/S53P4−Cu1
= 4:1 scaﬀolds on osteogenic diﬀerentiation in both hBMSC
culture and hBMSC+HUVEC coculture was analyzed by qRT-
PCR of osteogenic marker genes RUNX2a, OSTEOCALCIN,
and DLX5 after 11 d and 20 d of culture. The early osteogenic
marker geneRUNX2a expression was elevated in hBMSCswhen
cultured in the scaﬀolds of PCL and PCL/S53P4−Cu1 = 4:1 in
comparison to the scaﬀold of PCL/S53P4 = 4:1 at both time
points (Figure 10A). In contrast, in hBMSC+HUVEC culture
the scaﬀold of PCL/S53P4 = 4:1 promoted RUNX2a expression
more at both time points in comparison to the other two
scaﬀolds. The scaﬀold of PCL/S53P4−Cu1 = 4:1 seemed to
have a decreasing eﬀect on both OSTEOCALCIN and DLX5
expression, whereas the scaﬀold of PCL/S53P4 = 4:1 elevated
their expression at both time points and both culture setups
(Figure 10B,C). Altogether, the expression of the osteogenic
genes was more pronounced in hBMSC culture in contrast to
the coculture setup.
■ DISCUSSION
Tuning the Architecture Parameters and Balancing
the Mechanical Strength of PCL/BaG Scaﬀolds. The
architecture parameters in scaﬀolds, including pore size and
distribution, pore interconnectivity, and void volume, are
important aspects to consider in designing TE scaﬀolds.36
Optimal porosity in a scaﬀold allows the migration and
proliferation of seeded cells, as well as the formation of a
vascular network. A high porosity, greater than 80%, is desirable
to enhance the osteogenesis.36 An interconnected architecture
of macropores has a decisive eﬀect for the ingrowth of new bone,
especially in long-term tissue interface maintenance. A pore size
greater than 300 μm is of importance for the osteogenesis to
occur as well as for the development of the vascularization
network through the TE construct.37,38 Furthermore, the TE
scaﬀolds shall incorporate a similar structural complexity as the
native tissues, which typically have a gradient porous structure.39
The gradient porosity enables speciﬁc cell migration during
tissue regeneration. The gradient porosity is also required for the
treatment of articular cartilage defects in osteochondral TE.37,40
In this work, we have successfully fabricated 3D printed
scaﬀolds with diﬀerent pore sizes and porosities, as well as a
gradient porous structure (Figure 3). In the early osteogenic
diﬀerentiation culture of hBMSCs, the scaﬀolds of PCL/S53P4
= 2:1 and PCL/S53P4−Cu1 = 2:1 with diﬀerent porosity
parameters (SS = 400 μm, SS = 800 μm, and gradient porosity as
in Figure 3B) were evaluated in terms of cell viability and
proliferative capability. However, no signiﬁcant diﬀerences were
observed among the tested groups as shown in Supporting
Information S4. As indicated by this set of data, the pore size
ranging from 167 to 667 μm supports the proliferation of
hBMSCs well.
TE scaﬀolds should have matching mechanical performance
to ensure their mechanical integrity during the surgical
implantations and to replenish the bone functions during the
healing process. The modulus of the human cancellous bones
varies in the range 10−1000 MPa with respect to the apparent
density of the bone.41 In this work, we have fabricated scaﬀolds
with 60% apparent porosity, and the highest compressive
modulus of 12.5 MPa was measured for the scaﬀolds of PCL/
S53P4−Cu1 = 2:1 with SS = 400 μm. This has determined that
the composite scaﬀolds fabricated by this method are
appropriate for the non-load-bearing sites in bone TE.
Nevertheless, changing porosity and pore size also resulted in
Figure 9. Immunocytochemical staining of endothelial marker protein
vWF (stained red) in hBMSCs and hBMSCs+HUVECs cultured in
scaﬀolds at (A) 13 d and (B) 20 d time points. Nuclei are stained blue;
scale bars: 500 μm. (C) Gene expression results of endothelial marker
gene vWF in hBMSC and hBMSC+HUVEC cultures at 6 d, 13 d, and
20 d time points. Results are expressed relative to hBMSCs cultured for
6 days on PCL scaﬀold (n = 3, mean + SD)
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changes in the mechanical properties, as it changes the density
and the structural integrity of the scaﬀolds (as seen in Figure
3C). However, to achieve modulus in a much higher range, an
alternative fabrication strategy and/or reinforcing component
need to be considered to enhance the mechanical properties in
future studies.
Eﬀect of Cu2+ Released from BaG on hBMSCs and
HUVECs. The surface reactions occurring on BaG involve ionic
dissolution of critical concentrations of soluble Si, Ca, P, and Na
ions. These ions give rise to both intracellular and extracellular
responses in cells at the interface of the glass. The key
phenomenon is the controlled release rates of ionic dissolution
products, especially the critical concentrations of soluble Si and
Ca ions. For example, 15−30 ppm of soluble Si and 60−90 ppm
of soluble Ca ions are needed for osteoconduction or
osteostimulation.42 In the PCL/BaG composite, the primary
role of BaG is to release the biologically active ions at the
concentrations and rates needed for supporting cell proliferation
and diﬀerentiation. As discussed in the Results section, the ion
concentrations measured in SBF within 30 days were mainly
from the dissolution of Cu-BaG microparticles exposed on the
most outer strut surface since the degradation of PCL under
physiological conditions is rather slow due to the low hydrolytic
reactivity of PCL itself (expected to last for years).43 Above all,
the release of inorganic ions from these PCL/S53P4−Cu1
scaﬀolds can sustain over an extended period.
The physiologically relevant eﬀects of Cu2+ as therapeutic
ions, such as the antimicrobial properties, have been previously
examined by applying the composite of PCL/Cu-BaG nano-
particles as an anticorrosive surface coating onto magnesium
implants, as reported by Yang et al.20 Comparatively, doping of
Cu into S53P4 was strategically set to release the Cu2+ locally for
its therapeutic eﬀect on promoting the angiogenesis in the
present study. However, the speciﬁc mechanisms of Cu2+
aﬀecting the cellular interactions in hBMSCs and HUVECs
are complex as indicated by our results. The ion dissolution
products of S53P4 are not expected to greatly impact the
proliferation of hBMSCs, as suggested in previous studies.22,44
Regarding the proliferation and diﬀerentiation of hBMSCs, the
surface wettability is also a key parameter for consideration.
Feasibly, the hydrophilic BaG particulates alter the surface
hydrophilicity in the composite struts in contrast to the
hydrophobic PCL struts. The hydrophilic properties of
biomaterials as bone substitutes are important for the induction
of early cell attachment and growth.45 Regarding the role of Cu2+
released from the S53P4−Cu1, the cell proliferation results were
in line with the live/dead staining results, indicating that a high
concentration of Cu2+ has an inhibitory eﬀect on the hBMSC
proliferation. The generation of reactive oxygen species is one of
the main mechanisms by which the Cu2+ elicits cytotoxicity in
cell monolayers in vitro. As recently investigated by Weng et
al.,22 a dose- and exposure-duration-dependent cytotoxicity of
Cu2+ released from the nanoﬁbers of Cu-BaG was also
conﬁrmed for the proliferation of multiple TE-related cell
lines, including HUVECs, adipose-tissue-derived stem cells
(ADSCs), as well as hBMSCs. In line with our previous results, a
high concentration of Cu2+ released from the mesoporous Cu-
doped BaG microparticles embedded in a nanocellulose
hydrogel was cytotoxic for 3T3 ﬁbroblasts.19 Furthermore, Wu
et al. compared mesoporous Cu-BaG scaﬀolds and their extracts
containing varying amount of Cu2+ and concluded that a high
concentration of Cu2+ signiﬁcantly reduced the hBMSC
proliferation.18 In our study, the highest Cu2+ concentration in
the culture medium varied from 50 μM (the scaﬀold of
PCL:S53P4−Cu1 = 4:1) to 140 μM (the scaﬀold of
PCL:S53P4−Cu1 = 1:1), and these levels are still less than
the 100 mg mL−1 being equivalent to the 157 μM level, at which
Wu et al. concluded that the Cu2+ inhibited the hBMSC
growth.18 According to the proliferation analysis, the hBMSCs
retained their proliferative capacity when the concentration of
Cu2+ was maintained under 20 μΜ. In a previous study, the Cu2+
concentration at 50 μΜ diminished the proliferate rate of
Figure 10.Gene expression results of osteogenic marker genes (A) RUNX2a, (B)OSTEOCALCIN, and (C)DLX5 in hBMSC and hBMSC+HUVEC
cultures at 13 d and 20 d time points. Results are expressed relative to hBMSCs cultured for 11 days on the PCL scaﬀold (n = 3, mean + SD).
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hBMSCs.46 In the present study, the cell culture was carried out
in a static model while the culture medium was only changed on
ﬁxed intervals. Under such conditions, the Cu2+ released from
the scaﬀold has accumulated between medium changes.
Depending on the content of S53P4−Cu1 in the composite,
the accumulated Cu2+ showed a dose-dependent cytotoxicity on
the proliferation of hBMSCs. Obviously, the concentration of
Cu2+ is critical for retaining the proliferative capacity of
hBMSCs.
All the scaﬀolds supported the ALP activity of hBMSCs,
although the increase in the BaG or Cu-BaG content had a
decreasing eﬀect on the ALP activity. Previously, it was shown
that the ALP activity of hBMSCs slightly increased as the Cu2+
concentration rose, however, the diﬀerence was not signiﬁ-
cant.18 Also, the addition of Cu in BaG did not have a signiﬁcant
eﬀect on the ALP activity of hBMSCs cultured in the Cu-doped
45S5 BaG scaﬀolds.47 The high level of ALP activity may not be
as important in the osteogenic diﬀerentiation as the fact that
there is a clear level of ALP activity in samples, ensuring the
presence of Pi and decreasing the concentration of pyrophos-
phate, to allow mineralization.32 The osteogenic diﬀerentiation
of hBMSCs was also analyzed by qRT-PCR in hBMSC culture
and hBMSC+HUVEC coculture setups with the scaﬀolds of
PCL, PCL:S53P4 = 4:1, and PCL:S53P4−Cu1 = 4:1.
Interestingly, in the hBMSC culture setup the Cu-containing
scaﬀold induced the expression of early osteogenic marker gene
RUNX2a notably in contrast to the scaﬀold of PCL:S53P4 = 4:1.
RUNX2 expression is essential in the early diﬀerentiation of
MSCs into osteoblastic lineage.48 However, in order for the
diﬀerentiation to proceed, the expression of RUNX2 needs to
decline, as high expression of RUNX2 has been shown to inhibit
osteoblast maturation keeping the cells in a premature stage.48
Therefore, the high expression of RUNX2a as late as at 20 d
combined with the low expression of late osteogenic marker
genes OSTEOCALCIN and DLX5 in the scaﬀold of
PCL:S53P4−Cu1 = 4:1 is not optimal for osteogenic diﬀer-
entiation. Osteocalcin is only expressed in the late phase of
osteogenic diﬀerentiation, andDLX5 is an important activator of
several osteogenic genes during maturation and mineralization
phases.49,50 The gene expression of OSTEOCALCIN and DLX5
was higher in the scaﬀold of PCL:S53P4 = 4:1 in comparison to
the scaﬀold of PCL:S53P4−Cu1 = 4:1 at both time points
indicating the negative eﬀect of Cu2+ on osteogenic diﬀer-
entiation of hBMSCs. In line with this, Li et al. demonstrated
that Cu2+ ions inhibited the osteogenesis of rat BMSCs in vitro.51
Furthermore, they showed that Cu2+ ions inhibited collagen
formation and accumulation of collagen type I while inducing
vascular formation in vivo. In contrast to OM supplemented
hBMSC cultures, the cocultures were supplemented with EGM-
2, which explains the lower expression of osteogenic genes in the
coculture. Also, the expression of the osteogenic genes seemed
to go down from 11 d to 20 d in the coculture setup.
According to the immunocytochemical staining of CD31 and
vWF, both scaﬀolds of PCL:S53P4 = 4:1 and PCL:S53P4−Cu1
= 4:1 induced the secretion of these endothelial proteins and
supported the formation of a denser tubular network in both
hBMSC and hBMSC+HUVEC cultures in contrast to the PCL
scaﬀold. Similarly, 45S5 BaG has been shown to support the
formation of a tubular network in ﬁbroblast and endothelial cell
cultures.14 Also, the S53P4 dissolution products have previously
been reported to increase the VEGF secretion of human
ﬁbroblasts.47 The secretion of both CD31 and vWFwas stronger
in the coculture setup in comparison to the hBMSC culture. In
line with this, the Cu-doped 45S5 BaG scaﬀolds have been
demonstrated to stimulate the secretion of VEGF and the
formation of tubular networks in a coculture of hBMSCs with
human dermal microvascular endothelial cells.47 Interestingly,
they also noticed that the Cu2+ alone did not increase the
secretion of VEGF in these endothelial cells, but the presence of
hBMSCs was also needed.47 As expected, the gene expression of
endothelial genes PECAM and vWF was notably higher in the
coculture setup in comparison to the hBMSC culture with all the
scaﬀolds (PCL, PCL:S53P4 = 4:1, and PCL:S53P4−Cu = 4:1).
As several previous studies have suggested that the Cu2+ ions
have an inductive eﬀect on vascularization, we would have
expected to see a more pronounced diﬀerence between the
scaﬀolds of PCL:S53P4 = 4:1 and PCL:S53P4−Cu1 =
4:1.18,19,47 However, only the gene expression of vWF in the
coculture setup was slightly higher in the Cu-containing scaﬀold
of PCL:S53P4−Cu1 = 4:1 in contrast to the scaﬀold of
PCL:S53P4 = 4:1. These conﬂicting results may be related to the
diﬀerent experimental design on the Cu-mediated angiogenic or
cytotoxic eﬀect, such as the BaG composition, used cell type, or
medium supplements. However, we may speculate whether the
S53P4 BaG itself promotes angiogenesis, and the addition of
Cu2+ that was released from the scaﬀold of PCL:S53P4−Cu1 =
4:1 does not suﬃce to produce observable diﬀerences in tubular
network formation. A similar ﬁnding was also reported in an in
vivo evaluation of the angiogenetic eﬀect of the Cu-doped 45S5
scaﬀolds in the AV loop model: a tendency toward an increased
vascularization in the Cu-doped BaG group compared to the
plain BaG group was observed in μ-CT and histological
evaluations, but no statistical diﬀerence in vascularization
could be measured between both groups.52 Altogether, the
PCL:S53P4 = 4:1 and PCL:S53P4−Cu1 = 4:1 scaﬀolds
supported the vascularization and tubular formation in the
coculture setup; however, the angiogenic eﬀect of Cu2+ was not
notable in contrast to the PCL/BaG composite. The key point to
consider for future experimental design is to optimize the Cu2+
release and prevent the accumulation of Cu2+ in the culture
medium, for instance, by using a dynamic culture system that
would also simulate the in vivo environments better.
■ CONCLUSIONS
Using a viscous solution of PCL in acetone as the carrier phase
for BaG microparticles to achieve a homogeneous ink in
combination with the solidiﬁcation of PCL in ethanol has
enabled the DIW fabrication of the PCL/BaG composite
scaﬀolds. Because of the excellent homogeneity of the DIW ink
as prepared, the mechanical properties of the composite
scaﬀolds were enhanced, compared to the PCL scaﬀold. The
DIW technique allows a precise control of the scaﬀold
architecture with high resolutions. The reinforced scaﬀolds of
PCL/S53P4−Cu1 at various compositional ratios and with a
strut diameter around 230 μm as well as an apparent porosity of
60% showed a compressive Young’s modulus in the range 7−13
MPa. This indicates that the scaﬀolds would be appropriate to be
used for non-load-bearing sites in bone TE. The bioactivity of
S53P4−Cu1 in the composite scaﬀolds was conﬁrmed by the
CaP precipitation in SBF in vitro. The PCL/S53P4−Cu1
scaﬀolds as fabricated were able to provide a sustained release of
biologically relevant inorganic ions over an extended period.
The high content of S53P4−Cu1 in the scaﬀolds of PCL/
S53P4−Cu1 = 2:1 and PCL/S53P4−Cu1 = 1:1 inhibited the
proliferation of hBMSCs. However, in the scaﬀold of PCL/
S53P4−Cu1 = 4:1, the hBMSCs retained their proliferative
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capacity at a delayed culture time. Furthermore, the rising BaG
and Cu content in the composite had a decreasing eﬀect on ALP
activity in hBMSCs. The PCL:S53P4 = 4:1 scaﬀold supported
the osteogenic diﬀerentiation of hBMSCs whereas the addition
of Cu suppressed the osteogenic eﬀect of the composite. The
scaﬀolds of PCL:S53P4 = 4:1 and PCL:S53P4−Cu1 = 4:1
supported the vascularization and tubule formation in the
hBMSC+HUVEC coculture setup. Unexpectedly, the Cu2+
released from the scaﬀold of PCL:S53P4−Cu1 = 4:1 did not
have an apparent eﬀect on the tubule formation in comparison
to the scaﬀold of PCL:S53P4 = 4:1.
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